var title_f29_7_29808="Substernal goiter scan I";
var content_f29_7_29808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Radioiodine scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-Iodine scan of the thyroid suggesting a substernal component to the goiter. Substernal uptake is attenuated by the clavicles. SSN indicates the suprasternal notch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29808=[""].join("\n");
var outline_f29_7_29808=null;
var title_f29_7_29809="Myelokathexis";
var content_f29_7_29809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myelokathexis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow smear from a patient with neutropenia due to myelokathexis. There is an increased number of mature and hypersegmented neutrophils. The myelokathexis morphology is characterized by pyknotic nuclei with lengthening and thinning of intrasegmented filaments and vacuoles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29809=[""].join("\n");
var outline_f29_7_29809=null;
var title_f29_7_29810="Bilateral grade I IVH coronal";
var content_f29_7_29810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral grade I IVH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 217px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADZAb4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAqzFe3MNnNaR3EyWs7K8sKuQkjLnaWXoSNzYJ6ZOOtVqKAClpKWgBVUswUdScCrJ069H/LpcZ/65N/hXZfAltOX4ueGTrRtfsP2k7/tSgx7tjbM54zu2498V9ReNZfjVokOvazBqvhkaHYi4u0j8stMLdNzgY2AFtg9eo696APiaaGSBtkyMj4B2spB59jRb28t1cRwW0byzSMESNBuZ2JwAAOpJ7CvYP2s8n406kDnH2a3x/wB+x/8AXrl/hJ4dbVdc/tO5gkl03TCszhBnfJyUT8xk+wx3FAHHT6ZfW1xLBcWdzFPC7RyRvEysjKcMrAjIIIII7EVCbaYNgwyA+hQ19XXWvXl1GU+3MzkBreaCcgucn5c7sDdkZ49zWJq0msWupJbyXKOWINysd1tdiVIYAk+2d2cCgD5qEMh6Ixz/ALJpVjkySEY46/Ka9zm1K+eWe4s9RQSwhf3UbbSSBjAbPvkgZJPSo9JutVg86e0lieeXCohm4k5BDBTyQGPfkAHvQB4zcXF5PbQW9xLdSW9qGWGN2Zli3HcwVTwoJJJxjnmgzXyWcliHultHkEzW4LCNnUEByvQkBmAOMgE+te56nqBjtrqcLIks7B5kdj8smcbsc5IPTvg8dK2TDeRy3DzMxsZEDrAkzAsCRtZXbJ9VPr+dAHzrYzajYi4Fk95B9oiMMvklk82IkZRsfeUkDIPHAqKze7tLyG4smuILqGRZIZYiyvG4OVZSOQQQMEV9JaFqFzNetprXV0HCmWNTJh3UEYjU+mOeMDFdhb6hOz2dh/aFrBpWNiJayb2YswwexDZJA+mc0AfHckU8jsWjlLk5JKkkk/406HT7ye3up4bS4kgtFDXEiRMVhBIUFzjCgkgDPfivqLVobyDVmiSe7ks5ZA8ZjGdmfkKM64JYnnnPWsXxTow8QaXd6c0k9qwxuEse1Qy525JOSQcZBPagD5truPhr4Em8WyXFxcTC10qFZlMykM8k6W8kyRIvPJETNk4XarDduKg8Zd28tpcS29whSaJijqexB5Fdr8K9U8P6Dq7atrl/qcM8cVzbRwWlgk6ss1u8W4u0q4IMmdu05x1GeACh8OvDEPibU9Qa+uJLfTNKsJdUvWhAMxhjKgrED8pcllwGIGM8+tv4neDF8J3Okz2puV03V7RbyzivgoukjIAzKqZRSTkgBiQpG7ByBf8Ah34p0fwT4s1aS2kub/TL7TnsI7uewQvCzGNxKbYyMj7XTAQvg8Nn+Gqfi7xBp2vyeH9NlvdSm0/TRKk2rTwBrm586d5nkMJcjcGkZeZDuxnIzgAHO23h+9m8M3mvsYotNtpktg8jEGaZufLjABywXcxJwAFPOSAeg8c+B38JeHtKnv7qN9Xnu7i2u7WJt62pjjgcIzYwXxNk7Sy8gZyDWX4w8UXHiK4tYY4FsNIsEMGn6bExMdtGTk88bpG4LuQC55PYDf1u88ITeA7HRrHWtbmutPubq8iMukRxpM0ywqEJFwSgHlZ3fN97pxyAR+B/DHh7xBa2mnTX2qP4m1KQxWaWcCNa27MdkYuXbDL8wLEoGwhBGTlRwYjZnCqCWJwABnJ9K9F8C+J9D8P2drcNea1azw5GoaVbr5lpriq7MqzsZFCKVcxFTHIAAWwSxWsDwzq2n6FZXt+qSy+I8+VYEqFis8jm5Vg2TKvIQYG1iHDZUCgDZ0z4e/ZPEt9YeKL0RW+k6Z/aupx2H7y4gU7AIV3AI0uZYiRuKgE/NuG2jxd8PLzT/FuiaVoVvdynXbeK6062vjHHc7XyoEuG8tWJViBuOFI3YOQIPhr4vi8Pa/qt5qzSTf2lZSWr3TQLdvDIZEkWbynIErB4xwWGCd3JXBj8V63pmv6lolrNf6k+nWEDwTarPbB7m4Mk0s7ytCZMbt8pXmQ5xuyCcAAq/EfwxbeFNV020s777fHc6Za3xnUEIzSpuOzIDbPTcAcdRXJ16B8T9W8N66mjXGhX+qTXNjp9rpjQ3VgkKskMWzzQ6ysckgfLt4yfm458/oAK9G+HXgnTdb0VdV1ybUmt7jU49HtLbSkja4e4dC+W80qix7RjO7g9QBzXnNeieDfFum23w/1Pwtqdze6YLq7+1DULW0W7k2GPy3iVWkj8vcuQzK2WVihGCcgFO98J6b4d+IGq6D4s1N1s9MZhK9hGXmuDxsSFXABbLgncVGFbBPAOd458PW+j6nYHSWu30zVLVbyyF6ix3AQu8REirlQd8b4wSNpU8EkDrIfHOjaj8VNd8W6pBNYG4VpNO22qX32WfMaq7RsyKxCByOflYqedorjPF13bXut/a4ta1XXjMqtPd6nD5M7MMrtOZJMgKq4bd3xjigDM1fTLvR9WvdN1GHyr2zleCeLcG2OpIYZBIOMHkEiu51Dwj4dn8OX8nhvVr6+1LSbZLy+uZYBHp8q5RXW3YjzGcPIgAdVyFc+meG1aW1uNSuptOtTY2ckrvBatKZTChPCbyAWwOM9TivRPiJ4h8M63pyWeha7r1tpFjGi6foj6XHHbqygjfI6z4aQ7nJlKFjnBoAqeBfCPh3xJFbaW2q33/CS3yu1s1vCpsbc7WKpcu+HU5RiSisNpUgk5A5nwp4P17xc1yPDtg189qqNMFkRSoZtq8MRnn06deldf8PfFnh7w15N7JJrEbJC0V/oka+daa0wD7TMxcBFPmbdhjkAC55LEUn7Pupabp/xK0qLULSeW8vJltLS6jkyLZ5Q0ZYx9HDb9p+YbQSwyRigDjPCtppFzqP8AxUV3cW2nRxmR1tED3ExyFVIlPylssCdxA2q2DnAPUSeAYtQ8e+HtG0O8eKw1+Fbiyl1NRFLGhaRGEqpkBt8Um0KSCCnTJAzvhxqmlaBr9ze6vPNb3MFuRp91DZrd/Z7kOoEnlM6AkIH2kn5WKsBlRVDxTd2154hS8i1/WdY84I9xqF/b7LkMPl4Hmvuwqrglx6cYzQBt+MvCujW3hK28TeFbjVG0tr5tNlh1eJIrgTbPMDKI8qU2nGSwOe2K1/H/AID0DRx4itfD9zrsmo+HnDXr6jbxx28kfmLF+6ZCWZi8iEBgBtDHOQAcrx/46uNd8P2Ph6PU9T1eys52um1HVWLXFzKwwMKzOYlVTt2K5DEbjgnAi+Kvjq+8Y+KdVkTVtWn0CW8a4s7K7nYxwjkDEe4qpAJHHQE0Add4U+DltrmoeE9+s+RY6rp6XNyCv76Od/P8qOMY2kP5DkEtwI5N207A3i1ey+FPibpmkeMvAV/M2qf2Ro2kpaX9vGo/ezoLnYwTfhgpnGGJBGWxivGqAPZPgV4f0HV7TxA8ln/bviC30e6voNOe3LxxvBJC0SkAZlMrHbhCpChl53grreKPAuha/qvgq6sptPtG1aG//tJdMVbayjeyiEjpC7lgMkMhn3Mh4cDAIPsVt8O/H1vBHGIPh+7rpJ0Nptl9G8loQAVbZIBk7QdwAI7EVgN8FPHQl0YWupeFLOw0lbiO202JLl4NlwCs6szlpCJFJB+fI/h2nmgD56+KsE39q212uj6DplhLD5VuNDnW4t22MSQ8qMytMAy7sEcFDtG4Z4WvXPj34T1TwV/YWj3yaJbWTLNdQWmk+eUV2KK8jNOzOWYJGMbsAIMAZJPkqrnPtQA2itLUtF1LS4babUtOvbSK5BaB7iB41lAAOVLD5hhlPHqPWlOh6p/ZX9q/2bff2XnH2zyG8nOdv38bfvcdetAGZRWvZ+HNZvbGS9stI1G5sowxa4htZHjUKMsSwGBgcn0rIoAKKt6bp15qdyttp1pcXdywJWG3iaRyAMk4AJ4FTXmjajZaimn3mn3kF85ULbywMkjbvu4QjJznjjmgDOorY1Hw1remWzXGpaNqdpbq4jMtxayRoGI4UlhjPtWQeDQAlFFFABRRRQAUUUUAWLG2lu7yC2t03yzOERfUnivofw/pyaTo9va6TE8cVlEftchK/wCkSEZaRckEE9OM4AUV5j4A0mS20251l4nEjxtHavzgDOHYYHXqo6d67jT783Fo8l7eieUIoS1CFQNx5+fgAgfh70AWoIoVv3t7y5NvBAftBVojuCZx83fBByRnmus17XEksNPhKw28jhRuiYgXEY5+6QSMcfLnBGc1z0tttWKDT7SOfTdwjadDvWRnUcdQSw74xgeuedey067ksp49HsRGi/KZSANy4wZApJbj86AOPWC2vJ/Ne7iiQu0ZaI52kfNuA6KNu4EgZBPWtOG0gOmWbRmbTniQqzRhjiItwQS2AxHPXo1aJl0y82Fp57aa3Ug/ZDuzzzgsoyOOvbOKsPHYXSLdT6lDN52BMbWWNgQuSABkAsQefr9KAMbUYxeSQ2emRT38ZlQRyxROrREAkZbnLegycjrV1tO1+8mnso9L1BbiGJPNFzETJEjt8ziM/e+Y5HT3qXRvEcNmIIy73QLrtkliZIwFPcIR0XBLc9h0zXqfhmK41G9mmv4ZLpbmJkMNqjpI4DDaXZvuj5R82efTigDI8E+EpIIJ7+ewkaGNNqiWLy3d1zuJBGEAHYZzt4qVrNbvUlVIIAJJhGraXbeZHGi8ncgxu3ZHzZ4rpfENtqdnaZhsLi2e3AVlEhmiuAxADYA6jByeOvfNaem3V6syE64YoHiMj2/2Py3U44+93yDwKAOf8S2uh2XlLO097eyISFRlEYPA+VQBgdB0zxXk7tDLIGvJWVxuPnkDJbjDMnRjn9Aeea6/xhe2+pTSf2VFLdX8T83UEhkWMnGMsw4bOeMVxs9nMt1cy32m3lslmudzkKgYH5d3IIyM4wKAPO/id4da6s5tdhnjklgZEuBtKu6sOHxyMA8dclSP7pqn8HdJ0DUtUmGrv9rvzBdrBpzRHZhbOaTz2bBBCsgUJ8p3OrZwpU+lTM03kx2pDWu/93FOVCTKVwN2eWGSR3xXnktxJ8LfEUxXQNK1CSdJTbXV21zlIpIzHJENkiKcBmUkgnnII4wAY/woj0V/Ekza6LR5IrOWTT4b91S0muwB5aTsxAEeNx+8vIXnnB67xRpuh6P4x8Ca5rtnpENjqRFxqltpLrPp6xxzmLEIQtnKIC43Nli3TpXmR1ay/t/7f/YGnfYv+gZ5tx5H3Nv3vN83r833+vtxVq88YatceJ7bXY5Ire8s2i+xokYaK1SIBYo0R8jaqqo+bJOMkkkkgHofxdbRb/wdZ6l4Tt/Dc+lpfi3uL3TtGm0+aOYxsyRESTPvVl3E4HBQc889X468F6FY6P4u0QadYWSaFZLe6TcLARqN+qeWrzTS52mHdPtG1AHIOCPKavGNe8YNqWgLolho+m6Ppn2r7bLBZGZvNmCFFZmlkcjapYAKQPmOQeMaGu/EnVdZS/muLWyTV9StxaahqaCQzXcI2/Iys5iQZSM/u0UjYMEAkEA6Hw/bC08LaDYaf4Mh8Sy67ZT3t5Ilo81/bqLiS3P2d0yIwFjVgWRsOxJyCFHlL9MjP411+geP73RrTTRFp1hPqGlB103UJDMstmGZnwqpIsbgO7v+8R8liDlcKOO3cYoA9H+AFtZX/wASbLT9T0vTtRtry2uY9l8hZEZIWlVxyMHdGASeNpbp1HSWGh6ZffGfwPFeaZpQTVNkl9Z6eA+mlg7oBAwJV12Im4hnHmbxngqPNfAXiubwb4hXWLSwsr25SGSKNbvzNieYpRmAR1JO0svJI+YnGQCL1p49vbLxXoetWWn6fbx6IAthYIJDBCoZnIyXMjZd3clnJy2M4AAAN/VPDMGkfA5by/srdNak1y1dblWDP9knsTNGhI6A8NtPOfwrzE9Sa7HxD8R9e8ReEP8AhHtYe3uYP7TbVPtHlBJfMZWBX5cLs+diBtyOACFAA43NABmvR/Cvh2LxT8Mrm00axim8TQa5bb5mGwi2nAgjTeTjBmdeMZHXoK83rqPAc2u2uoXM3hvT7u/nNpNBJHBFLJsSRGj3kR8gruypPRgDQB0OvanoVl8WtZuPDnh+31Sy+0GHTNNmgYQNIdqYeHAZh9/aoKnftPYqa/xia0j8QadbxadpGmalb2Ai1Sz0lNsEN15spKdTlwhiDfMcMCvUEDD8MazqPgjxdDqX2GNtRsjIjW1/G4AZ42Q7lyrAjdkcgggVVn8Oa6JbMT6Pqglvz/o2+1k3XJIB+Tj5zgg8Z6igDGoq5b6ZeXNu09vaXM0C7t0kUTMo2qXYEgYGFDMfQDPTmmSWVxFbQ3MsMqW0xZYpWQhZCuN204wcZGcdMigCtXX/AAe/5Kt4P/7C9r/6NWuRUZbFev8AwT+GfjG98QeFPF1hojXOgx6hFObhbuBDsjmw52s4bgq3GOccdaAOY+Fun6LqfxF0638QM8lu97Ckdoq/8fkj3CIIy2CFUBmdsjkIVBBYEZ2qjTNM+IeprqFhJPpNtqM6taWsogJRXYKisVfaOBwQTjjjrXpUHwu8a/DvxZJrL+HdI1C1tLz/AEC81TUobWNnSXfHKFFwhDEJnYxPBIIOKhvfhZ8QvEWtW/iPSvBOkRRySC4IsdUimt7h/MLFyXuHPJ4IUgccAUAYvxD1PStQ+HmlS3GgaFoniee9M4t9KtjERYmIbWlBdipdmDKDjKbWHBBPQeP/AARZaTffFK8hi0D7JbRr9gtrW9ikmtCbyBSfJUlo/lZgcgYzjvVTxJ8Fviv4g1/UtWvfC6LcX1w9w6pqFttQsSdq5lJCjoBngAVZvPBnxK8QeIPGiR6Bo8upa4ANQtrfVbVntsTxy8L55ZfmjUfNnr9KAKXw/wDE2jWnhye68UeD/Cs2lWEJghke1cXep3PGI1lLkAgOHdwhCjaCAXWvHK91Xw94r1WLR9EvfA/g/Vb3TYPsFuh15VmOwszAxxXqgvkksdueOenHkXifw3qnhbXbjR/EFuLPUrcKZYvNSTbuUMvzKSOQQeDQB+nWaKwf7XbcQCnBPr6/Wj+13/2P1/xoA+Xv23XB8VeG19LKQ/nJ/wDWrw34cwQ3PxB8MQXcUM1tLqlqkscyhkdTKoIYHggjOQeMV7J+2bcfaPFvhxzj/kHN0P8A01Yf0r55BwKAPVvijf8AijUtY8fQtNNe+G9L1iSAi52SixUzyCJYN+WiU7NpEWAQoDcACugN1eHVJdAa4uv7B/4Qj7WNNMj/AGXz/wCzBL5gi+5u8395nH3/AJvvc147rHiHWNaitY9Y1W/v47RStulzcPIsIOMhAT8owq8D0HpT/wDhJdb/ALC/sT+19R/sX/oH/an+z/e3/wCrzt+983Trz1oA99+HV1JD8MvAwh1LWormB9SvotJ09gItXWGaN5IJQXUH5N5wQ2U34BOFb541e6S+1K8vI7eG1S4meVYIVCpEGYkIoHQDOB7AVKmu6oiaciajehdNkMtkonYC1csGLRDPyEsAxIxyM1Tu7qe9uZbi7mlnuJnaWWWVyzyOxyzMTySTyTQB6B8CrhbTxbqNw9zd2iRaLqLtcWh/fRAWznfHyvzjGRyOQOR1q/8AGbUp7PUPD1rBdaneXljEb628QXrBbu+ilZXhcOHZtihcpkhhvYFVIIrzKyvrqxMrWVxNbtLG8LtE5QvG42shx1UjgjoRT7jUry4sbaynup5LO1Lm3geVjHCXILbFJwuSATjrigD0j4x+IdbvdD8D217rGp3Nvc6BDdTRT3UjrLN9ouB5jAkgtgAZPOAB2ryurV7f3d8tut5czzrbRCCASyF/KjBJCLnooLE4HHJqrQAUUUUAFFFFABWn4d0w6tq1vakusTMDK6LuZUyMkDuecD3IrNXrXs3gvQltPDYsb67AF1PHc3MMLJ5sTLkKRwHDIGOVzg7j6ZoAuxaDDeM2npBbx33liNUurlowyJ8i7CQVPGMA4HBNJYW0FveW93qp1HT7u2PkPKkSOBsPUoflK46Hgmu70zQ5UjudKs7yHUbsxllt9RcKk7djDJ0zjsTj2rn5Y5r+8vNHvES2uYtjG1uCxbHGQrAcDtg9/agCCS6eLUkuLOe1vLXaIYpm3RSZJ6yKQepA52kZxzWhL4wia6K3WnToyLl3tkaLeD/z1wcDsMqB61rPbaHpjqLrT4biLcVeJrhnLZAG0kHch4Hy9Ko6pbwfb7UQW0yWxxNEqzb2iHQqeBlMj1oAGnhso5plSaO2LGWO2tblZsk/eZy4yfl6DIrJ8TLBJ5T6ewWdpUaBryOKMBmTqoHAUrjkjGRXWtpnhW6s/t+qW0aEIzxzWOo+TgjoQjJ976kj2rCltdP1S8trLw5bwXUsrLJCb9FknVTnL7k+Xg9OB9KAK2nW8y3SiaZ0i8oQCCzETo3PJyzfI3PTHIJx2r0jwhfQ2Jt47iWWNTujxdWwZpV6khQ3TA6AdDWf4d8Pq+pPpms6tfGSBN75niiBxyH2yYJA79cVma9oz28drcW97d/ZMhN08hMc69ipBymfVsdO9AHqOranBrPhlItH1FTZRtiYvGEicZx5eVyV59fzzWz4c8NadbBHu5Z7u+iCMzSO5I+XAUjOTj1PXvXlngSVreOOLTJ59SkkmjNxCkBaNQGJRHc4HOTnPpXpuoS+IdPhee7vdLsPOl2pcSgbiOirIQMfQjOD14oAk8R6A11ZqdH0y3tbmIOVuJo8svHVQhzuz0zkV414wh1K41KP+3GvmmJKCSRBGZwOhDYG3344FdFqfxO8QeHdeubK6vdK1KJlBjmfEaoT0GBgmuevPHepeJoidU+wSCMERAFvLXPBfgckegzQBhafNCZZ7bUbW4mlw7M1sTgf7IZv4evI61jeJ7CDxroMen6YpaWEbrWOVyZICByCD0DHC4/HtXWadHctpk8xjeNISo85gfOiHQbAwxz29qXw5Z2/9oFJ47m+VpP32AsTlj/eJwSfpxQB8q3VvNa3EkNzE8U0bFHRxgqwJBBHsQRUNewfHLQrue6OtRyXk9vahbSSOdwy2yZ/drHg8JyQR0DH348gIx3oASiiigAooooAKKKKACiiigArvvh1f+IYNN1BdK1a50XQrN0vdVvrHbFcKn3FUSLiR9xO1Iy2zewJ2jLDga6a30zWbbwBd63bXhi0O6vk0y5gjnKmaVV85N8Y4ZRjIJ6EUAdbGb74g/Ei88aLpCHRU1eze/DlHjiSSVEVXVvvBscjBHJzxXtOj6nFe+L9Rsje3GoXel+MbTbcSzSSRWySzXC/ZrZX/wBXGioqsVC7iWXlFQnw3S/BfiWDxH4n8GjxFYaRFZRCTVGuNRa3spFV0Vd7Yw3zSrjcOpqr42vfE/h/WNLt7jx0NbltIRPaXOl6xJdR2pJZNqvkbHwvQdiv0oA9Z8Hatp2sfDN5PKey0dbq8S5jtLWKJxIdCna6kVFIVsybygJAC7VARQFFS0s/Cc3grwI9xp93rfhOzj1a4uZNSka0ktoxPa7pAsDsWbLbFXdgtICdoBI8i8QWXinwXbw6Td317bWNyjXIht7hxAzvGYplI4HmLl4ZBjIIZTkV1et+F/G/gPRLa90/xlBLDbw+ZFbaJq8ryQWsxDNMEUDbCzqmWHBYp7UAeZ67JYya5qL6PFNDprXEhtY5v9YkRY7Fbk/MFwDyee5r7s/ZZ/5IZ4c+tz/6Uy18GTzXOoX8k9zLLc3dxKXkkkYu8jsckknkkk9T1Jr6y/Z38d6tpPhS18K3Ph+ysYNKvXsJb/VdUNmJbh5mYwRoYW3SqG5TdnjtkUAen/Gu0nvbbwtBaaPputTnWGZNP1HHkXBWxu22nIIzx8uRjcFyR1Gn8IUB8KNeR/YoYLy4eWOysN32ay2gRNDEGVcDdEzMNo+d36/ePjfjX9pSHRvFl/pV54FFzLpF9LHDNNf7GDLvjEqqYTsLIx6HoxGSDWVb/tX29vJcSQeA445LiTzZmTVADI+1V3MfI5O1VGT2UDtQB9YV4n4CtpYNR8Gam9jplvBqRCxalak/2lqObOZwNQ+UDkIZHw8n71E4P3l4H/hrn/qSf/Kt/wDaaybD9pTQ9O1W51PT/hhp1pqVzu8+7gvESaXcwZtziDLZYAnJ5IzQB33iLw34c+Gmu6Nq8llqWoX0YN602m6fbebtgllEjSOzqfnN/CpIyT5K5Pp84/HvXIfEXxb8Q6hDa3dp+9S3kt7oIJI5Io1icHYzKfmQ8hjXq2q/tPaXq8ZTVfhxZ3yGNoStzqCyDYzKzLhoDwWjQ49UX0FeH/EnxTB4x8aalr1ppMWkpessjWsbhwH2gM5YKuSzAsTjqTnPWgD7TbVPmbkdT/EaDqh9f1NcSdRbcf3p6nuPWj+0W/56/qKAPKv2qrj7T4i8Pt6aew/8jPXhtes/tDTm41rRWLbsWbD/AMiNXk1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFT2drNeXEcFrG0s0jbVRRkk0Ab3gazt5Nagu9Rijext3Uss0TPG7dVV9pBCnqT04969r0fVNHlt7m3ks7a0vIn/AHEN0Wnil3NjIkA3Ln0OR615/ot5Bp+naX9gaeC9t1cFBCC8xJ+YkgfOmezdABXepo1hrNrpdu17/Zur3AIie43Lbzlug6AxnIHHI+lAHa+C9UitryK01CKyWG4kNtPHZwrLGuCCCA5yAR3XHtzXdah4fNxqVrFYXNl9mvFbAij+0ywogBZvNOGZfursOTlh1xXmkmganpU6QXEF4mrzsimdQuMEYHlyJ/rRnqDziu88HafJY21xe/YrOUQOIZIkuvID7TkvtYcHocZUZB4NAHH/ABB0mPw9cGTVLJ76JgQCkMhOTwMKRx6fWqunvaMslpewWun6bAvlo00fzH1XaQCOo+tepeMbK68X6Vbi1tZ4pZQGGzU1ieEf31HKup4ypxnHasFNG1m01eO3u5nnkiCo80YJWTsBgA8Y75GD2oAwrnw1pl/B59tfaN9oVRBCLiBiyLnJV1Qhl9uMetZuiCz0+e4htNP+y38alvOsZVKS47fOVYfTJxXqr6Bq080V1ZRQWU6MUk83bKy45x5hyfocfUVwPxHh1f7bm502JLWNC005t0Ek7AdPMQAZ9CP50AbNxp1zeaFbalrmn3slysIlMt/ewxxrwT8hZGcnpwcfWvP7XX7y4Sea3hjgKwq00KNl5TuxtwCAVzjBHStyzvr0WcLm2u7i0eNGjW+m3mBcf3XG7Ax0HNdxN4Dn1eTTrn7NpyxpEs4lIbMr44UkEMowe3H40Acjo81xqUkq3hit5poxLFLPcsrIM/MrLkfMP7xGKo+MZdRW0t1GpWkgEfzpI7XYh5wCodtpOMHbxXdDT5/ArWEi+H5de1K5D+Y8DgiGNACRHlCzSkHhTgEK3zDoe31bRwLdZNNs080yecyEJuZ+NpJYHpzxxQB886fYa0L8Xdpqceq6a0eY0TTYYZnO3kuyglVyM8E1saVa69dKb64sGW3JURQAAkqf4lPfjPTnpXok2i3ENxdTzDSL/U5V3ss05jm3dcbU+X5c47lsdRWNpXilNJsXsrDUEknKlUleYyFTz8qxlRzwehxx3oA5a4VrSdDPKW847oAZDg+2APl54LH3xVOW1M1yzalcW0WI2k+ZTNIrDHKKpHygkjnrWrfyx3czNbXs0k03M8kSCIyv/vgjB/3fxzViwv30xbiG2smMkqll3xLIdwwAnAzknv049aAObtnh1V5dJN286XMLRXCL5cUZib+F2bkE9sdOo5r51+IvhG78GeJptLuWE0LKJ7W4U5WeBidrj8iD7qa+oNLjvb3Ud7xWc10pIl87bKqu3TcFALHHG3t610H7QHw8i8S/DK22NEmt6SDNaEAKJcj54hnpuxkd9wUd6APheinsDuORg+mKZQAUUUUAFFFFABRRRQAV6r4X8SafofwUuIp7PQ9Xu38Qqw07USzFE+zEecqJIj4z8u7lecda8qooA9+v9U066+MXxPntJ/DepQ3tiVtF1O+jSzum+0Wr7fM8xASFRmGGHK+xrnvB0kOkfHjw5qGqP4Z0u2a4Sdxpl9HJZW6BWU/OJHCk7ckFurD1AryKigD1fW9T8NyfAY2OgGe0mPiRJnsr6/iuLhgLR1MgCJGRHkhclSM9+1dN40u7DT9CaSXWNHn8zwVZ6EsdlqMN0/2xZo5GQrEzEALG2XPydAGJIFeBUUAd94Y1Sz8D6VHrVtJb3fiq9jkSyVJQy6ZGQF+0NtP+vOXCoSNgXcyneuOq/Z+0LTm1nRNce50m61VNbhtYtOu7+KBoY/kZrkRsQ8zfNtRUxhwCdwG2vF67f4JWcl78WfCiQ7Mw38d05c4AjhPmufqFRiB3PFAGD4vl1CbxPqcus3cV7qLzM09xFMkyyN6h0+U/hWOaluWVp5CnKlyQcds1HQAlJTqKAEFLRRQB9Mf2h8x+p7j1pf7Q/wA5FceNRfJ+aj+0X/vUAcz8Z5/P1XSyM8WxH/j5rzqux+I9wbi+siTnEBH/AI8a46gAooooAKKKKACiiigAooooAKKKKAFFeifDDw5JeLc6h5MtxJHGxSC1l23KoB80iofvDtwc9a5TwjBK/iCzljitZFtpFuHW7j8yAqjA4kXuhOFI6HOOK9V0vRtTnvm1PTrSyinhkeRoLRinlKxJxEoPABPABIwKAKMEirABPp9zIjHzEltmKPGQePMGDwcda9G0MX17pK21q73Fgknmlm2ie2yATsLAq5PT5SD61x8upzLqkU1xcRC6UGMsQYWDejrwA3o3Q969Bv7+/n8OE6fp1pfSIoWZo18mRM9d8eQA2f4h1oAuDU9RuoolFu/2KB8C8YhSyj7yyx/3gO4+tW7c+HJvst3ew6jDqG4BoQq3kcir/wAtOhI7n1ritKsmNjdp4inu9IlvR9nkmuJGlEIAyXPXapwBnrzWhYwahpGnPb2upaNqKZJW4gTftHGGWVQCGx/CaAPa/D8N1f2cc9nLp2q2cbMEhuQibFPTaUQkD/ZYA8VY8R2F/pzQX1re2bsB5ckF3ESsq9wPLxyO3HavI9G1/VtDT7bZRard3bblk8/MqhByG8wYAJOflIPauptvHGuaj4bsNUvY2GnNumnlsZgJYgD8odNoLIeh2nPPSgDO8afFXWtO1yLTtLOmrLHGGZtzESAZzgN2BH1qrN8YPFEGn2F3Pb6aIpOJAI3Vn4+8M5CjIPWui1LQ7bx/p9nffZ5CC4eG5t7hLqNA3dkOH2/TmqA+C+pSnzv+EhtBLEwa3dLUsp9dwZiBx0xQBlw63ovidZGt5tD0zWnYXDJmaZpSejAjjOTycZBrX0PQfGGfPku/Ev2gFkLTXKxwuSeWWPO76FgPpXKat4b1vwTrFtqmqSwXksb/ALkWWnlVHXcScbTkde/pU/iDxbf6RaRf2JrEOn3L7ZJI7SVLrcew8vkDsDg/hQB3v2XxdPul1O01WC4SNo0FrqQaKXspIUZRiB97tn3qDTdd8ZaZqTQavJYWtrFB5nlXeXbaMABWU/OxPPzHNeZeJPjB4p02/t5GvvJkaP8A493iVVkwPvAYyOa0tC8f+IvFqI2qXENqYyMvHEm1Mnur/KwIPH8qAO4u77WL03Sm7vHnuGzbR2MRWNMjKhwQOTk5OefWrujeAL67t4m8ULpMCQptCWsGXOM/MXJ+TjsM/WqPjvxlcW0djaWswsJI3DxagZ0kjc45DEFgueeDnrXkOq+L11ueWbVdZuI5S2Y90szozdDtjAwB+FAHt1zbeANH4eOLUZ1/dMzSeYIwem4k7VHv1rl9QvPCS3sQ0rCBpQrRWcpeMjoSHHIYeo4yMV4/bWD3Jt7ezgumtypEUcVsBEuerMOx5PTOM17p8MvBMn/CM21tqF5BDEg3ypbvmU55IZyOn0oAt+E/BaWTeZAZZLeJjcJas6pJIT912znHtms3xPqup6lLKl9Hbt9lJYQ20bSOXOQqEjOT7rXT6PeaJ4cN2LyO3N7aOYlngYs9zGwBViPp8pyTypxiuY8WXmhIftNsqWF/cESIY5syY6hs9ENAHzr8ePh/J4anstZXYh1IF7y1GAbWfOeQOgYc/UN6ivIa+pLSeA381xJp6yXzAkXd84uTu6B1VgUyM5G5SM8184+JtEuvD2tXGmXwXzYW4dTlZFPKup9COf06jFAGTRSmkoAKKKKACiiigAoor1TwVPZeF/hbdeKl0TSNY1OXWV0vy9XtluYI4fIMu5U4IcsPvZ6cYoA8ror134Lz6NqPxh8mPw9YS6PqFvdbLHVAt6LfZC0ylW2rzuiAzt+6SvXmua+JqW81z4f1e3srOwk1nSlvp7axhEMEcgnmixGg+6NsSk8/eLHvigDh6Wgd6+jPjtaaHpyeIbCey8E2VrbyIukpoaRrqQnGMLcqORFsMhbIHzCP8QD5yr0r9nYN/wALc0dgCQkV27Hso+yy8n0HNdr4D8H2WoeJPhrfz6Zp0ujiwto9RikjX9/NPPepGzL/ABn90Bk5Pyr26aX7PdtBH8PbrUIrPwk1/JeajA8+uKgdol04MqIWxmPcSZB/zzLZ4zQB84GkrvtM0Hw/rnj/AFWHSZr1vDNsZLqGJUL3l1AhH7qFMZLnucfIgZyDtIOXe6hpPiTxs17qcEXh7RriQbotMtg4t41TChUyoLHaMtxkszY7UAcrzRzXX/FSCxtvF5XSrFbCyfTtOljtlYN5e+ygc5YAbmyxJbA3Ek969Y+J/hyysvCfijTZ9J0TT20La+lfZrFY9QuIY7iK38+6lB5VxKSMqPMILjATBAPnilr6W+H3g/Q7vTfDOg3+maaNO8SaaLo301sJNQlvW83dHbzn/VxxrAjMQr7fMUEfvAR800AdP/wk6f8APvJ/32P8KP8AhJk/59n/AO+x/hWN9hH94/kKPsI/vt+VAD9b1AajLE4jZNibfmIPfNZlWLqEQsACSCM81XoAKKKKACiiigAooooAKKKKACilrf8ABumSXurRSmy+2W9uweWHoHHp/X8KAO5+GVhpI0yRLloG1C4XzUeUMFA6eWxHIGOc981NqNhJDep/Zsc1hdkfNF9t/dOOn7tjyf6VM1taWksqaJKLJQu+MzyBTEe6MG6j8DXWfDnTJtd1SA+IZLawhglIEm3Ns7Hphv4MjoRxQB55Fr2pR6/tvL+yR7fbuS5h8xWH91jjOT/PvXolnqttqN1HFeahf2M+wr5NvBuRPQ7nOSD9a9k8X+MfCNhpUem6tYWt/Lj7NKspVcL/AHhIAevbFeLaZb2EXiGeXSnujawBnaW5kDRTJj92uG5yGKjg8+tAGxqGhyLbWcNhqzzeVEyNauStzhidzbiMOCDjC/dwMetb2meIrDSvDEenWmmT216FK+cN58w+jED5vxH41wTR+bfRQJdX1/rRYtN9lDK1t3ZlXJx+ZFdS2vrpOmR31jq08mpxjytiYedj33bslG46HIoApWHiMm0u5bS6jF98zGG4mkSNmwfkCkbT07kfWpk0XxDPoQa2h1k6XCqwyQQbXjcEdFQYkZfUnI98VHqHi7TtQ8Pz6jqTxsilG86VxC7SLzholUq45xhhzzXDr4x1DxFObLQYoNLgnfJvHi2JEMfdhQcKO+T19qAHfFfW7vRVsrrw7rVxp8sw8q4sFCxMvGd6gEnb1HXriqvwi8M+Mfi74i8vUtf1ltDtSDeXc11I4A7RJk43H8gOfQHq9L+GWiMDLfXdvcidN0txLqKSzMCMM2FBI59h9a9F+FFpo/h68lTSra1tzFAIg9nNLdifp87r1VyR7denagD1JNMj0TTLfQ7HQbdfDUCbCBICFQYP3OpOckk5JOT3rjviL4VgvfCuoOJ9V1C0CF7eJEj2wbeSRkD09D0qzrkEsguH1Sytrddvmm/j2+YmTx+7YbwffFUNN0y21JJdPsbaN1SFgLjUb1llGRx+6X5CcnOcD3oA+c3nupoIEu4TJE3yBGjJVBxyMDA+hOa9Z+E/gx7m/mtxqMat8srpJE0pCdgCxwMjsR9KwrfR7mx1abTb+ySe4L/uBEjkMOjcqNp989M1778M7JbWzn/0URup279ncZyue+PUCgC1beB9AimN1e6ZayTLlV3OWjI6Y2H5R9MEVYsvsEN7Db2fh1LdkQkYhijMYBxx7fT8qx/icfEb6fcw+Fb19MuxCHW8byZELgnCMkgPB/vDBBx16H5KvfjX8TNAnu9I1C9S3uonKyo9qiOrdc5AHXr6HORQB9c3VrcaZNLL4o1uC6tXB8mIDyCD6BV+9nv0zXm03jXV3XUUgiMdokmwP5TMregCRdugwTXBeB9c1jxP4Q1PxJ4i1COe6SZYoI12M20A5LAktySMKAOhIres7DWJ7K1k1GZfs5JYNPcLHnJ4wpxtA96ANbT9d1MWzvq1p9mnmhZBDbREFoxyBnpnj3PJqtJBYSaYfMlmW7mA8tJVVEcf7xyePTpWXbeHtROqyXd5PMYzMrQD7WfLfA4PHOB3z1q9DaXtjql7dm9ihtQu2KNUeR8dThACPocjNAGNarrN1dXFra2qI8eI0uTOMc9ge/vWH8Y/h8yaJFdxvA+q2ykssTtK069WXPqOWH49zXUXc15cBGvbOXbCwMZaVY1A/vMAeOO1VLvSX1DU4dT88Ga1PyIsuYsepx1/GgD5fPXikrtPihplra+IJb3TWg+y3js7RQqQsEn8SgHsScjnjOO1cXQAUUUUAFFFFABXYeEfFGoWWlT6Iuj2Wvaa8pv/ALDeRzOsciRndMoidTxGDkkkBVz2zXH16j8G764WDW9OstIjd7nTNSM+orA0kpQWM22AHlUBfa2VAYnCkkHFAGJonxH1fTfHl34vubbT9U1m4WQM17G+xTIuxiFjZOdhK+mCeM4IxPE/iCfxDdW0ktrZ2dtaW62traWisIoIgzNtXczMcu7sSzE5Y9sAO8MeGdS8Q+IotGsokiu23GRrlvKSBFBZ3kJ+6qqCT37AEkA+kfD+90OT4v8AhHQtCWK48O2l+G+0XkCh7ycrh5juGVU4UInAARSVDlqAPLtd0DVtAmji1vStQ02aRd6R3ls8LOucZAYDIqz4z8TXni7xPf67qUVvFd3riSRLcMsYIULwGJP8I7mvUfH9zBefBK2aWW4u72112O3/ALQvpJHuLz/RXaR180blh3kBAAuVCl1Dk1yIs4vAWkQ3uopbzeJ9TthJZWrqJUsbaRWDSzKwKmV1ICId21SzMFbZgA1fDXxC8daTeeDodI08sNPs5odNshZyMt7FKzGRyAd0mWXGVIA8vgA7s6PwH1PxDNFeadoNpvGjQajrME9vC0k6XUlmbeNQOQ+WKYXbknJ6Airfw/1iz/srSfGU0vkXnguxns1iCs0csjEtZK4xuzK8t0CVJAES52ZyXfAJtQtfC/i64u5NQg8Mf2fOJJ9JEQvBcB7f7p4f7jcAnZy2Oc0AeRSa1OniNda0yC20u5juFuoI7NSI4HUhl2BixwCAcEmrV74kW98XTa7caLpTCaUzSaeFlFqzEYPHmb+T82N/X24q78VkuY/iR4jW+i0+G6F5IJY9PJMCtnkISASPqBzmuSoA63xn40/4SlITL4e0PTbiNYo/PsEmV2jjjEaRkPKy7Qqr2z8o565m174g32s6ffwyaZpVte6kEXUdRgjk+0XoVlYh9zsg3OiOdiryoxgZB4yigDuNF+JWsaRBZtBb2MmqWEBtbDVJFk+02cJDDy48OEwN8n3kY/OecAY4jNJRQB1/2Vv7go+zN/cFbn2TGQSev+e9KLMepoA4jX4zFNCCMZT+tZVdF4yh8m6tgO8Wf/HjXO0AFFFFABRRRQAUUUUAFFFKv3hQBJBFJPKsUKM8jnCqoySa3tKeTTb+NBBcFHGCYpHicnpnPb6Yr2H4IfCFPEXhCXW75bmG8uJttqo6vajh5I+mG3ZAJPRTxzk9bdfDSXwtfvef2kuq2qqEkjlh2zqO26M847bhxQBy3gvw/wD2/Amoa5ppvfsqkNA8gWZ0/vDI+bjtXZNq8tzYHR/A9hp86mMr9mZlMmP7pjbGSPb8K2/EOnHwv4ah1DQoGuNNmjyZ7VSyxMeqyICcDtuXkGvJNI1K/wBa1BooYEivGBLvcSlJCAeGBwTkdiOaAH3k0eiI0epWmmpfyMyGJ2YCLplGQ8r7A/nW94VeS18Pxww3FhECz3BiePH7ncVOFOVJ3KeT2ApsVotzeq09y9zqQlCSteF3aUHsWdefQYNT6pFYR31reeFLy7mvhbiJo7R4ykQGQEUEcKTn60AUl0yx/tWzmsvENzpUu4slzBbhmi/3TGcr6Y6GrHiJIZ7xdXutal1tYwPLulsPJcyKcASqw55688+tMhfXtalivbzTXdrZtszyBEMee58tc4z1OODWndTyy7NIaSZXa8iimguWV0MfL7kkxgjK4OcEZFAC/EPwcFs/Dn9pPDdXmoxmfyliSFLZthO5QMDB9wTnoa1xo95feHLaWTVrqaK3YQxXDWBWSE5wd7Ywy/7YJ4qT4kyQ6t4zuoVmubG3061S2xDai8zu4I2njAC9ue4755CwvbnQlu5NBWWe2snUIlzBKqXZJzgxscHnpj+lAHQ6ZDZ2N5qs1xPp51qKTEc19bPFBgcHZcg4BHJIxirWnarqXhXUY5rfS7e/1K9fet4ZjOeeuwodh4zxkU7S/GdxqUd3aapqdlpVvckOll9hUrbDHDMmd+4MM8YHrmprQ2FtqMbaZeaFf3HmfNBZXtzaee5HD4O5OnYEAUAeofa31jRhPq+jC1t54/8Aj4TbNKc+i4JX9a4JrqeKCW91KO7h0W0xFbNDFHJ5g7MuGVmPatyO68SXvh4xeTqsDw/KlvB827B+48gAJGOhVh2ya4G9eGPxRJFrMLWm+LAhuDk2W4/f4JOSOm6gDo5dd8IrrCi+1GCW9u9u2CXThM6oP4HVidrepFek6L4p0KVBa6NHNJ5ahnjtrGRAgPfbtHB9s145q+neBkuzMLPVb5hDlmS2Clu28vnJX6A+1dH4U0rS30ydtHuHtEgVWf7UzCOJTzuX1JweD0oA7uXUUhvpo7jSYFnujv2XVwiBgOAcHP1OBXz/APtC+GZPFOuRzSWdjYXNoqLJfQBjHJGR0ZsYJXnHSvWLDV5kPn5tn0lAY4pb8NK6nGN4bnaCfavOPFNrfW80ttA8DC5kMkdzIJdkfPZfuED349KAOfh0LQb5obzwZ9p8Nalp6LHFeqDm52jGWRjsYHH4980tl8S/EXh+3ll8X+H7K9kmbyTrTwiVAuejIvA9f6V3Mvg/U5tHhmtrm01e3WIm5nWWNYFPXaEByB7CubudNW3MZgH2zDAywLbeVbx+yjJyMeooAzvEVxqHi+7tpvD0n260dfmlhdYbdD34GCABXWaTYWGn6OkVvey6lcMr7bSynaIQyHAQmRuq5z16Vy+laPo5vdSi0aKG3i3faLlmBSKLgfKMDJB9ABirOm6dp8LSX9sdUkmQ/fQbYHA68P1BHFAEmoWuntBeW2sTTy3qDcLe4lRowfUD+I57muOiS2guotNmSdUJ3+dJMsK478Z5rRulay1KR4rddXt58GOF+gjbkbevGM/lWvBpemfaIpbmzNpvZQE2q6AewoA0PFnwqivPDQu45FuoZ4gscrOCLc9dy9yfp6mvlrVtOuNJ1G4sb2NormByjowwQR/nNfdXhe6tGabRzfbXkI8kIsYmIA6Lu+VQOuevNeb/ALQXw9il8GXF9oGmWAnsJVubyfLS3MkSqwIErHkDduKgc7c5+UAgHyjRTm69MU2gAooooAK7r4dnxrcWuqQeD9Y1bT7GytptSvDbXssEMYSMsSwQ8swj2jjk45ABI4WvVfg/FeXVlexXHiPSLHRRDfoLLUNWjts3UtjJCkgjY8/6xV344GfSgDzu51nU7y5vbi71G9nnvVCXUkk7M1woKsBIScuMohwc8qD2FI+m3o0mPU2tpPsEk7WyzY+UyqqsyfUBlNbmjeHtMj8VXFj4l1q0t9LsFMt1dWE6XBmUbQEtyDh2YsBxnaNzEEIRVxvEmoa/49sLzQp7Tw41uottNH2oQRWMShsAynABOWLMcbmdjgbsUAV/ibb+J9P1+PT/ABrqd5qGqQ20UhFzdSTtAsiLIIyX6MN3IHGehPWuZ1K/u9TvZbzUbme7u5TmSeeRpJHPTLMxJJr0L4yaOsEmlahb6zoF/BFp1hp5j0/U4rmVZIrVUclFOQoZGG7p931rzOgC3BqF3BZXNnBdTxWlyUM8CSMscxQkqXXOGIJOM9MmvRvg9qF3ovhv4h6zaX11afZ9HS3Q20rJIJpbiJY3BBGNpzk5yAxxnkV5eOteheBmWL4VfEl5XSNJYtPt4y7qu+Q3QcIoJyx2RyNgA8IScUAS/Dn4c2/i7w7qmqT6jfQz2tzHawWNjYLczXbsjORGDKgJCo7Ef3VJ9q9D8F/s423iqyvZ4/EOraZNZ3RtJ7XUtFWKZH8tJB8ouGGCsikHPetT9lPUb/SvAfjO60aya9vvtlnDFEI2k2+Y2zzCq8sqBi5AIyEIyvUe6axcX3w78LRTaZpGp+KtQur9ftjRA+dIzj5pm2qx2qqqgHZVRc8ZoA+aU+AunP4kfTP+Eh1hbNZ/so1htFT7C024R+WJPtGd3mHy8bfvgj3rPb4Q+Ff+Ee0bVovHN3NHqkNzPDbx6QvnILeB5pldTPgMoTaQCfmZex3D3FtAvbnxHHpV3YalPf2niP8AtO0lNhIllbW51Brp3FwSUaVonKnGOoTG5SxpXPgy6tfhx4bv7fTNSk1m50tIL60MDsY/J0a9hQGPG5SWlCEHqzKBgnFAHn8H7NthPqOi2cfi+783VrKW+gJ0lQFSPysh/wB/kN++TAGeh5HGfHvip4MHgTxzqHh1b43/ANkWI/aDD5W7fGr/AHctjG7HXtX1JL4PvPDdrY388HibxhA/hu5WfStVY3Ko/mWZWBAIwVY4Y7TknyeMYJHy78VbCy03x7qlvpttc28BZJTDcWTWe13QM+yFvmjj3E7FOSFxyepAO/8AsByfkHU9h/jR/Z5/ufy/xrtTox3ng9/4T60n9jH0/wDHTQB4b8S4PIv7EYxmDP8A48a4yvSvjda/ZNX0tSMbrUnpj/lo1ea0AFFFFABRRRQAUUUo5NAFu106e6sby8iMIgtAhl3zoj/M20bUJDPz12g4HJwOa0PCOgya9rUdqCEt4x51zITgRxAgMfzIA9yK1NG0WXSLCw17Wp4bPSNQV0jURpPcXdv5nk3HkKVZVkQFsGQoe6k16R4OtLfwto11ZnBmupFmedo/ngYZ2ROw+6Qp+YcjLEZPWgDs9F1C80SWAWBeOwYjy4Y7gvFCVwFMfopAHXHpXsa67pfiW0tIdUgt7mSQ/u5g2wKcdGIO5M+x64rwnU/NuJbMaVa3NtqL/PKsL/u5ABksh9RxxXb+FNUigH2e6EVzJIC5aeMqd394OvQ0AaXibwJeJZTf2VJLaW24PJC0zMGBPVipwRx19eteaWWi6Rc6tcadqV3doASPLSM7o2BzgkfMpz9QRXr+ravFbzW8mp2n2GUqVhu9rtbyAjkMVO0A47gdK858cNq8ZtrnTk3IuVRIXQ5jPcMPvKOepyKAFvbPTtNZbiO+uGMCGBBcOdqswwPrn0I46g1k61p5gkgLaXd2NlMoBuoWEScj7ylSytj0GK1LBbaZYLbVZZlR4d9xI7jeA44U+oC+vTdWdp/hWBri40nSvEcv2Y4mtUd9ykA/dYL257rQBn+F47/QdQl1DQNX8hRJsa9lnIhfHBBB7k4yDxWrr6313qBvpLCIGf5p1tbzbHddMsp7HH8Oee1QboNPJtdS0u5uLONvKnto28qOUnndvb5JPcYU/WqE95ZaLHcyacoUyNlLd38wRoe5wOD9KAL1nqN3Z3NxDaGK0kmA/wBMWNpYJBjAExX5o3HTOMUl/wCJtTvEt4W82dbchHgguyY29JEXOevv17VN4f1K+e3FiLeKS2uCcvaXqkyKPmKNGQAxx6j8add6QdU8+exutA08ofkjupxb3BI/uMOpHoc46UAVdSmi1qxe71HVrWS6t4iYYpxNBMh6fMxXLfnitDwnah7S2XzbvVZzGftCafeo4Cn1SRRnnsDXN6l4f1Oa4WO6K3Nu8B3XF1eIjt6cbuD9MZqhbaLdqsFtouriaaVN6iSdl2KP4dpBz+BB9qAPQ4viDrekWE1noV7cXKQSFRGUTzokUcgRENwAPUD+dcrp/iu88deJI7ITww3N/D5ovWhdXdV6iTaxAGOOw9D0FZEep2kmpw6drovZriMiN7hpI1cA9QEADMPx+tdR4n1Twv4cnsrXw7YW1/dlc7ls1t5TgAESOcr0C8Ads0AdVN4Rl0W6Q3fiTQBaOypb2f2qVl3d8Zzs45GK2tJuIrZ3lebTWkggkkLXjtLFGVJ4QbQWfaCecnivItT8T6jf3CnUdLhltpAdptWJeDH3QRgK3TBIArkvEtxq9yYrnVTcziV/lswAFJLfKBGgClskDncc96APV4fijaeJtXSBLzUrC1WIzLDb20SRzsD98Fjlc9cYzxTr17/V43u0liv5BxBbMjs7LwcyOCOay9C+G+rTanpV9fw3Mgih8xba0hmif5kPyyySqgjC5/h3knPTrWnHBY+Hru++27or2LlHVvPQ9epU4oAfCdas42vvEtoTJECzyYVVVB0VsY7d+TVm+8SeGzdaZfXBDxt9z7OGjBJ7NuHP51mWer6pqNo0V3cXUkTOZIWiIQOnqVPPHpVfU+dq3QvLqZgSk00iFUOONybe44FAGjqNrq8txPJpqw7ZmV0WGEPIF9Dzg8d6v6n9g0xoptWGtxyyoEkg2LECT0+Vs/oKm8N63ZaTcJNM00MYjEZMLbX57kY9+1U72bwleavcQW+nXlzqD5lSXUL1i5J7qCeBQBFqtvaXNjLZW2slVQea0K24d0U42q2QMjknII96x9LtL+0VUtEt5wOFmlZfMJ9EAyMVswDRre1leCzDXYyJhjCYJ53SMfmPt0rFuLdbLU2vT9ni42hlQ7Ap5BUL0yPU0AR6Lp7XOvTyatOLRIiXjWH5ndz/ABZPOO3FdTpktx9vWxWaafdkRGWf7vr0OQCO/FcTaS21xqcrtJIhzmS7MQXC9lUZ4/MVJft9nkaTT7e5s9PkYGS6ubkqzgd1C8/hwPrQB5L8VPCq+G/E8q2mDp1yS8OCP3ZH3oz6bc8D+6Vria+v7/wMnjfwO8DJHp1pIvmwXEwAKyjO1woyxzyD7Ma+TdX0+40rUbqwvoWgu7aQxyxsCCrA4I5oApUUUUAFFFFABRRRQAUUUUAKOtdhpX/JJfEf/YZ03/0Te1x69RXeWdi1v8EtUvpXQRX3iG1t4kGSwaC3nZy3GAMXCY5ySDxxQBQ8GfEXxT4JtrqDwvqz2EV0yvMohjk3MowDl1OOCeldF/wvv4l/9DPL/wCAlv8A/G68wbrxSUAeof8AC+/iX/0M8v8A4CW//wAbo/4X38S/+hnl/wDAS3/+N15fRQB6h/wvv4l/9DPL/wCAlv8A/G64fxN4j1TxRrc+r69c/bNRnCiSZo1XcFUKOFAHAAHSseigD7sbQ/mb5F+8f4fc0n9hj/nmP++T/hXp50c7iRt6nufWj+xyeu38zQB8XftPWf2PxBoK4ADWBPp/y1evFq+iP2z7f7N4t8OIO2nMOv8A01Y/1r53oAKKKKACiiigApQMnFJXX/Cjw/p3in4haNomsm/WxvZHjc2C7pgfLYqR8rYG4DcSMBck4xkAG58GfBD+Ir641a9ik/snTmUZXH724PKpz1AALHr0AP3hXpziW0vju0x5mdtpu3IVblT1Vx90t7nBr2GDw5p/hPwJFo2l6X9r02x8wCeKbfNliSWlUqPmbjkegxgYFeVGZRcfadOuDAsj5e1vHOyQjqM9A31waAM+6tYbK4b7EJY7cjzPJlRg0D+uRkFPXFWtIuJdP1iG4sJpbeU4MsTudwH96NhxIvsea39R1HRtTmtCdOns9RhOQkC7QfoK5q9sRuCu92T5p8vyfkliyeA6HAb60Aemawq6joclxYahPdBk3SDTrgKI2/2omBU89eledaRp9rcTzXVzLa3UZJEkDy7/ACyOcnupHWu5+GVhpZkltNUFl9n+4TMnlPnrkHI4z9Rmm+KfC+k6HqM1tZywQ3ckXnMzSf61SwwgYDIbAJycDGKAKb6NdzwNcRK0mlSn5nSJbp4W4wwZcFBxjB4pn/COpf2r/wDCPWsiatGp+fCv5mOvynlT9fwpbWHXTdt9jn1C3jAwHDo52n+HIxuX60l5NFY6nHH5MMl+IzvlaB7C6j9i5O1x6HJoAxdTnu9NubVZdOvZEJ8ufzQVMbDo2Pu9elZGsand317/AGhAuo3V5EeJdMjVQVHHzoRg45HIOa970TUINQ0eOK8iluXx5U1rLdEuVPfD/ex6q1ea+KvB+iWupzXGmzz2F0sgYW91bSAlRjlJ8c5HbJxQBxvhfxVqWj2t/cWuiTXU6hncz2C+Wo/vEKFZT/unHr6ViPrEGsrcST26TTXkhfz4rVLlBjjac/NGOB69a9LN7b6loTJcW8DsG+R7ezM0rj03gqw+h4rirawtRdHy7SS1YPgW9urKV3cfM2ePXv7UAR6JrGjxaRH/AMJTpX2tH/dxXInH7sA8BlIJHTrWhY+ILO71SaDT1hs5VXMPnO0jPnqRIGUAdPvCsqTwslzemOO5mtI4ZBI73Fu7g4PRSozWpptxoomkS+XT7mZG8sXNzbzKGX/Zzx+VAGZq0+treNusbKU2/wC+OoQoZJ415J+dCVB47nrWJquot4jv9IvIhebY45FQ3swknuNxByAg9unNaV5dLHrVxp/h6+sbG1lgZzHDHOxkOG64zjPQZUj+mdpNubOy0+YRXdld2v8AqiGIlh4xgMuMcEigBkMkkzmNLx2CkjbGAMEEgjNR6LqF7YXEixWY+1pI0kGtTwyySWz44RWRisfGTnaDzznitnSZNG04Rx/YxGqdAThR/Wqmv32lWmkznQbm70+bzlud1vNIsXmAcOVBwWA9qAOj0rVtavHtG8T6rf6iMGRYXMtuTz0aQ5yPwBNTeIL67+2pYCxiaxZw8auwVIh2IC/eOe7VnT+I9VuoY7i5iSO4Cxhg98LoTFgMt5SjC8cgE55/Gp7nW79TJp0NzbCOVW32dtbBwT2J28D86ANqK0hvVhv73W4CyDZsihCsgB5w/Q1jeJtN06yvILu1udQntpXXaFIDmQnqSei1Fpskt5bGPSrFbe9hBBnAUyKfbOcZ7YzVmOzlE8b6fp17LcRR+ZLNM4kQP6uTgg/WgC5DaSWhjjdHRGG4SHfIA2e5yf8ACmT2mnSXCGJr59ZlO2NfK3Fz7kc7enFPm1DUbmZXSdkwnz20G5lY+pYcDFdDoWhNdWnnWU7TTucNhiFjHfJAyf6UAVrXQ4IIvtGuT2fAOIWXzGz3wucDnjJrGv7lvsKz3Fo72NrJgQDCCVSBsI7LgjH5V1+oaJBpVosV/rFrKQT51ppsoQJ0PzHYeeQSWIPPHUVz1/DpB8z7Lbzm2aMwlRIJEx16twSCAc80Ac9aXkursws4rPS1Y5Lbg5Y+zHrVG2sVklWe/czoHKQ/aJGUO4OAQBwR+nvWjcyWskTRPH9rERwu5gu8Z6Z44HfAHtV/SNYstO1JhPp8N4yhV3O2EX0UA85HTFAHpelahdpoEEMXlW0KptedVEa57nc2OfYV418efh093oZ8WaPBNJcWoxqPVjLF0Wb1JXo3Xgg8YNeqXV5/bAt7rUra5eLAKQQW5b6AD29qzfEviO9aO4sXhutP0qYCH7K7CZpYgPmBUZwpGQQ3GOtAHxoRjHSkrvPjPeW+peNZbyx0jT9KsXiVYILBAsZVcgk4AG7PXjsOvWuEoASiiigAooooAKKKKACvSpT/AMY5W3/Y2Tf+kcdebDrXpMv/ACbjan/qbJf/AEjjoA82PWkpT1pKACiiigAooooA+uNG/ajvdZ1CKx0zwC09zKeFGrABQOrMxhAVQOSzEAAEkgCrut/tHazot/b2d/8ADzM9wdsH2fWkuEmOcbUeOJlZskAgEkEgV5R4D8GS+EfFFha+Ir628vxZ4cuVs1smLyt9oi2xxAOEXzCWAALBc/xCup1C6g03xF8OtH1jR7ey1LTzq5j0GOXYbbzo/wDQY/OT/lozhMTZ37sOSDzQBxX7Sni3UfFPiXTP7Z0KHRbu1tCvlRalFfblMh6tGMKQVYbTzXjtem/GnQo9IudOnudAbw1rF2JWudLa9e8LIGBW5MjMxy7GRduf+WWe+a8yoAKKKKACiiigBwUkZHSvrr9j/wCHos9Mk8a6rAjXN4Gh07eMmOIEh5B6FiNo6HAPZ6+dfhN4S/4TPxtYaXMzR6eG86+lTqkCkbse5yFHB5IOODX6FW+mxWkEf9jCG1SKFY4Y4hiExqAFQoOOAAARggADpwQDI8f31lp9l5uoWV1Ip+VZrZ9rAdwSDnH4EVwC/De01GylvvC+rzPcN86w3gDsuR90jjI9zXS+M/FvkW0ZuBBBAS0N1b3ShgPSSJxwce/bsDXD2fig20m+zupIbu2XdxGXjkT+8CM49+1AHF6xpGq6Vbbr+C4t7+LJWO4iZPNxnmKQYB+h9KsJrljrlvaNdCB9SiASR3LRSso/2gSCR716Fb/FXw9r8E+k+I7eaMSLgsVPlbum5GPKnuM5x615F4o0u30u9mlimtWiuJMQTId0UvfD4Pyt9MCgDv7eHRtXhijFzJayouI3mUOPz7/jitweAb77GL5Nal2p80kaxebHImOoU/MD7Kfwrybwnq8cVoytJLHcA7GM5EmTngdBx6V2ek+Ob/w8Mw3Fylpn95GP38Qb3RgXjz9aAIdUtU0e+D2YhmtHPF/ZOUaMn+F0bse/b2qjdXFtqCfZ7jUAyW7jzcxARkZ7gZA/MD6V6x4X8WWnii2MUMOmI7IfMi3BkYeoVlBH06VXuEtNNaWFH0qO8cfIbq3EDN6eW4O1/wDdOPrQBW0LXtF0XS4304XMEjbVLW0R2Eeu3JU/hzWu16ms2Ukq6Vaa6hJZ1nuI0ZAB0Ve3twK4eLU72zhcS2lrfM7HMNtEsTD/AGgy4PHcEGq02tPMFSfw5pj3D5Co6iCcjoMOpCsfwoAq+IbHRRbedpy61pnzFmgZvfoD97Z1z1FYk6X0duj2FrbzDbkXe7AX03Bck11+k2HiC7t5tRTTptOhQ4Y7PtDhev8AeLHp6VNf3E/mIRJoN1cbMqJbOOGcrj+ElQc/1oA4JPPbzLk6rcW9wjb4ZLUybjxzljnPPbpUP9p31/EiatLcXDbhIwnyoVf4ThcZHua7jStKYxyuuhRhpB+9kVpZXI64O1wB+ArmNS0CCDUhcpNfJMF3FdwlCD3V2BH5mgDIgFp/a0154ik0mRNuyOd4S+yPJ43YJU85HSuS0m31GC7tLTUL3/Q958y6hu45WdOxQlup4zuA7/SumubKFTPIJ9cjixmSaLT02Nnvlnzj9KittK0BZrUi+kgMi5VhbRQBx78k/kKAEfRreGQC7lvbllbLoJ4EjK46NJt3LnjoM1Q1HwpqN3Ncpp1qyWE0amJH3zMnA3t5gXDDOSM4ru7u1it7KSV7M3FiCCJpliRJmxgctGCxqx5FvADeNBt3oAYI5lKt9FyOR9KAOFto4reKzgljiiktoxE0nmpGGwAM7VOR2qvbw2TalFaqsU04J2zvMzovfGNw9a27W+Fu5kg8NIlvDJtSZsyOSewbGB+dasN7I04t52On3rr8kcVskrKD0JbGM+w5oAo6Ro8txfuGguVRFO0j/RoQfUAZZq6gaStuiwT6kssj9LWCFk/Fi+Cx/DtWTa6Mr3ufEF9ql7EzYVIZvJic+jDPJ+mPrXXaZ4bXUZ447G2sbSwQcxS3P71vclskfQUAXPD3geS5gifS9Gis0D/NdzTtl/XCggEf1r0CDwdLJFHHqus3tzAqgG2hIgibnuEwSPrz70zStRutMgitVgsZbCFeZUucFMf733z9MCsa+8emITNZw3QjD4D3LxFGJOOOchfegBvjHwto1qiBzp+l2p6MZTvk6cBcYAHsD69a8ivrWVL6dbeaN4Jm8q3WI4dx6KOvNdZ421l9QeEiSAyEfvGt4CwA/PmuKMt1b3v22GSe2aLgSJtG3/eYcKfpk+9AFo6HqtlKF1CO3t41+dsK27H8IOegH4c0tnpN7dXMk9uC0YbcGeFUQL3YsfarOvXJu7e1N3fXEt24/dRs52sf7xRf0Jro7NSdJWye8trm5Rdwt0BkKns0ncn2oA7DwzeafY2H2jVY+CAquThAMf3uMmvEfjL47s9ZebTPD8FvHppbbK8Zw9w2egxyfrxVL4iyzweXb3V/NcXAzlEmKoPUY6KPbmuHjW8tWee2tY/3jBtyLuz9OOKAH32gw6zpjWNmjRXSASReYPmZ8Y2k8nB6c15ZNFJDK8cyNHIjFWRxhlIOCCD0NfQ/hqznjhjnE6Qq6l2ZCNyjvk/w1x3xY8KPdWc/i7Rrdjp0bpb30vI3SnhZQOytgAnP3v8AeoA8lopTSUAFFFFABRRRQAo616RL/wAm42v/AGNkv/pHHXm4r0mX/k3C2/7GyX/0jjoA82NJSmkoAKKKKACiiigBc0ZpKKAFycYpKKKACiiigApRjvSVtaNYSpJY3w+yTq0zKluZ0MjMoB5jzuA5GCQAcEDNAHt/wa0m90DSkm094pLq7xJe20iZLKOUUeoXruU5DMfSveLfxhHJp32Z2AZf9WzvseFh23c8Zxgn6V4F8M9ZsLh1glW5sJgSwkBJAI/vIenPXFek3Tra6lHLPGssdwu10Uja4P8AEmen6igDN8afaNcv5DPcCwnMYjMDgPFK395lPGe+RXnTX13Dcr/aSfY9Qs12Le2h8mdPTKjqpHp+NeneLdGt7jTJILYpJCUyscr4x7f3k+oyPpXliIkcr211qMiXEfyiKYCTj/Z78D3+lAG1bQ6tqNjJdWmuxXbKvzOqLHLGf9oD5WHvxWPZXBid4tX1CVHOQzmJRGfZs5GPfn8K1vBj/wDE3S3twtvfKCYriynU+aO+N2Cf905rvpdW02zZotdt7C4G4b7mzRbO6hz/AH4W+RvrkZoA8w01dslxdWb291BjaRM21QfcZII9wePQVeNzqceneRq8fmX0gKlbVAkojJ42t/EMd81q+INOgEUuoadqbalp78AWtoY5oj/dliPDDtlSRVDRoZrW2jt7RIxMx3RwXAe3Ye6ZIH4UAXdDiktL+K50vUikXDRPIv72HHVWAGf512Fp4vmuNVexkn0+4m2ZdFcsGxzna2cH6YNZFhoGpXOnTXM32GZ0cO6wSbZU77XA5/HFHh82+qzeXb2NibqJ94NyTJIhHdeA386AOklunu7dbWCx10y5EqzLKgVQf7rEE4/pVSLS9ae7lLWguo4mDJLLhGQns3y7cDqMVavnvft4nlsb8Wqrhnfm13DqoZRuH0NVJPFNyt3G8NxaWWmg7CbS6R4pD/cYAhgPqKANNNXvLeUQXmuWULxPkvFDukVQOCTwfxGfpWhpusWutaY9hfxWWr2SEjfjaMnneGcZ/WvNdTs7TU9TmnsbaA3ESkyGK4JdM/xhTglfbODWnG18yx2QdLqWJQY1lPlsPUDIww9iTQBt6THo+mPPJcXF6kLvsEWm3au8fsydRRqMHh11ke0m1ySd+kV8EdWb35z+lc/p+kahLNJPFbacYTyRAiu6n354P4VFmPUZNtyd08Z3J5bLlSOhxwR+JoAof2VcyXQ1SKSWO2V9ipbzBssPYgjj0rWuZG1mzVLtJdSu4idjyMVZB6bVTH4103gy9NiIbOGxgZi5LSCBEU5OcMATXa3WlaVeFjPbWmmmUYeWO68gufTlTnH4UAeKx2k63jPfrAIkQbRqMUsi7v7qgcE/Wp/LW7V2+w3RYcb7OPyEX6heT+de62HgnSIrFGupLySJVyDLdZAHqGUCqeoWPhawaOJbWwlJOdzmSdh9Tz+poA8S/sG6vJsO0pWFS8UlqrSrj/bCkgN7kVs6DpFva28z3s06ojAqhtmlkbP1XnJ6nH41395oOnrcre26ssbAgCytjDASR1IUHgfXPrXPa9b3unX8W93liZfl2kwrn15O4/hQBXvryGS0ja8e/khh5aOGzEUcaZ6sxH8q5TxFqdnJclbJbaKJgu5C7TqB1ySeh6dMUmpu13NJDPOzRA5KSzl2Y+3zbc+npWFFfT2d6LfTLMaa7AjEiLnaOrMeef0oA6nQbQTwoJb6zdYTu8yW4fn3K98e5qlr8lm+sIouINQuAnMsNuriEf7K9M1yiXcUUy3F89rPC74RcuyKM/eYgjJz2q7qOpWuoXUNtFdxx28ZyVWAW0bH1OAS1AFuaCS0upJLuTbbOgiiivWBMrHncdpyD7cD61oWd4b6GCG5aVp2+WG2hRAB7gAY/KsVDa6Zby3EspuMnMfnqGUn/ZU8/ifyot9UUNJPDKFuZ1+aRUMZT2GASfp0oA3hoNnBezLePJb3skfzfvS0gH0HQ+lZlvHqVpvtNGs9QklVdqbiqFh/ekYHgH068Vm2lzKksz/ZmnaPLFbb+E+sj8kn261aTVdTh02Z7m4itbSQn5ZSY93sR1YfWgDn5Le+tr+5n1JIL65QdZnHlL9Cewq9BfyizMuuajbLGeIrSyAkmmPYHA4H0xWBqZne5ARTJHG26Ty4v9YfbJ5rrPh3pbalqL3FtbLE0Mm2RJQFKe5wP0zQBtaHo13qvkPfQjT7TbiO2GFaT3buB7mu/Sw0Kz8K3tpfF7uCaJ4ZE3kx4YfMFzwe3I7gVS1Dw7b2zrPqFxLsPKwJ9+U9voK4/VbxIZln1xltPD1sSS11c4VjjOxF+9I/HRQaAPnHxVpH9ia5c2KSieFGJhnAIEsZ+63P5H3BrIr2D4pfEfwv4ul0yxh8OzxabYNKRdQyrDcygoQEXKsqpu2sdwYnHG3Jrx8nJzQAlFFFABRRRQAo616TJ/ybha/9jZL/AOkcdebDrXpMv/JuNt/2Nkv/AKRx0AebGkpTSUAFFFFABRRRQAUUUUAFFFFABRRRQAUuTjFJRQB0fhrxZfaLdxTELeRowPlzkkgDsrdRx+HtX014F+I3gzxXo40yWdLG/ZQW0zU5Fjjd+n7ifhQ3Tg4yT0618hU5SA2TQB9aSRtY3NzYNFfvaFfNiW8hIKqemyTv+oPavIPEliYdZeWB1dZH5ZwGBPoyt0PvXFaF4x1zQo44tO1GdbZDkW0h3xYJyRtbIGcnOMVq3HjJNShkW7tVhkfjMZJTPXjuvPpmgDYU3BlZxp8mN2GhLlSD6p3U+xqxc+InmaCK6u7USx/Li7G7j+7u4ZfxzXI295K7rKLi4ZF+VJ45xuQnoGXuPwBrXu5LzULOOG8jtJp487ZZsLIw9OPvdsc+1AHZ2HiC3hnhjuorF7ZcHy5S6bf9pJVxx9a9CbxXdXMcNtDqAvNLG1xEHjuQv0O3ePx4NeL+HyEiuIY7dbaYAgqXyhH/AFzbcOa2/DWsRoWgnltbYxHdGktsG2n04PH4cUAdx4mvYdQnEtu8RkUYKNCyc+vIB/ImuZuL42l35kzXSXSqPLaIeZj356D61eN+mstDHcybZ+qxuQgkH90kD5h7HmqFuNutyW89xdaPdKv7qPynlGO+SvVf5UAadl8RPFeg3ls1lqMqW8x/gTz4pGPqrZweOqkV6RY/E4vau/iPw7YSM6/M5tlw3rnkn07Vw1j8MtF121RbHxHptvfNJueWKb7zE84U4Ofzrom+FVxpcCRL41sLhWOBBqsLRo4/3znJ69qAKV/rOj3Mo1Ky8Ipgn93PplwFx9QV4/OopGbVmF5fMfIwYyJoS0kCHrllIz07CtrTPhrdaXdG5GhTvaABjNo18kqSn1EbkfniofEGkPZytjRtUt4iu7z5xtbHqcf4UAc7/wAI3/bO/wDsJIg0eA0ttLgSD12lgSa3dJs4fDkape2N6LyQYEosS4b6kn+Zri0sdBW4EN3qM0KKd0ciqwK+oL//AFqp65rFldW8lhpN7dQTxjAc3TvG49+OKAPStIjMx+3X9lPcQB+H01PKY8nBAOQMd672C+aK2e9s3juodvNrdTtJL9SDgD8Oa+dNH1fU4LOFSyzKG3NJb3UhXIPGVyK9M/4SBLqxQ3lj9tkMYysTBQvuTyWHtmgDrtMvdT1Oa5XTyt9cqfmtopMC3B9S3T6HrXYWNt4pk0owXFxDaTAEARojtjsM5wK8jHjePSLlQmjQzPIPuqrQgYHswB/GrEnjGLW9EnkvbKxt1II/cReUR9ZCxP5UAaurrewNLBd3WoJcW3ISK48yNu/OD8v0NZTatZ3QNzqyXGoXqKNkdwCYh7DBAP41BoEsU4jWyt0t7BsB5uChPuchz9az/EEs6zpa6dcWN/ISNkcY+RR3BySR9TQBha3qFj52ItA+whyS5ZSg+vXp9BWHPJI0ci6KlmIsjzmkcIrexbOW+ld5POljbs8mhww3bLs8+WVJuPQAc4+tefatfXX24+VdWlu6NnzIoUUqPZTzn6CgCte6fMhga7t4LeZm/dpC+Fl46Jnqam+0PeXzWzJLbyRL86l94T/ewOvtVLU7vU9RiS7m1N7kLx9okRQVT0Bzj8utQaZdX2lWcptpERjLuikgjLsy4H3sc/maANyLRr+0hZzDf+W3H2u82rGM9SGYcVIum6bp+nu2l6lPPcA+Y7W3yxkdwztyfoKy/smray8UVzJcXdyuJJJp3BVF/uhO4+tazxiCSASfZZrpThIRKWBbsSinC496AGeHJb2KCdVubLTYHffGJmzIT3IXv9avXWkT3wCQSXN5PjPmzt8ufUKO31xXS2vhf7VDHq1/DEnkAu80k4ROnPOeQPwArk/E3xa0/SbeXTNCltjEPldrKDcznvmVjyPpkfWgDNsNLeRvNd7iK7hDLP8AZwXAGerSE7R9F5qva+K9J0O7ZI3nhlXkF90a8HgkD5nP4c159rHjjVL+AwQv9mgY5YKcsx9z/gK5eR2dizMzMepY5JoA9f1z406kA0Whqhcgg3t3GGfvyiZKj23bu3SvLNZ1a/1m/kvdVvJry5frJM2449B6DngDgVQooAUknqc0lFLigBKKXFGKAEopcUYoAB1r0iX/AJNxtf8AsbJv/SOOvN8V6RN/ybna/wDY2Tf+kcdAHm9JTqKAG0UuKWgBtFOooAbRRRQAUUUUAFFFFABRRRQAUUUUAFLnpSUUAKGIOR19a0rfWbyKPy3dJoyMbZlDg1mUtAG7a6pDNMv2nNqQPvwLu/JSeK0Zb6YyLPYatDJIpwAU2Nj3BH+NcjRQB7HbWOqSaas8iyGKVdxcxHGD1OV4x9RXQRPfSaVbC5WCaygbJd71JUZem3B+ZK8K0/VL/TnV7C9uLZlYOPKkK8jvite38ba9DcNKb7zS2dyyoCrfUY5oA9lutFsfFasukJCdigP5E3lseOjbc5+opiWfj7w/p6QCfxBaW5Hy+VIXt9vYZII6dc15TH491BLqOeGK3tWX7wtowob8DwPwrtrD4wPMgtbqa5s4WHzSRoSB9VD4P5UAaVhd+Ior6S6gS4e8ZdrJAgIYj1II2/lWw2veLp7OGOayH2oOCZbiX51XPP3SDz71gW/izRnmjuY/ECHa2CkkBiyPcDBIroR4p025jAuZ9ClsXG4+VerG3PqjPk/Q0AUlu9anvTHcaDp0jSN9+OPlv97JIFbfh66GoRYOj3Ng6FkmiMYyQDjP3RwfY8VPpkGh6zZJcW+kmOM52z29y0Z+owSD+dB0SKXTHvkv9ZuZgPkaeMARjpj5T8345oAq63YQCBoG8LNsUjZdXErFX/EcD8a53VbTWmtYLb7LcLYhgUgtmUAD229R7GqkXiW/0adrO08QrPHu+a0a3LAj0O6txb7Rru3a5XQbi2nzlniWQL9QM4/IUAUJZ76eGOzNtKsaHanm7C49gcAj6VaW4voGSCQwacIhw91PhXz2VBnmn32pyahZxpaHVWCt+6Bt/L6f7fUisbUtTv0u4rK4ubXT5oSGZZbiGJhkfxZJOT6GgDpore5uS32Sx/chSz3K27NGSeh3sQAPwqOA381o0cl/A9vjaUt4Sqn8Vxk+4Nc+njO00+RrS81VLyRRvaRbjMZ/2cjIP6VlXvxKhktblYp4oYCAsdtDAwYn+9/CCPXkUAb1xb6tcu1ut1GhU4V2dAsSdhtB3Z+tXIPCGmeW91f+ewdMMfLQFj/e3nkV55e/EODy1isbAxhRlnwqFzjpjBwPfJrmr/xTd3LKIh5SKcjLlz9D0Uj2xQB7D9v8O6fAPPvoJ4m+VY0tzM/B6Zxird3caHpNmwnae0WQbgomVGbd0JJxtHsPzrwSbWtQl3f6XMgbqIjsB9sDFZxJJySSfU0Aesav430aHyEsWluoh99FRhnOeSz459eD9awj8SdQtTJ/ZNjp9nuHDtEJnX6bht/8d/OuEooA0tY1zVNYmeTVNQubpmbcRLISoIzjC9ABk4AHHas2iigBMUYpaKAExRilooATFLRRQAUUUUAFFFFABXpEoz+zlan/AKmyX/0jjrzcV3/iKSVPg14LgDusEup6nI8YOFdlFsFYjuQGYAnpkigDgKKDyaKACiijFABRRRQA2iiigAooooAKKKKACiiigBaMUCloATFGKWigBMUtFFABRRRQAUUUUAFFFFABnpRn2FFFAB3pc9eBSUUAOV2QEIxXIwcHGRTevpRRQAUufYUlFABn0oPWiigAooooAKKKKACiiigAooooAKKKKACiil7UAJRRRQAYopaQ0AFBoFBoAAcGppLqeS2ht5JpXt4SzRxM5KIWxuIHQE7RnHXAqGigBaSl7UlABQKKBQAtJS0lAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal ultrasound scan showing areas of increased echogenicity (arrows) typical of Grade I IVH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29810=[""].join("\n");
var outline_f29_7_29810=null;
var title_f29_7_29811="Foreign body impacted in RLL";
var content_f29_7_29811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    68-year-old woman with an airway foreign body that was misdiagnosed asthma unresponsive to therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDATsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiinojOcKpJ9qBpN6IZS4rWsdFmuGG5kjBIHzHGK3bPw7AqqZCpY4xmVcDPTPHbBz9RXNUxVOnuz1sNkuKxGqjZeZx6Ru5wqk/SrtvpV1OQEj6kDkgdTj+ddpDY28f+rAA7BinHpnj0yD74rRgghxgiNlx0XZn7vI+71K/KP9uuSeYP7KPcocLwWtWV/T+mcTb+GbybZhR8+NvK85baO/qCK0bHwm0hUtubdgKMrgliQufm74b6Y967JI4tvOx853Bdo3ZGDtwndcIP8AbBqfKlW3FJAwORHgb843Afu/4gAF/wBpWrlnj6r2PSpZDg6evLf1KFhaw2sSCFI2DAbd6gZGDtz8/cZJ9Cq0x1RshcEHGCQvPGRn5u6/N/vVoP8AMcsrSFs7tnHmE8nHydHIBX/camxqxJAYyF+Dt3fNzu4+Tuf3g/2QRXHzNu7PchGMVZI5zUdKhvFJwPUcqDwM+vdf/HuKx5fDDLu2Mpx/00U9s/yOPrxXefZ5CwbDvk/fAfB/iyPl/wC2v04q2kciIPmkjHqBJx/Fnp/D/rvocVvDGVKekTz8TlmFxL5px1PL5fDNwoO2SJuowDnOBx09c4HuDVGXRrxDhYmk5GCoJznpj68/ka9jfeiHiaMDnI80lMc5/wCAZ8z38zHal+wiYOZUkgCqc4Eh8oLy2Pm/5Z5BHr5h9K1jmlRbo82rw3hZfDdHh0lvLH9+Nl78ioipr3g+GbOYsLm3jiyHVx5LMYuRv25fnYSij1Dn0rK1j4dwSEyBXicsWdYljVUIIWRRl+QsjIo9QSe1dNPNab+JWPGxHDk4/wAOVzxukrrNa8GX+mhzJ5PybwQJlJyjbG6H16eo5rmpreSFiJFKn3FehTrQqK8Hc8Svgq2Hf7yNiCilxSVqcgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU9EaRsICT7Vc07TZbyRQCqKxA3OcD/APVXW6bpVvaxo+Y2c4I3MhGTwufyOfwrmrYmNLTqevl+T1sY+Z6R7mFpvh6efDTrIicn7hPTj+ZA/GuosdFgtQB5RZuARscHOeR/31+7/HNTRNEoAiWPtjeE6YIGfwzn3C1MrIw4EQB6Z2Zxt4z77c5/28V5VbE1Km70PtcFlOHwqXLG77vX+vkTohVcBJHB4x+8G7PGP+BY8v8A4DmlYyFcb5ZS3qHHmZ7deN2Mf8A96iVInA3YI7hSmcY7cdSvT/bqZUjwwcxEc7thTJyBnbx1Ixt/2g1crPUuRbHds/PLnoTvHmZ5B6/xYLexSp4Q5GVaTHUON/PG7d970/e/XimyrGC2fKY87vL2YPQtt+XoeNv0apIkAQktDnPJAXBO7PHy9N2GH+wDUvVA2SgsAeXA9QG+XjdkfP2H70f7RxQzMFOQ0eASdufkAGSR8/8ACCHHu5qKRfdN2f4dv97P9z+98/8AuU6NAGBVljAIwWxhSDkH7nQElz/sEUgHkcHexQqDuA/gxjcF+f8AhyNv++1Ot4vnJfYmMltpU7cHBx8/ZiFH+wTTkRlP7tvLC4xuz8mOmfk525JPs61JboysrIskAHQuG/dhRgZ+T+EExn3cGpbYXLLKkZAfylOSCFEZAIbBx83QPhR/0zzT4o1dsgW4zgfOYsA7vr0D8H/pnipwsgSMKZYk6BSJDswNmD8v8IPkn3YGpkSRIzvimbnGCZR/sY6f9u5/Os2yVIjgtomIVTACCMFjHgHcdu7joG3Fv+me2ta0soosNEYoyAuwzmP5ME7C/wAv8J3F/wDZZKksFkl3ZE8mcDafNG4sdgB5/wCWhHkH0CZ71qKk0mFQSXhcKBvMgE+47RnL8eaVMZ9BED3rLmZlUqdDLCL8nlskXlhdhfZ+7Azs3/u+qAtv93SlgLRrGIgYAuNu/BMeAVUN+76opZG/2pFrV+yvJsZQZ2cLsL7h527OzdmTjzNrbvTyl9arRxHfGImNwSAY/P483cCylsyfxgM7f7SJTvZEqUWRw+ayoAHQAgBOQyYXYAcR9Qh8g/7bg1kax4Rs9ThfdZMZCAil/OcjBwg6Dvi3+vNdLb+UY0GE5AIZioJBUsC2ZOpTdIf+moUVE/2cFixUdTz5efuZ/vHny/m/67GqjOUXeO5jOEJppo8S8SfD+6s5JHsVmlTKkAwlAAx29WPaTKf8BzXDXVrLbStHMhV1JBH0OK+nZo7aQP562rA5V1QQkkFMMF4P/LPAX/psWrB8S+E7LVYJsIrT8MBHIiqXUDIUJH/Eu2Nf9sNXq4bM5Rsqmp4OOyKnU96lo/w/r+rHzxRXV+JfB97pLyvGDc26lf3sUb7CrfdIJUcE5Ue6muWYEHBFe1Tqxqrmgz5TEYaph5ctRWG0UUVoc4UUUUAFFFFABRRRQAUUUUAFFFFABRRTkUuwVRkmgaV9EIoLMABkmt/R9DeUpJcIwX720qSMA47ep+X8ataFpCqPMlKGQ4C7mXAJ9c9sZ/HFdEEiXhPJ24GM+Xnpxn/gOc/7eK87EYu3uwPrcpyNaVsQvRf5i21r5CKixOeCMfON2Tg/mf3f4Zp08jsBkyNnOc7/AJs8H/vrG3/gNRF4jwNuMcZCDPH/AMT/AOP1E7IR0Tv0256f4Yx/tZrzbNu7PrE1FWS0AGRm5DS5P+182f8AHH/jtaVuHIB/eNuxz8/zZ5/XG/6pissbAfn2kZO7bt/HH4Yx75q2joF5Cd920JnsTjj1xt9t1E1fYtSNRdxztkmPcMBJz/Fnr6fvvqMVMiuvzESRAfxjzPkx827738IPmj/fIrOWRN2ZPK4z90R4znJxx03YI/2MirVuyDhAiMCMMwTaMHIJ+XoGyx/6ZkVg00GpJIrBj80kO3qqhz5QXk4+bnZkEevmH0qeOJ1Ub1eMLnP3jswdpH3+dpIj91cntSxIoUbDGmMbfMCfLgnbu+T+Eklv9llqwluibCibNoG3zMfJgEDf+7/hBKN/tOlZt6EuRVkjZGCtmPbnIBJ2kHaR9/8AhYiL3U5ppjbJAAY9ArHjrtx/rO7fuz/sgGnSgRBdg8r0WQDK4G0A/u+qqSjf7TKagklJG3YxU/w9D024+512/u/9/mmkxplheSCoR84278fOSSF3Zk/iIKt7KtSwtExQxsJM4x5u3D5B27sv/EAxb/aVarRyswC7Hkz1A3fPngj7n8QAQejIa0AZZSM77kMDkIJB527k4+TjzMBh6eWfWpd1/X9foVzD7YpJsCCFg2Npl8vLZU7S3zd1yW/6aBasIsDKFJQr2/1WT8vf32f+RcVPaCRlUsktwz85Hmjzd3zcYHG8jzR6eXjvVqDzJW3+bM2TkMBL8xPz5/Hm4+q7azdyOcLBIU35ELDBBAMWSCoDAfL1KYVf+mu6tYmIu4lSOZG3BlgEfz5ADBMJ/EoVU9HV6pQNIpZgZeP4v3nAA37sbuqg/aB/tNtq7LvRWZnltwg5KbyYto3HH7znYrCVfVpCO1SzOTV9TUiWOUNuCSs6tvWLaPO3Y3BMRf8ALTChPTy39ahu0Z+GIuy5JLQ5AlLEFiuIukhUOvosTetVFkeNH3s0QUHeEJ/c7QC2z971jDKU95H9KiaXBxd7YlQMGEJUlMEBgn7z+AlVT/ZeSp0M1TV7/wBf16F/Lfu2JZ2ckkrv/e5O8sMJ/ER9oHoqY71G7TSLlZ5j82QQsmP+em7oPe5/JapSrGSATGGBbeFMeFO4BgvzdA+1V/6Zb6sW6hOJFtmO7kDysZ3fjx5n/kEU9BuCSumSBJkLEpNFt5L/AL0+WAN+fvfwg/aPcttqRw0W/dNPAVUkkbyYto3HH7zny1bzR6tIR2p6C3AYx+WCCCpcRYHzkgn5TwJMuf8ApiFpPNC/6holwVKswXCkEspbEf8AC+6Rv9goKhmbu/6/r+upT1XTbe6tZYtRt4ljETLIAocxKAC4TMvPlgqyerSP6V5B468GeTM89ssUcm1vMjV41QSJ99UCscjBXb6nd6V7VJhcGJZLfYAVaTJ8nbkqXAi58ss0jeokT0qjcW8hVdjS2gjUEbhIxtwg4J+QZMQYk+plHpW2HxVShK8TlxGFhiIuNVHy1LE0TFXGDUde2+NvAJnspbi2tJIJId0mwRyMUQY81CzH/lllfqX9q8d1KxuNOvZrW7jMc8TFWUkHBH0r6jC4uGIjdbnxOOwE8LK+8e5UooorrPPCiiigAooooAKKKKACiilHNACqpZgqjJPAFdJommiMLJLGWY8gYPPoOPXn8qqaPYj/AFkoznjGR079f85rfTYOyY5zjb6c4/Dp75rgxNb7ET6rJcsUbV6q16I0I3k27QZJQ3GPnHmZ7f8AA8Z+q0SSOQf9ZJnuS/z55z/wLG76rVTep+/tIOc7Av444+mPxpGZcH7vOc42/U44+mPxrzuQ+s5ywXdv43fI6/Nznn9fv/UUqBjg/OMc7vm475/9n/SqxZed2zvnaF9ecceuMe2akDKM/dyPZcdfp68/7tDiNTv/AF/X9dCXlQpyyY9A3y459e33v+BUKzqeN649C3yY/H+HP/j1QA/MMbBj12+vfj1/8dp8JXIwAMdN23A9M8duc+xFDRcZf1/X/ANO2Ryf40x2+Y7ccY+92JCfRs1tWVnI2FAdmzgRNkKTu2bSd/d/3J/2eay9MCFlx5a4wB5m35eCBu+Q9BlT7sprqrCJWiQMilMY8vjdgrtx/quuz9yf+mpB61x1G0wqTaWgz7M+MBPNzgLvJHmZbaN373+JgYm/2UBqVY94UIzzlgNofjzd2du7MvG/axb0Ma+tWZI0YMWhZskgqDguCu0gYi6soEI9JVJqK4lkdZAzefvU7hGCPO3Y3Bf3X/LTau30MT+tY6mHM2YV6q7FKHzlbBV5MZk3AlSf3nBcAu3oyisWaZeoYnI9gTxkH7/Uj5/9+tfV7gspMu6YvkuyEqJtxyzL8gwJCAy+mxvWufaRixbdnPUgHk5zn7vc/P8AQYrppxZ0Remv9f1/SLFvcLuAkwBzkjbkDGTj5uoHzD/aJraWeMLiRYkXkyeT5YI6btnzdvl2fV6xrYNxIu9SDkPh+MfNngfw/wCs+hxWpA7r18232D7x8w+Vt5z7+Xnd7+Z7Uqi1C5qQyRHd5nlYIO8ReVxyNwT8duz/AGd9XrfYjDLWu7J3bfKwTuycfL034Zf+mQas+0mniO0vNbqg6AyHyNvHqM+Xu2+4kPpWlF5iBQ6PEATlQ7ny9vyED5/4CRCPVXJ7VzsbLaLFvBDRF92cjZtzu3A/c6B8yf8AXLFaC7UTdHJHEV27WcKQmGLDOIv4GJlb1jZRWVHIwI5ZSGwU3MQMNsxkyf3v3B/2OelTvOy5A2SbjwJCMMd20Z/e9C4MTf8ATNQelJpGbVzQk/dqPLJh2Bdu4E+SFyVLfuufL3MzeolX0qvZzNE6gGW0ESgKXDkwhcgZ+TnywxU+vmj0qn5qSnCPG2QNpkK4fJIXf+86MwYP/sqlS2XlYRongYkLsa58vDE52GTLd/mL+4jqHZD5UkzXt3KBP9fCoOAP3p8rHyY6c+WG8g+pkz2qaaVki+aOVCGxszL8uP3e3Oe3Ft9CWrGE9ugj2NCTgbDL5WcbTs39edu7f/00KVU86FtojUqoxjeEyBtwM/KedmVP/TUipsZ+xvqbpvCQy75pMnG0+ZhiTswcv/Ew+zn/AGFzTRc5dzt8wNjCvkCQk7RnMvR2HlN6IgPesZpEVWVgrA9VUKCfl2kDEfUpiL/rrk1PGyykqYXkBOGWPPz5AUgYj/iUCEf7asalrsN07L+v6/rY0VninKlHErNt2+dtAkJJ2b8ydHYMH/2ESrdqkLhDEbZ8hWja48r5ic+WZMseDhmk9hHVMhy+DvufMGGVN48/d8pUYTgSbRGPTy2PetWCKefBMc16HGc/vVFwXOPQYExXHsIvepOeo+Ujit7UlCvlAYUo04hOOCUMnB6As0nuUrg/H/gaDUbeGS0KReUgj/eP80cXVNypH1jHEh9XWvUbdJZNuJ5bjzOhcSgTl8kE5YYEpUsfQRAd6mgtvPKKdt0JAMGfIE28bl35lHEoDSOOxRQa2pVZUpc0XqcNdQqRcZnxlqmn3WmXstrfQSwXETFXjkUqyn0INU6+hvil4Fgv4YbyzYCVwsZkkMce7IJhkclidzLuaQnp8tfP08TwStHKpV1OCCMEV9XhMVHEQutz43HYN4aWnwsiooorrOEKKKKACiiigArR0mza5l3bcqDgcdT+fpzVO3iaaVUUEkntXWW0EdvAFABwMcYOR3xle5wR7A1z4iryKy3PXynBLEVOefwonRfLQKu4DAAxnp1Hf/gX1pdzcfe9c8/X1/4F+NNbqfufgBzzk4+X15Html25xnH1AHrn09ef92vM9T7SMktF/X9f0hQ7Duy49N3y45z17Z3fjShmA5LLj6/Lj8e2c/jSbQuCNq+mccf+O9jz/ukU0kADGBjpnHHpnj15PsRRYrm/r+v+ATKWAOcx46kZO3H49s4+jVPHu5B3Djpzxjj+92zt+hqnGwGNoC46FscemeO3OfqKtREDsAvuBx25+XsCQfciokmawmv6/r/IkdGXqCD6ZPrtx971+T6c0xCdwwSc8YJPPbB57n5T9BUmVIO1SOO/pjH9z0+Q/wC1g1C3XnnPbHXjH930+X/eFSrmqkv6/r+u5r2EpyoUCUk4AckeYT0z84xuwSfQotdLpt0rRJmTK5HzE8tkbs8y9SoMv/XRQK422Xe4zG8gPVUz8+ew+XvgY91Nb9rPMDnLSE8lkDfPk7iR+7/iYCUeyEVzVYlTs0bskqSKx875fvEgqCBt3ZH73rs/ej/prkdap3UgTzPM8mMAHPlFCV4BYp+86qCrL7u4qAahPjduduchhvHOd+4fJ3b9+P8AZBFJdXsnl5RJYAmCGzIfL2/MD93nYWMnuJMdqyUWjJXRjaoQCwcxqRncIypCkY3BfmPAyNv1aseRtrNny/Tjae/bn14H+zmtTUb10+VPMhUYAj3OfJ29F5HOzJPvv9qw5JG3fdZMdsn5ccY/Dp+NdlKLsVKoktTStZEwCRFnqM7MZzxn/gXX/Yq5BPGrL5flZBBUyCMjIJ2luOx3bv8AZ21k28smwKN/uuW/3fX/AIB9DmrcJkYrjfLuP3WLAPnjB+b+IjYfZQaU49xQlc3rOWPchjaJQoUr5gQ7MZ2l/k/hy2//AHkrZtfJCx7EMeMY8zb8uAQu793/AAqSjf7bqa4+OeRSCuX3dN7H95n1+f8Aixg/7grRstQLsuZGlz03kgPkZG795/Fgsf8AaRa5p0+pskmdJGxDfKGVc7QhHKjbswf3XXb+5P8AtnNTOryBg0Uj5OCo3/NkbMcR91Ag/wB4E1kW86yKpV0bOBucrlsjOTmTuuXP/TQCpxdwkAFht9R5e77uePm/ufN/11NZOI7I2U8xmcYkl3DDKPMHnbvl2/d48zaIvYxk96dNJNNwPOvCy8/6xfP3/lgS7ce3k+9ZqzQhJC3l9w2wxE42jcF567cbP+mheq0sqSSt5yxsOd/2cR85xuCcdwFCe4es+W4KN3cur9okKnfNKX6Elx5pb5sn5hjzNpkPp5YHerEblVVvMeQt8wZ93z5G4E5f+IAz+zKBVZRG3LeW+4HeIwnzkkFtmE6MQpT/AGUeo724VUO50lySWMeAHJIYlf3fRnAkX/YUik0Ozelv60ILu9y5xgYOQ2TnGN2f9Z12/vf984qOyuv3nL4AzkjGRxk4y/UKd6/7bGqiyFy0gBJJ5YZwTndnhP7373/dGK2NFgZ5NyM6nOd+2T5SPn3cL/DzN7ggVTXKi5WjE6KJIGjJuFgUANvWDyiV4G8R/MeQpXZ/ts9bMC27KyzrG3Db1t/K5zgOI8A8kbVj9/MqlC0sCAbbi1WMZD5mPkhfmz2z5YbzfcyAdq07cyQKd8k9qFUkhfMPkBAM4+cZMQYMPVpT6VzJnmVZXNFIkYFZDDNuDB1hVP3m4jeExH/GQqp/so9TwRM7AvF9oL7gwjGBNvILbcRcCRlDL6JGfWoYnwCJF8hUBDBGJMW3AYLmXrGGCr6mRquwtHwJiI8Bg4iZPkIIVgn7z+EkRp/sl6pI4Z/1/X+RMYWvYfKnL3KzhldVEi+cHO5uQgwJCBJx0WPHevnn42+CLiOUa3bo8jOfLuZNjjzXOSkxLHrKoZto+6BjvX0fE0BH70WxyW3LF5frhgvzf3sImf4A1Z+u6Xp2q2EsN4IpI5EeOQQiHLAtztODglwNnpGrV2YatKhNTRwVqMasXBrf+v6/G58L0V1fxC8PTaDrk8chR/nIZ48lGP8AfU7QNjclcdq5SvrKc1UipLqfKVqTpTcJBRRRVmQUUVYsoTPcIg4HUnHQetJuyuyoQc5KMd2bGg2gVPOc7c5+YclQOrDkcjjjvmtxsAHLFADyFyduOuPn/hyMeoY02CLyo0CgxkEYLAnZjpn5P4fvH1BFSeWwQY+XbjGQflx0z8n8OST7MK8irNzldn3uDoRw9JQRGRtyT8nrjnbjrj5u2QB7MalUkFgSVI6jP3ecH+Psfk/3Tmoyu0/KrRgYxvydmOBn5P4c8/7wpSSpIA2AcYYfdwMYPydh8p9yDWbuzqTX9f1/kSE9OOg/iPvj+/6/J/ugGq8mCRzn2P1x/e9fl+gBpzE4xggY79uMc/L6fIffmomPH4dD9Mf3fT5frzTSYSkv6/r+u49MDGMNk8bj97sM/N36H6CpRID0O4cYz/Fnpn5u+OfdRVQtnjDMfbPOeP7vf7v1FSIzEc5bd1xn5s+ny/xYGPdTTcWKNVf1/X+ZcRwRkNuz/ewM8Zz97uMt/vAVHI3PUYI5ORnpnP3vT5v97ijzyOpeTPdSRuzzkfL3IDD/AHTULzOzlvm5HXnr97PTufn+nFQou5p7aJcglUcs4XGclcZHckfN1AwR7k1oRTBc7vJGM5C7OMEZ2/N2OAv+yXrEimlQgq7pjnd83y45z07Z3fQ1t6Wk0iMf30KoCS+JD5QXgtx/c3Y9xL7VnUjbcf1mK3/r+vkWZJo85f7OpGeE8vAO7kD5ugbAH/TPNVziXAi8jqBmTy8Z3Hr7Bs5/2NtWUtbyZysSXMQTgj94fK24Tb152bhF7+ZntXZ+F9BubhGSVLiRx8jQt5oDEny/LY7xw7D7MT2ChqwlJQMKuKUYtnlt4Uh2ghfbdsyOTjd75zu/2dtQiO2kTMUqqcjAkdcgHO0njsAQ3uVr2XUfC9nIcTQm4kkK+W8qygzMW2rnMvHmODA3oIlbvXnnibwtHZYk064lmjcDaSmzzFcnyycyHG8q4I7eWPWuinVi9Hoef9ac3ozm4tqk4KkY6HGeR0PHXHH+9itW1QOgyoYHI2rjLZGCB8ncAKP9oGudMjxzZ3FsjOST8wPIP3up+99RWtZXa4BZyq4529RxkkfN1A+cf7RrWrDS53YavzaM1SmcfI0m7OQoP7zPBx8n8WAo90agK5Y9Zd3UoCBJnnj5f4sZH+4aWKaJ0O4qBg7tu3KjGTt+fqBhl/2mapykB3ecIgBncIvL46btnzdvl2fV643oenCRLaTyGRciSTJzkbhuyd2Rhe5HmfRcVppcOCC0koOch8Sf7+enc/v/AMMVi+TGMk+X1OdhQjqN232zjb/s7qmYBCeYN3X5QmDznjjpu5H/AEzBrOSTN07mys77WIaWMDncDJ8uPmz1/hz5w9S+O1TwvsLNK8luEU5KlyYQoycfPzsBDD1MhHasSEjblQo5BBIXCkEkE/L0DZc/7GKsRSGMfusRMMFS6g7MEkE/J/CSXP8AsstZSiM1pJRGrbi0WwMGCk/utuNwX95zsyAvr5jelYWoXBBw22M5IKoRhSDggfP0U4Vf9kmrikpGCQ8W0DaSD+725wT+752ZO718xfSsu8VlxtEkSjACkNlMDG0/LyVB2n3aiEdSoNXFspN8mCy4PBBKgZzju3TPy/7ma6bRmSGYbvsrMCMbvLIJ3cfhu+9/0yArntMRwwwJMA5wA/H8OOP+/f8AwLNdZZW0shUmOXk4PzSfMSdm37w6nEH0G6prMKr0sa1vJG04MPlqcqUaVYyAQSQW+U8Bss//AEz2VuwskSIYGijZQpUzKuY9uSpfEX8GWd/UMlZdqj54kadyQu19wEhLbQpzJ0dh5R9EQHvWjHGZTuHlz7sYEjACQk4XdmXo7Aq3oka1y6dTzqji3qOhkMLq0SS24UAAsCTFtBKlsRc+WCS3qZF9K3tLlmjVVVp7RUX5QRITbhRgZ/d8+UrbT6tIPSsSD7P8pEiMzBNjTmPD5J2F8ydGIYyeypWrZSWqiMwm2IO3Y0/lc9Shf5j/ALTSe+yrRz1oxa/r+vvNmISIVDRXNuqjqDMTCANuBgDJjUiP3MhPaptrovLT24Xdnb5h8sABWA+YZ2ZEQx13k1kxz2qmNo/LjVQCpmER24BKF+DyBuaT/aZKuadPGTH5TRxbQCN4QmPAIXd+7PKKTv8A9t1qjhnTktf6/X9fQ8z+NXhA6jost4Yo0uLRHLEEZMakBly0nPlNtjQAcgsa+XpY2ikeNsblODg5r7n1NHW0AhEtrJFho5SGPklVKqSBHzsUlCOcvIPSvkr4o6CdI11p4beSC1uGbbE4f9w4+9CSwBZkyATXt5TiNXRl8jxs1wzlBVu35f1/SOKooor3D54K3vDtuufMfae/JXnsByRwTwfasNFLuqgZJOMV1Vq62scMbybGbIAO4bjjB7eny/WubEyajyrqexk9GMqvtJ7RNSLa7Lgq2Om8qMnOBn5+5+U/7IBp6hdox5bDIxuK884Gfn7nIP8AsgGoI2kOPld89fvc5+X+73HyfXmpVMpIyJDnPHz85+Uj7vfGz6jNeW7n2Ct/X9f13ACPaPLKOcjb5hUbs9N3z8ZOQ30Wq7lf4NrZxjdt+b0z83fnPuBU8rSvjPmS7s5wH/eZ4Pb+LG36rVY72B3b2LH/AGvnz+H8WP8Ax2mhSt/X9f5kLsvYg56bsc+mfm7jk+9Rkg45Xp6j0+vpz/vVK4ds5LyZ9N3z559P4sZ/4DUDhjkncff5uc8+nf734VtE5puwwsueuQR7f4+nP1pyt1+6BznGPTnHPpyPfNMyeuSfz+v/ANlSB3GNu8Y5BBPGOc/h978auxz81v6/r+uhZbGMuYxychNvHrjn6Y/GpYoi7kAJn/gOOvb8f/Hc1Jo1tcXM+A0sKLlmcBm8sL1bg87dw/77r1TTPCr2tks00cyFMhhtm/d7SFccSc+WzCD3WUt2rmq1eTQHXUdzhdG0V5nRnFuvIwZCm0HdwWyPuhvmb/pnz0rs9I8N6cjRefJFGzKDH5kkO1TkhPMynRTv8z2aI11C28iwrEltMP4SrSTYJz5Ww/vv73+iH/Yw3SsLxJLPBCHFzc3BfqkjyAShiUAY+dx5jKYW9BCrd645SdR2Zg8Q5MfJZW2lTxS2htUiULtF0ISUXaVUSfuvvKpdZP8AbeI1JoOtWU8k0KqqptPykQq+3btKEiL7zRARj/ptz3rkk1q91EBZJpJkfCkySv8Avy/dszceZtJb0MSetYeqamtnKzWlzIN4DFwSGcfeVz+9PzEfvcdpBirhQbeu5FSceWz3PSfEGq2w8xm2XAb7/k7B5gZQrAfuONyAQj0mVj71yV94gS6eQXDpOjM4dYQqmTcAHC4h43hUC+jRv61w9x4kmkjKZ3DJO4l8j6fP6/vP98msxr1n9E7/AC9vpz26j3JrshhLbnNGcTT1qVZbqWQHzGdtzSKCA5PVgNgwGPzAdgDVGCZ0OQxB65/X0/4FVXdk/MR+GP8AH8vxpR/wH9P89f0rpVNJWN41mndG7ZX8ibfnZcYwQT8uDkHp/CSW/GtmC9Z4xtaSEryCGc+WB0P/AADJPvv9q5O1Us4ACk+vGB7n29fataa1nscCeIwtwcSpgg9QDke+T7Fa5atKNz2sNiZNe8dRb3REY/eyxbRjgufLA4OPm52Z2j1Eh9KmAYgB1MYGcgMx24O0gZf+EkRD1Via4+C4KEbdowQRlQcY6Z+Xtk5+orQgutuMKUxjqBxgYGfk7AlT7sDXJOg1sehCtGRuu/lnliM/wseDg7SP9Z/e/df7gzUBuhu48tycYEhGDzjB+foTlT/sKKoy3TONoz/u8+m3H3ey/u/rzT7OOWRhuikkz/CNw3Z+XHA/i/1f1Gaz5LK7N4svRyCXG0o2MY8zb83XG75u/O72CVE4DkbCu3jBk2Zxjgt74zu99ta1pE3P+slB6j94vnbjjHt5hGz28vPepXtnllQIXuBKPlZt6+du6E5bjftJ9vLHrWLmky4yVyppsKnZtEePVgmRxjn5T0XIP+2Vrr7GGKG3QquzqPmVcj5duP8AV9dh8v8A66tWTZQMFjKOXBxs3EjzM5ZSf3gxuAMh9GQDvW3YsssKhp/M3YILsBn5d4Y5l6lcyn/poFFYzlcyqyT3NC2ctFIrL5gOVMca4JBAQgYi6suIR/thjWrFJKyOpimlL5DBN48wthGUYj48zAhHoUY96yBDEkQLvEnuGTIG3dx+8PIQ7x/01apRJEgbmMKMghTFkDaM7fmPIUjb/wBNWasmjmlGMtjaeOe4Th5rhn44WUecWO04+UY80rsHoIye9Ojkui0alZrp5OckyqJ95+ox5xXn0EXvVWJ4mVjKLZsZyIVhyeAGCcH+HCp/t76lEEDyEyRpITuDiEJhs4DBMR/xYVE91ekkZWtp/X9fcaoLThNsktxvAx5pcCYtyu7Mgx5pBZvQRr61PZk7UKMJiwBVpGx5ucspfMvG/DSN6FVqCP59wKx3G5SHWFRibccNtxF0kICp6BGqWaRiGzHJMXU5CBwJyxGcYj4EjKMeixn1pOVtTllzbf1+n6EdzNFJs2yqxfaVNwYyGyCyl8yfxDdI+f4gleT/ABg0e1uNFaeDymB2hyPJEgOCYnOAWB2ljKc/eK16Nc308jqBJLclz281ROWOT/CMCVl3+yx471lavZ3mqWTjy57lnUhVYyhbrfltp+YYE2DIfQIB3rShWdOopBUw/PScZ/1/X9XPkYjBIPUUlaviSxSw1aaOGVprdjvilZdpdT0JXJx9Cayq+2hJTipLqfBVabpzcH0LulxebdqOOPUjH610yxROQdsRC/c37M9OCefTr/tYrI8PRE73Cs2eNo3Deey5H5/hXQx+Y5P+slz05cb88+vfG/8A4DXBiZ+/bsfVZPh1GgpPqEaw4GSmCP8AY9Pr/d/8fp5WLOB5WMdf3efu/wA9v/j9WFWQA/NMQQMf6z5s/MO/fHmf8BxTWaQchpWyM5y4/wBoHr3/ANb9eK476ntcuhSkEZPzFDnP3dnpzj8MY/2s1Eypg7jGOTnbs/HH4Yx77qsySuCuHkUAcYL8fxcc/wDbT6nFVy7ADLOMc5Bb5cc+vbO7/gRrRGUkVpSBncE6nOzb+OP0x+NQsQck7ffGPxx/T2zVl+nO6MA9snbj8f4c/wDj1V5crnllx9eMfj2/rWsTlqpogcjPO38Mfpx6/pVnT7V7iZFQKMn7zAbV9zweB1P+zVcKzOByD069O3r2yB9DXqfw90WFkDS4kZsALIdqn5wmCRMOGkPkN/sHdwOaK1RQjocMp8t2xPDulRWluJFWGKVdrILkRsFIzsLgwnhMs0n+w8ZrpYLiRo0hMUcEKbQonjT92FUqok/cclVLJJ/tyRGtK6gSFj5SpcBsbFnlIEpYmMK2bno7qYX9EiRuhrjdd8SxwzYErTKwBXzCf34OcF/9I6yFTv8AQwxnvXHyuW25y86buy9q+oW9lahY4GXjhXCbgNuzB/cdRHmFv+mxVutcZrGt/a5GSYxugUl9oVd3yhSoIhGCUCx/9dFY96zNa8QC8fZBK8/XDzEqXH95synlv9Y3+2orBBVwpmf5Ty7BlLYxk9W64+Yf7RIrop4dLWRLqdibUbqW4Z3b5wSSzquFct1I+QYztAHoVPrWVJKWJJOSe/rzn09eaZcXQcbVAVck/KMf1/H6k1FuB9P0rvhTsjllWvoiTB/z/n8afGSO5Hvzx/8Aq61ECD6fp/n/AOtTsgf3f0/z/wDWqmhRlZ3LSkgdSPz4/wD1f1qaMMT0Ix168dvX8KpxN0HA+uP8P88VZhIHbHpnt+n4fWspKx30Zp2PQfhdo8eq62kM6K4JUAOCcksFVD84+VmxG3opz71ufGi1+xarHCsjS4yA7uSZCG2FmzIcEMpi/wByNTW/+z7oB1AS3LN5UaNtOV5CkbWP+rwQy5h4OQx3AZFcd8Yb2S78XXYkVmKttIwR0AQJ/q15VQIj/tIT3rzbOVW53Qm3Vstkv6/r/hzh4nJI5Bz/AHj1+vPfv9BWhH5eBtIJOMb9vPHGfm7jJPuFrNhDM4GGYk9Bn5s9unfp+FblpG8yAJvlZzwAHAcnn/x/GfbZ71pVdj1cO7/1/X6jYwnBzGRjvtz069euOf8AfxWha+S7AbV2kc7Qmenbjrt4H/TQ1XlSRcEb2DY+Y7huz8wP3v4sF/Yrin20xVhtlcYG4H5hj+LP3/8Atp/vcVyy1R3QN6NYdr5ELFgQQgjyRjDBRs6kYVf9sNVgQeYv+q84vkHyVH7zOMhcR/xYAX/ceqdokjx5LlAvO4PyoA3EjMn8KnzB/tMRWnA8alvNcwqgO4RMvyYALbP3vVQQV/2neuKVkXexZRHOAUMhcHdsU/vcnJ2/uujlQy+ixsO9W7R7jchxJPuOflV1EmTvyMR9GYecP9lMd6qySxhmWU267QwZYjGduMbgnzn7vyhPZnpnnQJnzBCDyG8nyzzkbtvPTdgL/sb6ysWlc6azupggOblTnIf97g8+YD0HfNx+AWraTS5yss4C85Jl+THz5+8Pugmf3Lbe1ctDLEX6W5Ynk4j2n5snHynjfyP+mQNaMUkTYZFhYgjaVVMfe3DpH035k/65ACpkrGUqR1ULPEDuM1uq87g0hMe0bsjMnPlqfNHqz47VMbpYnk8yV4doOQjE+TtGW2/vf+WakMvq0jelc19t8lT5QEZGCpYA4wSyk/uuzZlP+wVFNF7M8gEIeMKBglSfLC/Muf3f8BJkPqGArJpmfsJPV/1/Xz9TprrUo7dGMgiiCghhCykx4HzBP3v8AICf7TtWXeXyyswby4+G3LEY8DoGCfOenyqn1ei2gkRQzLPa7APvLKfK25Iz8oz5QJc+vmAdqtwwunCm4txGPSUmDaPqMmINn3MntUNvYUYxh/X9fqVLe1jclrpbR+odYPKOeQGCcHqdqp/sh602t4ZFZSkTFgwcQLFh8kbgn7s43EAJ/sq9SrHJDgSC4swnGFaUmEKOcfvBkxBgB6mQ+lXoI2RSrO8IUNuAZj5O3AYL++5MYIVfXe1VHUxqVE9f6/r0Pm340aNNb6mb07GZ3Jn8pCFLH/lquEUCNyML/umvMa+jvjppIn0gyOkUdwisybWQAlMeZGSZG+WMYCepZq+cq+uyypz0Eux8XnFJQr862aOh0hVS1+bGCOnGcd+o69MfjWiDHlt4U+uzaM+uPl9cY9s1TsgUtgeVx1YE8Y6/xfw54+tW1Yr1Zkx1wT8uPT5u2ePqazqO8mz6PCR5KUY+RZDLg7vLPrtC885OPl7nBH+yCKbKy7jnYT6qFwecnHy+vI/2cims5QHjYRwSCflxxx8/8PQexNNZzgkkr2wCeMccfN2yAPYmsbHZdjHYZ6J+AX1z/d9ef93ioyy8YC/kOOf9315+lK7YPpj36dv73b7v0NRlgeM4x2z+H97/AID9K0SRjJsQkDG0BcdMgcfX5e3OfYiouPUL0wWHT6/L27/UU/APcH6kfQfxdzwfYCo3I46HPTJHP1+bv0PsBWisctRuxd02IPdqIhsOQAWBOztziM9M7T7spr2Pw/o91HZo8pzGwAEYicNjb5ZBP2fqFP2Y/wDTVg3WvHNDdDqUYUxuWb5RMVCse27LjGeSfdVr2bTbmBLKHNxAylQQTJBkhlJUtmbgsgaRvSdUrCqveseRVbuN8UCcWzbopZS2QVVZB5m5RGR/qBjcoFt7SIW715D4jNxczNtLyfMdxVGw7NgZHyDG7aFA9Yz616Tq+oafMxjeVWQjcxXyM7SmeP3h+by/n/6+Ca861+W2VjHB5J5JYqsROSBnBBPG3aR/tl6dFWkTe6sZum2U1y5SNZJnkOMIr/N34wvfBceyGoNfkS3jWCJizOAzN84+XqOGA4Y4kHpuxWlpbQ20cjzhCCCG2eWTjgnZkdc7dvtvrmb1jPeSyOEDMxYhAAoOewHAHp7V1UlzTbeyM8SnCHKupVGalUH3H9KesY/z/n/Ipwj/AA+v/wCr/PFdTkckKTGcgdxS5P8An/8AX+FPK+2Pr2/SmgHOMH6f5H4VNzTlsPQ/5Pf9asRNnGDn69/1qGND6H/P4fhV6whknuY4o1eR3YAKoOWJ/wAf6VnN2Vztw8G2j6M+DWpw+HfAl5cTG2aWRhtErx4ZyhZVY7/ubcsQcYkx3rwrxHfrf6zc3CuzI7ZVmxuI7FuT8xHJ/wBsmvXda03UNP8AANrIkdxNbPGAOZVDq53A9ekxAm/2TFt714lMzyTyO8jOzEsXOcsTzn8fvV59CTnq0ejGKUnJdRYyu/5sY74x+n9PfNalvInIdVYHIYIFyfUL8vfjH0asuMEHOSMd+eO/r26/jVqOTZghihHoT8v057dR9TWlRXPQoNpal+ecMDwhJznaq4yTk4+XoTgj0ANNtnxLu+U9+F75zn7vr830GKqlyx5OMds9Ppz26D6mpYl3HHA+hH09fXj6ZrFxSR6EG7nV6RdgQbFBSQMD5uCQFB3DgR/wtmU+q8Vsh7i3X5HmhCc8rJ+62/MCfk52bjJ7iQDtXMadCseHPlFwQcMUKnnHc9N3X/YzXQ2jRyY2/ZRjGPMEWM54LcHjdkt/0zC15tZJPQ6Ui7bJKUD4ng2Dhh5pMIUcntnyw2ffzPapbi2ljClmltRGDuC+YTFtABUfPz5e4IPXzCe1FpBGV3QqihcbWkWPCkZKlvk6Kcs/+yUq5b2ykAIyRBVG0yopMeAdpbEX8GSX/wB9K5nfcu7TuUFhnDYZ5FCk7lDN+7x8pA/ec7SREPVWJq/FHKqMJnKDPKh899mBmX+9iL/cyanh0543XETxBf7yNmIAYG791yUU7G/2nBrSgtHjACJLbBP4WWQmMAbMH931UHyT/tPntUtsJTRniNWOHkRyTjDMmD823/np0L/If+mYq7bxQFsx+Q2cAbzFz82Bu+Y9Xzu/6ZqKvR2c5X5452wTuCrLx/AR90dOIPqd1WokmQ7SJxuPI/e/Nn5D3H3jiD8N1ZNmbqaf1/X9bFaKGJioRoWbK7TN5RB5O0vwf4sl/wDpmFrVtLWECNYxbD7pRpBEehJUv+7PQ7nf/Z2VNZpLKcHzZmYYwTJh8nZjmT+JgIfZVzWmIpPV5C3d2YeaWO3nMvG9h5Z9FQHvTSOStWS0f9f195BBZxKA0arFhV8syKh2YyVLfueduSz/AO8lXba1kQKYwUCBWTK8xbRld37nkoCWb1LrT1lBXCSrOSBgysP3hJwM5m/jYEN/soKmSeLKEtFISF2lyh3kk7d+ZT94glvZVrRROCc7/wBf1+JzPxD0wXPhq5RoZ44hDl1xKfKVBlXOIwcQgl2H8RbHavjO8i8i7miJJ2OVyQRnnrivuDxGILjTZEia2Y7V8szmEqzZ+TzMsflJy0n+yFr4y8T2yxeIL9I0ZVEp6469yMDGPTHbFe7lErOUTw83puUIyNe3QC3XA24x1H3cdM/J/DklvUEUoXb0ITBGNw+7j1+Xt3+oogdPKXB3DjG7HzZ6Z+f+I8H2AoDKxGNrcjG7Hzemfm7nIPsBWz3PbhpFWHlQAMApj+8D8uOmfk7Z5+oph4HXbjGMg/Lj1+Xt0P1FKTHxtYNyMb9vPpn5u/OfoKjwpOFKEcYLFRn0zz35z9BSsXztCMCR91hgdweO3Py9un1NIEIOPm+mD9P7v/AfrSnZj5SGzjG7bz6Z59M598VGMdtuO2Svp9fT9cVSM2x7r0+83rjdz2/u9/u/UVBKWxjLH8+c8enfp+FSEL32njtt9P8AD/x6omCn+7/476f4frVxMajurFdZJEf5Sxz1HI3f/rx+lb8Piq/RQBPOVYEOvmv8+4hmP/AnVX+qVgyRg9QP+A4/z9PfNQ7c9h+GP04/L8a0cIy1Z5001ozrv7cnljZzdTtIQWPzS9c789f72Z/qMVjEvPOrO0gAyd+XJUfeJ+92z5mPViKytrAnhT+AI9fT8fpmrkMpjVSFCsMEEqCOuR/B6/N/u8VPs+VaGMVaV7GzqQNrEBl4XHVVL/uiByAfM52Agj18w+lcowy54x7Dt+v4VeuJZJFUAbVUAAFRwBk9Qo6ZJ+hHpVXynH8LD8On6f5zVUo8i1YVE57oaBgf/X/+v+H0oz6c/Xv+v+cCn7GA6Efn9PT8KMMeME+3PP6d+n4VrcXL0I1TceCPxI/Xn86kWNeP/rf5/wDr1PAjNgBS2eO/zZ/x/pVyK2kYjG5s+x5zz+uM/hWcqljoo4Tn1RSjiz0Ax+H+en6103grS7a81uFb51W3U75FSRVeQDGVjyD8x42j2aqUVs2QQGIxndz0xuz19Pn+vFbVjby2TJOJJLeSM7g8bfNGQNxI+fqqkMPUsR2rkrVrxaR6lHBKJ7H8V9Tt4PB1npEZtJlVWD/Z/LIcnl2QBMBWJXyyOySCvn2eEKSAVY56r0PuPl6E8j2rrNW1C4vIwLmeTEahAgcsIlX+FcydEDDb/vtXPXMIBJYIpBIIVgcY6gfMeBwB7ZrGjPudFLB+zjYoKuP8f8j8fpUiDHT5fqDx+nbr+NKVUenuOMfz9ePpUttGGkUZTORjdjHXv7Z6+1bylpcuFN3sTQW7kZIcY/2W+XHfp2z/AOPCtqys5IzkrLDjOTh/lxwen93IT/gftTLaOFTHt8rPGN+wgem7j1yW9ttalqkY2mERoBjBlCHAGcbvk7And7slcNWo2epThyouxxSxKATINpwUJk+Uj5SPvc4JEP0bNXbYPHIw8tm3HG0s4BJOzaf3nQt+5P8AsjNQQxKFjUbFxjG5V+TjA3fuuqqSrf7bKal2BQB5bLk7dpHIG3bj/VdQv7o/7ZzXE9SrG3Y5kyodpC2ABIxAcs20A5m6Ow8tv9hAa07eHGGHkzblXb5zriTJIXd++6OQwf2RKwoLiZnfzN0m7IIAYbgRsI4i/iAEPswJrbS6d1bfHLMXBU7fMHm7sKQPkGPM2iP2MZPespXSIlGXQtW6xyNEEeNxwVM5j+bOdpkzJ3wzP7qlXYBAFTyvsxXA2tOYc8g7S/J/h3M/+3sqCO7mYcNNcM45H71fP3fgMeaVx7eV70q308mD+8uzJzuJlXzSxyP4hgSldx9PLA71kQ1J/wBf1+hbVbYopCwg8bSfKyo28buD0TO7/pqVqxDFbnBVYkx6iPj5cf8APM/wfL/11NULa+kcA+dLIXOckyfvS2WBOZB9/BlPoUA71chvN6KUfzA2NrOxBbI3DOZu4zMf9sAUiJJr+v6/yLwgjU8qpznIjUZHy7TjEP8AdxH/ANdCTVyNnIOVY5zlUQ85AVgMQ9xiIf7YJrDGoRl0QSEE4wxYdxuB5m7rmU/9NMCtCG4hwCXiGPUx5Hy57y9Qnz/9dDVI56lPTX+v6+40Nksm7cks6nO7Ysg37sKwGIhjdgRD0Kk1fiEh5f7Q/wDe2iUCXd8pH3RjeQIx6bCe9ZYltMZkEKe6eTkDb2+Y9E5H/TRjVqI2pDZ+zDnJA8nI4528H+HAX/poWrSNkclSOmn9f15fcWtUilns7lWSa7MiFSpMy+fuONvUYEpHl+wTPevkjxnp0tx4p1KRDNcjzSpeTIKkcFOXJwpBUHuFFfWWoRwPa3HmJEVKMGEHl9MAMFxH124Rf9vNfNHjGCN/Et8Z1SVwwUeSQAihQFQ4h+8oAVv9pTXoYCfLJ2OGrBONpHGxszIDlnJ6kA/Nnj0/i+79RTlDejMD/vfNnj074x+FV4tuwbtnfO3b6c4/Dp71IQmBu29842+nOPw6e+a9Ro3jJtE5Z3H8b7jz9758/h/FjH/AaMuQeHfJ/wBv58//ABWP/HaiIXHzbOp3bQv44/DGPfNGF5yFPXONvPrjj6Y/GpsXzNkzO7Agl5cn/b+bPP8A49jP/AaYXYEnDNnuSw3Z5z17/e/Co2xznYck52hefXHH0x+NI2MnhSe+Mc/Tj8vbNCQOXckaRj0Zzxxy319f+B/WoznOefrk/X1/4F9aacZ6KfoB9fT15+lGAf8A635+n4/SqSsQ2n/X9f10HqxwAWZfoTx3/vduo9yaRIBzklcHnHbHXHzdsjH1NPiXBBHBHfHTHP8Ad7dfoat2tu7MDhkAP3irHZjufl/hzk/7wqZS5TSNGMt/6/r5DGtlEbbwqkZyFIwMHB/j7EhR6qxPaq8kChjyMjjGRjrjH3+mfl/3ea6CRDHHtRZIMdQ287MDAB+TqgO0+u8HtVOSGXPCyAAY2kPxxtx93t/q/qc1lGqynhI9v6/r0MfyuF/1Zz0yy+uOfm9eD7YpNq44wfrj8M8/XP4VqmCXeB5cjZ4x84z/AA46d8eX+GaryI4xhmfJ/wBobs/44x/wGtFUuL6vYzzEp9PbOP8APT9cUogTuB9BjP8AnH61b5JOSzZ7nPzZ59e/X8KBxzkj3yfrnr/wL61XOxLDR3H2sMS8Mu4nrjbyO+OOp4A981pwwpJgsEcEnIjUZY9wvydzgr7K1ZyNtxyRj0P3e/Hzduo9zV+2uBGPnwo5GV5KepHz9Vz8v+81c9S+53UqaSsv6/rzLgjSMhioZ853IODznI/d9C3zj/YBFXbZsrlf3e3BVmUnbg7gTiLnaSZT6qwHastpVcneVXn7qkYXnGB8/QHCj/ZJqzA6KOPJJGOHKEH5sc/N/e+U/wDTMVztaG/ITzb0A274wmMZR/3e3kE/JzsyXPqHHpWbeRMq48qSIA4wd3y47cj+HOPfdV8SwNjcIQ2RjcIsE5O3d7bs7v8AYC1Rdod4EW3GRtMgT8N3H1z7bacNGOJReNl67lxxg547H8vu1YseGI2kk8AZYe2Ovf7n05prqD90KAOmQMgds8fgfciowuD93H+cenpx9a2eqsUopO5rpM6kZZm3dQWb5u2D8/8AERsPsoNWY78Ivyt5mf75bD/X5/4sYP8AuLWMMlcH9B14x/d7/d+tOCu3Ytn0BGc/h3xj8KwdNPc6oWZ1cN2DGrM+9mwfnYHdnkFv3n8WCzejKtMa/iODv3Z6F9uTxwT8/UjLH/bxXNpLIuQGbBz0zzn8O+B+VOaWRiSWLE89Tz3/AF6/hWXsdTaMUdPBqNuykkRD6BAenXr128/9dDT5NVhVCMLz12iPjIwcf8Bxj/b3VyyyOpyGYfiee/8A9enB2JyWb8Sfr6/jU+wVzVRidhba3E0bCQR7SDuCLGDjHzBfl4JAAX0O71qw+rQOSJFRiwIbygg3ZxuC4TvhQvphq4hZCo4JU+oPT9e3X8acszAjDspHoen69v61Dw66Gns4dj0SDUUT5mZJBzu2gfPkgkD93/EwBX0CtVyHV0kPI84knOzKiTJ3HGIv4mAceiqRXmwvHC4zgex6fTnt2+ppUu2Xjdj6H+XP4D2zWbwxLw8GesWt4ZAGSR5Dkn5RIPMJO7jEf8TDzR6BcVbj1KXcMidySDkGYbud+eg6n99+GK8ng1V41wwjK89FXIz6fyHtmpzqgZidqepwqdc5OOOmcAf7ORUOg0zN4KL6ntdjfSsU2yTjkEZM3++D1HvP9eK1oJJ2UHMuSQQcy9hvHWQdFzN9TivFdH17y51Mvkbe/wAkY/i3f3T/ABYP+6CK7rTvEFpLIP8AVMT12mP5vm3HGIj1f5/9wYrOSlHc8zFZfOOsf6/r+mdzMzCCTEkkeefvN8oC788zdVX97/vHHWvm/wAU+Y2v3jxxweW7B0bzFDSKVBEjjzuHYEMw/vMa90OqLJauIz53OVRM5f5twAxD3b97/uDHSvmzxbdRyeJNQkbT7m8d5S7XUUrKlwx5MijYMKxJYDHAIrvy5c8meBioyopc/wDX9f030w7It5KY3Lgdt3y45/8AHfvfjVkbsAksuP8Ae4xz69vvfjWbpTq0CD5cjHJ2/h27Hk+1aChfl+4PTO3jnjPy9jyf9nFetUVpMrDVFKnF+X9f1+AuSpHDJ16bvlxzx83b7w+tISR1LLg9iflx6fN26j6mhQvBACY6bgOO4z8vY8n2IpCpAGAFx6jO3Hr8vbqfYioOjQY5wTnKYP8ACSduPT5u3b6moiccE7ceh6f+Pdu31NSkbQMApj+8Pu46Z+Xt1P1FNVG7Arj2Py/p2z+tWiGk9v6/r5Ef1wD7Hp+v4fSpIo9xGSB+I9cevrx9KswwEclWXHc7vl7enbO36mr8MJBx864GCuH4/h/u9v8AV/U5qJVLbGsMOnq/6/r+mVILUbd2YccfedPXA/i/vcH/AGeasxCNQu1o88Y3bMHnjd83TOQf9kLWhGsm3aRKOvB83v8AL6d/9T+tJ5MpZQvmygnG3Eg35+UDr/ER5f8AwDNc7qX3OmMFEpp5RHyGLkjaZfL98bv13f8AAaQrHngRgYGMhM4xxnjrjOf9rFXUtZpVGPMnLHjO8b88Dq3G8gg+nlj1pywseMu4bBDHcN+eQT8/8QBc+hQVPOjeMLorLBE4wVXp22ZPHT7vXb8v+/UctuCvIjbk5CbeemcfJ34A9w1akaGNc+ZIRwd2SMjG8H/Wf3f3v+9xUFyxXOfkGckq3IAGeP3nUAhx/tMRUqepXszN+xh92BvbP8A4b6fL36j2U037IwPH1yAcHvn7vT+L/dq/vSMfMQh5zsYHbjrt+ftkbf8AealWSNm+YRj2G3A56fe6Zwv+5mq9oylRRn/ZmGMKw49G47/3f+B/Q0KjIRgMmO5B+XHOenbOfo1ajRwydPKB7AGMDr9f73H+5TfsUe4bGiHIxvZMDnAz7ZyT/sYNHtL7j9nYrR7lXALoAenzHbjj0/hzt/4FWrCHEGXWUcccycfwHv8A9sfoc1VjtF3rs8oYxjeU4HON3y9ud31SrT2yhMLHjGM7gpI4wM/u+y/I3+2RWU2mUVJi2TnfzkBSX5/hx97vjy/ouaouGZgSzSEnguSN2eOfm7kYPsorQa3ZSV8sjttK8jjbj7nXHyf7/NRvAxPzxs5I6AEbs8Y+53+59QaqMrDcblZB8uRht2OWPXPTPzd8En3AoSEPkhgc4wWZRnIyM/N6Ak++KtCJiANjuW64DDfn0+X+LGB6bDUuZmIALyL1HDjfuOc9P4iM/wDAaHNmkYJ/1/X6kMNmrkEsm0/7SA9M+vXb/wCPcVaFpCAdxGMc7dnpk499uMf7eRWlbs/kggyE+o8znPzfrgy/8BxTwHfBEsnPO4eZ/v5+96Zm+vFYOq2zRRsc/cW4VjjYfXaQfywPoB7g1DsPcA/Qdfpx/nmunNmz7jIGUdTjcdoA3EjL/wAKnzB6liKjl05EY+ZmMIDvC4OzABbHz87QVI9dx9Karo1VjnAPb/P5f5FPGf8A9X/6vx+latxp2zqUXBbcFZOCPvAfN2yAPUE1TmtTFkErkZBAZT04Pf16e1aKpGRpFdiuM+hx/n2/GlAPuPz4/wA9acIxnt+Y/wA9f0qaCDzCR8vHuOf8nk+1DkkWkyEZHYj8/wDPFLkj1X86stZkdMDpySP8Px+mKheAqeg/z+H40lJMtDVJ9x+f+PanbiM8n9eP1pNhXqCPqOn6UgBzxx/n6UFokVypByR9D/8AX/CrEF9LE2VkYY9GP0/vfh9Kqtx2xj/PpSDd2yPz4/SpcU9xux1Frr5S1mN04SHYd7RYLqv+xmQfN0Uf7JNeNa7dvPrF3KwSIvIT5cHEa+y4PQdq7a/nkgtyULI45DfN8hH8XTsOPxrzeU7pXYdCSa9HLKKi5SPg+LqijKEY7mvoUh5j5POAMnqe3Ufe6H2raXLBQBuz0JJ5ycf3+5+U/wCyAa5jSpNl0ARkMMEdyO4HB5PQV0wBbGAWBB+6DzkY4+TuPkH+0Ca6MRFqdzgyuqpUEn0AFTt2tvyeN3G7PAz8/c8H2ApvGBgqc9N2OeeM/N3PB9gKeFdmBIaUHJ+UMN2eOPk742j3Bpyq+B95s+m7588f3f4vu/VTXO2etBJ/1/X9dSJY0ONpUnjG8qM+mfm+ufbFOSNeNpjPTG4r+Gefrn8KsASMf+WkwY9t48zPHp/Fjb/wGpUR2XG2STcR/f8Anz/8Xj8NlS5m0aa6f1/XzII1jxlCmeNu/Z+Gfwzn3xVqIIVwDD0GNwjz04z/AMBzn/bxTkR3bCGSbccAHePMzyO/8WN3/AatRq2QcSSbsYyXG8HkZ+f+LG/6qBWUpnRGHYhSOHdjC7cd9men+7128f8AXSr0UUZGMRtkHIRUyQRggfJ1K4Qf9NM0sPJ3LJIxPIJ3AtxuB/1ncZl/3gBVxc/eLMo67wxyBjfkfveoX98P9s4rJyKcSM2sbuwdFlzksIQo35xkJiL+IBVX/aV6sLbF+qiQHOQi/wCsJOTtxFxvIDL7RuKN8ak75WiK8/u2zsAGTt/e9VUh1/23YVaTyxu3NEgAO8IyfJjG4JmX+HKhPUPJWLY1oV5bWfaG/wBazZ+ZEbDZO/I/ddGI80f7CkVRkt5Ad3lyIB/GVfAx82fudsmX/dYCt/y4iuJjboQTuERhIXDAMF+foG2qv/TMvVaeO23cfZw+eM+Ttzu78/d38f8AXEClGRpCbObuIpEGAJI1X+Eq/wAmOcdP4Qd3/AqgCyRsQUkUjjnd8uOMfhnb/wACraubaErmIwDpjeYs4ycbsDs24t/sbKzjbqfuhUAxgvt+X03fL2GQ3uVraMjoi7kltJLvAXzFPcBn/wB319/L+hzV13nD7WDPk4KszjPOwj7/AH/1R/2Rmq1moibICpjpvVTjjHOUPQEqf9oqasSfvXwY88AYUAHGNuOI+u393/v81D3Lsn0JYpGZ8/M5bs7EB8nAB/efxEYPtGp70C4EjL+9abd081sbs8jdmT+LBdvRlWo/Jc5/dyPnqoVvmzxjhP4sBB/tKahYysTkySluoUMN+484+XjcRkemw1Frj5E2WAY2w2UYHoZCmTkZBPz9SuWP/TTFVpvJYEkqBjjATOMf73Xbz/vk0NPI2S3mSFuc5cb8nOenG4jf/wABxSK0jKSXk+vz8/xf4yfpVK6KVOxVkCZ52Y5zt2enOPwxj/a3UIyFv3gjIyciMJz644+m3/gVSuH/ANoDrnLdMbvXsDv+pqIAgjcTGB1KknaAM8fN2ByPqau9yuSxrWtss7DIUjkkKFG7nJC4TucFf9lWq/aWuJRjY2D1RQQTnOR+76Fv3g/2FIqlaSGL5SxVVBL7T9zHXH7znbkAezNWml0q8P5cYBIbYQduCAQP3nQEhB/sM1cs7hJMvkeXhkjIIIKttOBglgf9V2Ymb/cIFVri48sgxMYtuCvDHZjJXP7vnaS0h9Q4HanSTxbDuMZIyCMpxg4IHz9A2EH/AEyzUOl2ouLosxteCCA5j27t2BnJ+7u+9/0zANZW7kxSSuy1BbzSEjy5rdYwMZWQ+UFHf5efLDZPr5g9Kt/2O5UGRJoAinOUmPk7eo9/LBC+/mZ7VdSC2jAaPyiRt2+aISCQTt38f3sl/wDY2GrNoYwB5a2ikbdpmWHjGdpf5D0yxf2KVN+xDqy3Rz02jyI+14pYtudwKyHy8cEdedpIj992e1RJprW8o8xHiOSMYc7cHaR9/sSI/oc1r3SgMohVEXgp5iRkrgELvxH2BO/3ZKSyscGJm2RkAY8xVG3Axz+6/hUlW/22WhSfc2VSVtSGLSmnU4BODyCTyc7ccyf3sRf7vNMudBU53Bd34c/NtGf3vd/kP+yM10pVVUbI27YwOV+XbziH+Ff3Z/22BpxinKsUWSMg9CrccbD/AMsv7uIf945qedmSrz/r+v67HCzaKjHEThjkbd5Qbudoz+8/vZB/2QDVK40famUZfbLIMgnAJ+b+8Dn2wa9DiiuUys0M7A5yAJBn+AjiPuMQ/wC9zU4s2k3FkuMH2m+bPykcL34h+ozVKtJGv1prf+v6/pHkFxbGLBypBAIyV/x/P8KhVVPdfbJX8M/1r1q90eS8SRVjuJvfbN85J2+gxuI8r225riJ9DuoLsI0E3zn5FKuN+Ttx17tlf+A5raGIvpLQ6KdeFQ4TxPIkVowBGCoz93PsPr61wldr8RSYrmOINI8eTtkYMvmEHDNgnggjb/wGuKr6TAK1FPufmfEuIVbGNLZD42KOrAkEHqOorqbOVJIFOQODkcccc9X7D5h/tE1ydbugzsQU3EEehPQcg8A8KfmrXExvG6OTKqqjU5H1NkBMYfyxjOdhTjjnHzdhgj/aJpCsWfm8vPOcbPTnHPpjH+1mp4mkUp/rYtvu/wAmOR2/hzv/ABxQ25QP9ahGf+enyY5/8d+//wACrzbs+rjEh/dch/LPJ3bNnpzj8MY981YiWNt27yyOdwUJz6hfl78bfo1MUshGfMhGecF/kxz6/wAOd3/Aqtwl41OTJEATkgufLx1x8/8ABnI/3zUyZtCLJ0SN928RyZyGEQQb8n5guI+rHBX2VqnEafMCocnrsA+fJBO393/EQGX/AGVYUxQUyXLQhc7ijE+Xt67f3nJTIC+u8+lSkBFYyt5YGdwQ52Y4YL+9/gJCr6hm9KwbOlX6jwHdhn94T3RPvZO44/dfxMPMH+ypFW41YbWAbOciTa2Bzvzjy/X99/ucVUBRQ28RJ1yIyh24IBx+87NhV/2C1SRvGGG4w5Bxj92VyGx/f6bsL/1zzWbSLNJfMQhleWDbgqSsh2Y+cE/u/wCAkze6uB2q5Ck8TlljngCDgkTHyAoyD93nywxb380elZMTRnobUnII3+VgndxnnpvyD/0yAq3CYGxsMG7jZ5ghxnJ2luOmdxf/AGNlZSiSaZeeIAYuLQJwF/fHyQo247Z8sN5Xv5ue1QyGYja/nHnHlEzYGPkK53duLf6HdUC+WoXyzAAAuzzliJUYIXzPk6gFt/u0dRNDGyABVC4+6VTcBtwAcR9QvyH/AKaMKixpGPcbIk7dFdyxx8xf5snZg5k/iI8k+yg1SkdpHwHaVmwBuZh5hJ4zmTjcQc+mxfWr6RfKcRscnBUAZII2kDEXUriL/rpk0k9oWDY/e7sgrGjfvM4BC4i434Cj3jb1q07GqaW5mr+8I2lZC2NplYDfnJBbMnG7BZvQqtMwu8MHByByWXkEZBPz9cZY/wC3itiG1kYtvR7nfk/Isiifd/dxHx5hHy+nln1pJBKE275Jd3IIEo8zJ3ZHyjhyPNHoEx3p85pGSeiKERhKjlQvOTmPdjGTj5uu3kf7ZNOmjhbIZYe+4ReX7bgn/ju3331aiZiQd0pGc+YfN5/i3dveb9KsEZDFhLb7R1BkJi2jcSPn/gB8wepcjtU82pp5mJHZpI7FwhHO4Rlfm6ZC8dzjb7Bqti2RRjMLN327TnnPHydC3zD/AGAauSExEndJDsBztLHytoGcfvOdgII9fMPpUfIz5q+TtyDtYny8cHH7z+HIUeqs1HPcq9ysYF7AE9SwAx1zn7nrl/8AcqsYnjJ2/LjoSpOMcg/c7ff/AN0irTShGw7YwcFVIIGDggfP2OE/3M0xpY24xEW6c7fX/e/vfL/uCmmaRuV7aR4G43R4OQcH5MdD93+HJJ9dwq7bzPCytGZIcdCdx8vHA/h/hBIPrvHpVCRYwwKlMds7PXjPPTOc/wCyBSRlQfl2Z4xv2/hu/XP/AAGm43LOntopWjDYlRB7SHYB8uO33ciL3357VtaUJY2IaKVTkqULS8fwFeGHXiA+3zVy2mXsSoq4iyMbdyR4zggbsqe27d/tbTXQ2SxOkax+Wo4wHEeQNuBu/d9QmUP/AE0Za45xaZzVou1mbcskjBv3ksuTghjKA2TsIOZP4mAgPsoaoXe4KnYplLcYd3HmEnbzmb+Nh5Z9AgPeozHyVKRjPYIo/h2kHEPXZ+7P/TU5pzAtkNE7Z4IAxkFQpHEPBKgRezgmp1OVRt/X9f10FjaSRky/nM2MCRsCYsSF3Zm4DkEN6eWtPI3RoI/KlB27WlZQX3Z2lszfx4LN6FVq1Gs0kUg2vcF+GWNXHmZwrAYh434EY9GQnvVi2sJ7tszRXEynOQolAl3cEDEfHmEBR6GM+tS2yufl3/r+vkNsbaORVKPG4ONvmPGN27JUtmX+IAs3o4Wte3tIGRB/o75AKGXycnI+Xd+87rlm/wCmmK0LO2dYwubibcOyzATbjzj5OPNIGPTyz61dijmcAlbi4LjIP78eduOc4xwJWG728vHergjhq4l/1/X+RhXNjYvHuUw9BjPkenGfm/u5J/6aYrHLWsSlQLcHtuEHAI7++zr/ANNTXdiOWdNu+4nJ+6P3483dz6jHmEGT2KY71i6lZsiPIiS3JccbvPHmlssM/PxvwZfYpjvUzsncKGKTfLL+v68/vKFlHZNFz5ByDyvkd15/h/ucD/pqaz9etLRLZpN9rGGzvZ/IAVduCf8AV8fIAme0tWPD9zLL5UCyTuzsMczfMOWH/LQdcGb6risz4u6zHpnh2QN5skYQPK0hmAlD5MUZxJkCTBlJ7MoB61dODqTUUTiq31dtv+v+AfNPi2+XUNfu5o02RbtkaFVUqgGFDBQBuwBk45OaxqfLI80rySszyOSzMxyST3JplfawgoRUV0PzutUdWpKb6sKsWUphuFbAPPQ9D9faq9FNq6sRCbhJSXQ7O1kibYUEWOMGTy/XjP8AwLr/ALOKkYx4Xb5XHTIj9eM8euSf9nFZGiXbOvlksxzjbubknjHH94fLWsXdlHLtn1L854/vd8bPoK8upDllZn2uGrKtTU4jImXcpUIuCMFgpxzxn5exyT7Yq9bkDaRsUjGCwU7cdCfk/h5J9mWqURJK9ZM/3ifmzxz83c/KfYVctm5HIbJGAx4fPQH5+jEYPsorGdjupNmhAGRP3a+VsIwXGfLxnBb93/Bk7vXetW4hImAgeILg5KufK2jjP7vnywSG9TIKr2pR9oBSQkjZ5u0CQnO3fmXo+Du9Nq1aTydqBTCynaV8zy/mznYX/ecbvmL+m1K5pWOhSH4kUfKs9vtHGfMPl7fl/uc+WD5Z9S4PapF831nXj7n73jHyY6D7ufJ/4FmoF+z5XY0LZC7DN5OOh2l+T1XcX/2tlIRAceX5GONu7yc42/Lnjrszu/6aFahotSNCNJc4EUxz/CTLgnOzH3u5xb/T5qvRLK5xvlmLYAUtKPMLHZtP7zjeR5R9BGD3rItzEGyETGMniPONuMfcPOz5P+uprRiKkFWEbhsgrGF3MCoUgYh6soEY/wCmgY1nK/QTNGOOSbBUvdFwNplZ188tnbuzNx5hVt3p5S+tQ+Udq+XMzhgCrM2C+QWBOZuNwDSn0dFHehsuG3xtcB9wfyhjzd2AwXEHG/aqr6GN/WnvJNIclnmLZJ2I480swY4xD0dlDr6CNh3rPUI3uUshQMy5B5DMy5wV3Bv9b125l/66YFPeSII5kMSIAcmJo9wAAJ2/vD8wUhl/22ercZml28TSlju3qJRvyd+4fu+jMPPH+yhWpNshJZDcW4UhvNxMQmMvvxtGduTP7h9vai5rzaGY3kMJBI0SkA7xEYcDGN4j+Y9Bt2f7ReorlYsMGNmSN2fL8rnkbgnB742f7IetOVJIwVDXFuqdv3x8jaN3qM+WD5o9fMx2qjKroTuSW32AjgyEwhRzjL/8swwx6+YfSmnc0g3coBF34KxMwJ5QJtPOcj5em75h/wBMwa0LNUXaUMSMNu1mVSFwSQT+7/hbLn/YIqNEbcFZnj2EgoGYhcYUj/WfwkiMequT2rVtrUAYdUY56MwxndtxzN0L/uj/ANMxmplJGzkktSvMgCgxYQqBtJH+rxkqT+6/hJZ29VdfSsu7xEu2OKSHaBgNklMDjPyD7gJz67x6VvzQoSRiEtkBdzJhju2jP73oXBRv+maqaybyGAMrI6OMAqZDH8xJIXd8x6kNu/2QhpRaNKclcyhuOBlkAHQhjtwMc8dgdv8AwLNWI7V2UErIO2MPx/Cfy4j/ABzT1ghcfuTH0G3zDGOP4S3/AI9u99tQqiqVUAAcY3beOO/HXHB/2iK0fkdSkSSWjkcCQ5/hO/nnbjr3P7v8M1TlSRTgh3LH+IsM5OP73cjb/wABrctoEeLaQnJ9Ez0x/c/u/L/10IqG+sdyMxjJPQgAA9MYGI/TCf7+aSnZ2I5tbMx42cNkFiT0ySN2emfm7kc/7orptAv5GliVmaXd0DscOTyM/vB97Bc/7SLXOSwsjEYJznIAPzZ64+TvjaPdTUtrvLMSGcEfMFU/PnsPk/iIGP8AdNOceZDlFSVj0a3mimZAjh92CpcgFsgspOZuNyhpT6SKtPhETMNkgfOGUsYwSCu4E5l67Mye0tYfh66bzGaRnkODkLvHm5OSoxHxvYBx6BCO9dPp91JdOVDy3JY5ynmjzSTvyMJxuYecPQIR3rik2nY8+pGVNv8Ar+v61IopYdzKwgVe5QxAgbc8fvOuz5h/01JratntEU5EIyDkRmDj5QW2/N2XBT/poWqr5cqyb1M+WOVcLN83O8Hp35nH021et2nBDB7jAIwR5w24/eA9e3M4+u2kpGFSV1/X9f1uXIpbcswl+yYIIYQmD0y2z/gONn+3vFW0NqrEMLf5twYReRg9C+z5T1+UJ7h6gjEqBc/aIAO4Mx2ADfx8/wDACZh67sVdXzFBHmTx47KZT5e0buP3n8CnzR67yK1hJHDNr+v6/wCB5k2oWkFuinfZyM4JdYfKO7PLbPk74Gz6NWXLaQ3CsHSKQHdv8ryvnyQW2fuv4iAU9lcVuWsbmZftJkgjUDOGkIi2jdgfvf4FIcdfvkdqu3WlXM0s8tsJIYIlwdhf90VH8P77qgIZf99q2lS9qnOP3f1+ZyxxMaTSk/n/AF+h5XfxjTdQe4kWKcEksLcJmVic/u/3OPmYAr7Kwrwz4t+Iv7X1aOzjeKVLUs00sQTbLOxy7Iyqp2HAwp6c17J8ZNabQdOllUNDOg+zxKrONk5GSAVmOPLUhkOMZdhXy/K7SSM7klmOST3r0Mnw1/3sumx5+fY9ThGlHd7+gyiiivoD5QKKKKAJYJPKkDdu/wBK6GCdZIw3y56HAXnjHHy9xwPfmuZq9p9yY3CsTt6dTx+vbrWNanzK56WXYp0Z8jejOjhYE8qGz1CgDPYgfL3Hyj3zV22yf4WYNkEKD82eCB8n8WAo91NZkTYAydvrjt34+bsOR7mrkUiqPvBcZ5BGR64+fqByPcmvNnE+upTZtQM8m7cHn3khlTcPNLdVGI+PMwAPTYavI8rqQRPJu9PMHm7uoHyDHmkcenln1rFiuIguJPLUAkt5ezIHG7b8/UDG33LVbSWAhvM8lR827Z5XA43hOe3y7Pq9ckoHWpGiJZXJBaa7L/w/vVEu7n2x5mN/t5eO9MaWQnJaV92CGJlHmbvmBPzfx4MvsUAqk/ktu3+QSd28Q+Vk9NwXjuduz230bY2J3eUzHO4Js+Y5524Tu2Cv+yrVHKaJouRTvuGJpX75JcE/xZ/1ncfvv94AVchmYgvuKAH7wY5AC7sjM3UL++H+2SKy1iUv8xRz6pjnnJIxH0LfOP8AYUir1qpQrtDA5+9g4GDuB/1XQN+9/wBzilJf1/X9eY9DTUoN4lfyioO4Rsh2AAFtuZuqqQ6/7buKsPFGC5m+zIFDb1iaH5MY3hP3n8OVCezSUyzmkhGY3kg8vG0srny8ZYE/uudhJlPqrgdqttJLEeI7q28sDaSZiYAvQn5BnygxJ9fOHpXO2xJu+gzyrdDiYWwI3BxEYCAQRuC/McgPtCf9M99MdYeNrWwYNwT5GzO76H5d+T/1xAqyJZoivN1aBBgL+/JhCjaRnjPlBvL9/Nz2pJGlZQpWYbTgxFpsLg7Nud46HFvn0O6k2Ur9Sm/lKFMIgJBBQsIjjDZBb932fLt/0y21CojDAxoE2gbDIFIQjJUt+652ZZm/2WT0q3N5hGGMnJwfmfB52YOZf72ID/sDNU1mlMpwwnLEAeaxAclioDZl6MwKN/sopp6WNEXbaLBQx4hCgYDqSYwAQA37nqikq3vIhrbtLSTykxBMgBP8EnyjGw5xD2Ui3P8AtturEsZPMljJeFwcbTKyfOTnaXzN/Fhi/wDuR1t21zbMIljlVwxG1pjF8wKkrv8A3nddzvn/AJahKykROXS5Ylt5hGwCzqCcFNsvOR5ZX/Vjk8W3+8N1YOrQXJMm9ZpgeOkg3knZjoPvFfJ9jHnvW7C1uQuxrdlP3TL5O7BTgn5jz5eSf+m5FVNTtLaVGyseCf4BCMjb2wp/gwB/02JpLRmlGbizn7WKViwAllLcDmRfMLHAXqMCQjHt5fvUi2rzOgR5LguAVzvHm7slTy/G/DMfQxj1qvdKsUjjYjA5DBAnOQA23CdxhV/2w1aGmBLliJlWYHdvWEKDJnG4JiI/fwoT3V6t3Sudk5Ne8ixBaOREU3OrYKlmI35BZT/reNwDSn0ZQKV4UlXHmls/MD0JBXcDzL3UGb/f4re8mMqPk84tnd5WcSknc2zEP/LRgGT2jcU2SFiq7t0+47v3SuBJltxIxD0dx5q/7MbCs3I5VWbOF1S3Cyf8s8dcqyZA27uP3h/h+f8A3yRWYxWPILBSOuwrxxk4+bsMEe5NdvexTOMBJW3NwyrJg878j92OpzOP9kbawL60mTLYlQL32yccbs8gdATL9Gx2rWE+jOylUurMo28oVWBMYGDu2FMjpnbz1HG36tWtY3kUe4yCMDnd5Qj+p2fjjb/s7hWVGk0XDLLFjv8AP8mOc/8AAQd3vuq7ZRyDIZ5YgoOcbz5W3qfvc7Afx3+1E0mbPzNq21JZZ1G2AliQwVI8DnJ28dN2Nv8Asbq6iCaCOMGXyGOekYhIHzZ4+Q/x4YesQNcjbJJDMp2vCY87iDJ+529cfPzsBC+4c+ldF50iRqHeS2KAllUyHytuA2P3vPl5EY9Vc+lc0kjkrKOlkbYvYERQvkhwepERHDZz/qum/wCf3iq/ZyKcMvlcYxhEIGGyP+WPZsyH/pmaxIEkchXLDaTnLN8mDtOP33O0kRe6MTXQwQvGq5Z48Z3bWJxg7G/5bc4YiH3Q5qopPRHnVXTirf1/X4m5Y2M32UywQBU4wxVSFw2R/wAsezEv7oRVufXW0bQ58DYSQkeRyD1H/LHnbzIePuc81fs9QbTtHxcphcnOW3Dghccy84YiPryuO1fPnx08fPavPYadNJFcKzwDY7qUfpIwZZThlx5YyMFCe1elCi+f2dJ77nztarGSlKqvdT/I8q+LXiRdf8TypaMhsLPMMJXYwbklmDKq7gWLEZGQCBXDUpOTSV9FSpqlBQjsj5itVlWm5y6hRRRWhkFFFFABSjg0lFAGxpd5jajMFIwM8fUHoeh5rahLELgsMcg/MduOc/d7Z3fQ1x6sVYEHmt3S7tZAqtt3ggfMBgntkk9CeD7Vx16P2kfRZXj27UpvXodBD5keMebFtOQcPmPHOen8Gc/8CqzHJPGmP30YU/8ATT93t5/8cBz/AMDrOhKHbsMeCRtL7PXjdz653e2KngaMhceVxjaW8v1O3d7ZyW9ttedKJ9LCoaKvImdzTW4U4JBkJi2+nzfwZ49d5qR2cBs+bHtGCAX/AHeOCBmTnZkIPUOaoIYxtMflqRjaXCHH93d8vbkt9Vp0cihcoFTBXbuCnbgHGfk7And6llrNxZumn/X9foXS7RswkHl7chgpJ24O0gfvP4SRGP8AZYmpoZF3/MUL5xg7cDnGOZOm7Ef/AFzyao7wo+X92ABjdztwMDP7v+FSVP8AtMDU0Er5ON4HTaN3HG3H+r/unyv95s1LTsUrGtbSx5UKtrIcjAk8rBO7A3Zk6F8q3/TNRU0cttuHlGBj8uwzeTgnJ2l8k8Z37/8AZEdVYpJWUAJM+eCo835sjZjhO4xD9Rmp/Mndzl5592QV/fATZ+XHQY34Eft5ee9YNFJXLdt9nZY/Ke1U4XyzN5GQOdhk+U9Bv3+5jqWK2hJQxhFGAMN5eVXbgbsRnkJlG/6aMtQwNPI2f31wJO7GYCfd0z8wwJSuD6eUPWrsUskjR5lllLEYZzIPN3fMCcyj74BlPo0ajvWbaHqiMJsACgoM4IIGQNu3B/c9Qn7o/wDTQ560joWY5iklDZBRFYFgQEK8Q9WAEP8AvqTV1ELrGU/egkYaXjfuUspOZv4lDTH0kVRUcghUAvtAPOVEYbGzdnmbr5f70f8ATU4qdLkc6JIzKzkNHPOWzkKJAJt2AQP3XHmbQg9DEfWtiwe4nK4e5ujIPuKsy+fvO7Awox5xXzB6eVjvXPkWxD7vKCgHdsMOQNoLbf3h5CbWX/pozirsLwDeJxa4Ct5gtjBkDjzBHyefuCP/ALaVEoilrsdfaLLIsRVbm6aQgq/79RNuO8N1GPMKm49jHt7024DmP5Zrk7+Q2JvmyDIDzIOozdezDbWMs9u28SLAc7vMFuIMHkFxHhT1bZ5f+wJKspcdA32ViScmMREMd25tuIjwZMOv/TJWFZ2Zkqct1/X9f0zOv9PMhdyWUHndhsqNu8kZl6hD54/2nIrHmRrJmbc0AXOfLbmMhQx2/vf4UIdf9p2FdhGiuMhQxLZ3IFwSH35GIenmZmH/AEyGOlYuqK0YLRMI8EbWIY7cMXGf3I6MWn942A6Vd3sdVKtL4WU4tRwT5hWMIDu2kfuwAN2zMvVARs/33rSS4gxuuDDGEDbxCYjswRvCZk/hJVU/2Wkrl5Lxo3+QvFtwVJ3HZjlSfkH3SWf3Dgdq0LC6mjACSzWyoBgkSt5IUcZ+XnywxJ9RIPShxOqVN7m062oBDG2By2Qvk4BDDcF+Y8B9qr6xbqo3tvbMPmNluUnOzycZ3duvG/p/0yrRtVn2qXNzCEU4yJz5IUY/Hyg2z383PanXKGOMh/PtivDI3nHysfKR152ZEPuJM9qkxTs7HLXdrbqGEHl5GMZ8o9Dx0Xs+Sf8ApniqNu5jKqPJBGACypgYPyk/J0ByW/2SK6RmdwEYzL8xyD5pxg7CPv8AY4gP+yc1C+n7gzyK6jJHIc99mD+87viE/wCyAatSVtTeNW2jQ3TzEuwxFIyu0q0uzCEZ2lv3f8OWL/7LLWpCQ2wQtFAqgbTKFPl7chd/7r+AFt/++tc487pKUSR5QTja5YbyTtwf3n8TDyz7KDV62vHkJCfvAQAC5P7wk4AYeb/Gw2N7KpqJRvqOS6nT2jJbKmxWRlAI3Y/d4BC7v3P8Ckq/u6mt/TtTEMUcmVhRAG/eD/VhV2jd+4/gXMb/AO0yms3w1pw1ZwiyvIXVSrSY/eZJCbv32f3hDK/+4prj/iB4gh0NWiVvMTaWBcEmRASBu2zc+Y4If/cU4rSOHk2rbs8rE1aKupvbc6L4nfFSLTNMFvaDFzAgaNSyFkmK7UDK0XzGNMq44+8K+WLy5ku52lmbc54z7DpU2qalc6lcvPeTSSyOxYl3LEk9TknrVGvp8LhvYq8tZPdnweOxarS5aekUFFFFdZwBRRRQAUUUUAFFFFABT43KNlTimUUDTad0dFp2ombCOWZz1G5vmJ4I4/vcD8K3IHkfbnzZN3b95+8zxjr/AB42/wDAa4IEqcg4NbOnakq/JMq45zhVzgjBwT3x09DXDXw3WJ9Jl+bX/d1t+51peV8Z8yYseNxk/ebu5+b+MjB/3BUBckcEvkjGc/Pnpn5/4sEn/dFVhLHJuJEbkkhhGUGem7GF7jAX3Bp2Rhs7TnO7bj5s9cYXvxj6GuHlaPoo1E1/X9fmWFfcByJCcEeZ/FnkE/P35Y+4FPWSMf3CMAgkLkjHBPzd1yx/28VXZi4IJ8w5OQmRuyecfL/EQCPZTSxsxY8sSf8Ae+bJznhe5G/6LSaNE1/X9f5mpBPBtAYoB3I8sEDb2+brt+b/AK6GrPmwMDvW32nO8RiHOMDdt99uNv8AtlqoW8jkjDyHjr+84/iz09f3v0GKvRSfKCBNFjneDKdmPmz/AMB5m/4FisJKzNltoWka3cN5qQnO7eIvKwcgbguEPUbQn+0HrSt9hJ3GGQtu3iHZ+8JILBMRH7zBWX/ZR6zYWdQcPcQbeSB5p8naNxI+fnywfMHqZMVow+aoJdJYUjBLFd5MAXAO3MoyY9yqPUSt6VhKw2zQikJYB1Nxndu8njzctubbiHo7gSL/ALMbDvUolmkxtkckt95RJgnO/cMRd2zcD/ZXbVTBRiJ82zIG8xUA/dbcBwmZv+WZKovqrvVkKgJEsdqpG7eF8r5cMAwXMv8AC+2Nf+mZasrLoZ3Q8faACwadQDkSBZ/lI+cN90fdybj6Ntp6NPA2T9qstgzuAnP2cIN2ffyg2/383HaoHWBGwwtRLnBA8grkPjn5jx5vy/8AXEVEPJVh5L2wOVKGbyMA7jsLcHjfuL/9MtlKwk7m3FNPGGJkurdYl5C+cTbBBzj5xnyQwx6+cfSrXzxKplje1EYbdtMh8kLw2P3vPlbljHqsrelc/BLEhUwm3Qrt8sv5J2kE7C/7vnaxdn/2GSrVu6Axm3MduqhAhm2fu8AhC/7rnYCxf/fTNZtP+v6/zHY2vPEIxKzxFdwZVBIj2kKwGZv4GKwD1jYmszUlMoYyCFTkgglOMNtPWU9HxF/1yGaWFtgXY4h2gbQ/JiwCq7sQ/wDLNSUf/akU0m0/IuyWAL03+YdmF2DOIv4EPkt/tOD1pK5cE4u9zmZrSMS5JiLA8AtHgndtAPzdN+VP/TMA063kiRtsf2ZsYCmbyueSF3c9N2Q3+wFrYuVkXOGl5ONm2XjjYQfk7DFuf9r5qyL1ZtzZSdi2QQfNBb+Ejp3wIfqua2vfQ7oT5ka9pPbgx+W1uBhSnmeTjuE3/ju3+2w1dRbZkQwy244XyzO0OV4IQyfIeg3h/wDaMZrm7e4mZmBeeTPDD95+8z8uDz/GR5Z9Nma1EvJWX/ltc7hjJMo8/PGD8/HmEYPp5QPeoasKcH0HskTFBE0SpwV8zy8gbSFDfu+oTKt/tspqOQwrBhSi88BymQNu0Bv3XZPkP/TQg0S3juF2SSzF8YJ8webu6Z/ef8tCCT6GMetVJHmlRTGZLncRjzCw8zdkqTmTjfgufRkFNJE8pWkRXR2yGBPQcHpjHEfdcR/79R20qrI/mD5edwJIyCMEf6vgsMR+zjNLNcCOIMxY7sbTz+8yNwz+8/iAMns6iuD1jxAI3K20jvklssGUsP4c4Y9fvezV00aDqytEwxWOp4aDlUZ6NqnxDTRtPu4Y5vOmlBhPlOmTvAEpwYuAUAT2ZSa8Z8Qavca1qk97dMDJIc8Kq4AAA4UAZwB2qjcTyTuWldnJJOSc9ahr3sNhIUFfqfn2YZlLFydtEFFFFdZ5YUUUUAFFFFABRRRQAUUUUAFFFFABS0lFAF+y1Ga3IXzHC8chjxjoePTnFbttfRTJkNtHXgN8g9st/D2/3jXJ0+NyjBlPIrCpQjPVaM9PCZpUw/uy1R2TsMHf+75Odn8Prj5u2QB9TShkGchB6gbeOecfN2OAPbNc9Z6o0YCscYxg8YBHTt7mtW3vY5R+7kwRjHzElRjj+HsMj6muKdGcdz6TD5hQr7Oz7GgJVOSRHnvgJjr9fXA/3c1LFIgKlfL3D+8ExnPGf+Bdf9mqiswHG9eOnzcdvTt9z8anjZ9/O844K/P9Mf8AslYNHpQl5mrZyR4UJ5AIwVL+VkYJ25+Xs2S3+xitezuIo2QwFYiu0xmXy/kIB2F/3Z+7li/+8lYFu0pI4kYnr/rPmz8uPvfxH939BWjBI7nCvLMzcAMH/eljgA5fo5BB9oxXLOKZutTdtLvy2j8hxAqBfLMhBMG0EIXxFz5YLb/XevpWjbTFduwTQAYwXMn7oKCoziLny0Jjb1aQHtXO2zbnRgfP3Y2eaCBLuOFLZl/5aEEN6BFq/bvCSgRhIW27DMExITnYXzL0cBmf0KJXPKCJdjdzPtQKbmIdPKP2g7QBsxwg+6MWx923USR3MhIIuJSx+ZW+0DcThDnJH3iBan/d3Vmwy27KhjFsykDaZfIDMCp2Fsv1Kbnb/prsqPzLN8n9yOne3Bxs/H/ll/5GPrUcrMbI0TDPlsrNIzcYYTfvCW2YOZON7jyD7Rg1ZjjkbIQvdk4C+YHUTbm2qGzL0ldTG3oIlPesnzLUrlDb4bII3QA8oAR9w8mLCf8AXbNWfNikV1kWOYsDuELRjcCoDAYi/iQLEPSUN3pNMq7NBEMu0oBMX2+WZePOLEhN+ZukhV9/p5aVD5KytGYXWbeFKGZo18wMDsL5l/jCuz+jKlKsqfOX/fbgwdYzjzdwAdVxDx5gCxr6PG/rVwTS3DnzQ93uU7xCHHn78b9uIuPNKqF9DE2OtRd9i1OUWZTRxyRIFEBD4KtIYQSCp2lvnONyBmb/AKa7apS2tvtG0xfNgjcYM4K8Z56+XnPpLiusVZWYEmW4ZtxynnAXG47jtxGMecyh19PJI71FcwT3AXa9xeM53DYLgecWO7I4GPNKmcenlEd6amXHENHCXOxQwCwAHnjys8r06f3MD/rpmqbkHJYIwOchNnIIGcfL1IwB/tA1113ZSuVKrcPuOVfbP+8z84Yc/wAQBuB6bcVzerXVvYKXaZwONpZJgDnlSPm9P349zit4e87JanV9ajFXZE7/ACHf5ZBDbtgX5s43bfk/iwAvuGrL1DWoo1YSlH+9v2FF3dC2Pk7kLj0wayNW8Xlh5dmu1Q3BjllUAD7uAW7Nlx7sa5G5u5bhsyyM31NelQwDlrNWPBx3EVOknGjqzU1jXJbwkZBB3bjtUZLHLEYA9vpWIzFjk0lJXrU6caatFHxmJxdXEz56juFFFFaHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU5XZCdrFfoabRQNNrVF+11B4uHw/OcsMn/Pf61q22pQuBuHb+6o9u/8As8/71c3S1jOhGZ6GHzOtQ0vdHZRXMB6lOn+x6fT+7x/vVbinQg7ihByCE2AkEDcB8vUjAHuDXDRzyR42Oy49D+NWodTuYsYkfI6EMRgjkH8Dk1zTwbex7FHP4/bVjvElRixkKuzbg2wgB8gbtuE43ABV9CDWjFdvyrOJgdwZYzjzN2NwGI/4yFx6bD615/DrsiYBTpwDvY7fTHPY5I9zV6LxFH/FFFHnIyquSue4+bquMj3Y1yTwU+x6dPOcPL7X9fM9Bi1CWRiP305bOSjSASljubACDAdgHHoIyO9SR3Ert8s08rMc8Gf94Sd/oPvEGf8A4DiuETxJbHkgR5OSEh+7nrty38OAF/3mqQ+JrVgcoihh82yBeM8nGT2ICr/sk1g8HPojX+0cM9eZHfRvM7KyGeYschv3/wAx+/nqOvNx9Rip4zL94TzoCQdwWb03gjMnXbm5H+0cV5wPEtruyY8E9QkCYGTuOPowAH+zkUx/Fg52xqCeu2CId95xx/fxj/Z4pfUqr2RnLMcKvtnqquVHzs4QDhgjZUbd5IzL1WM+ev8AtuRVppoIQ5ldbdVzv8lVzHhAzbMzfwRkSJ/tu4rxhvFlzuBTAOQf9TH13b/7v9/n6cdKqy+KdTcKBMgCgAfuk4w/men94k/p0qo5bVe7RzVc4w8fhk2e1vqVlbs/2kqoUMZfJER8oABpPLzL/ApQx+7yCszWPGOkWuUu0MT52SC2t4G2HhpAmHPC/IIz6NIK8RuL2ac/vXzjjoB3J/mTVcsa6aeVJfGzzq2et/w0drrnjeW8Vlt7e1QOjbj9mVSrOwZguOgGML6KSO9cjeXkt1M8khALNu2qMKPYD0qsTSV6NKhCkvdR49fG1q/xPQUnNJRRWxyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUtFFABmlzRRSGhM0EmiimFwNFFFAhKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view shows an oyster shell fragment impacted in the right lower lobe bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29811=[""].join("\n");
var outline_f29_7_29811=null;
var title_f29_7_29812="Invasion of inflammatory cells into center of myofiber in IBM";
var content_f29_7_29812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Invasion of inflammatory cells into center of myofiber in IBM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep invasion of inflammatory cells into the center of a non-necrotic myofiber in inclusion body myositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven A Greenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29812=[""].join("\n");
var outline_f29_7_29812=null;
var title_f29_7_29813="Creation of bladder flap";
var content_f29_7_29813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Laparoscopy assisted vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transection of round ligament and dissection of bladder flap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29813=[""].join("\n");
var outline_f29_7_29813=null;
var title_f29_7_29814="Dapsone (systemic): Drug information";
var content_f29_7_29814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dapsone (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/22/9573?source=see_link\">",
"    see \"Dapsone (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/20/39237?source=see_link\">",
"    see \"Dapsone (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8016738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8015321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aphthous ulcers, severe (unlabeled use):",
"     </b>",
"     Oral: 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bullous systemic lupus erythematosus (unlabeled use):",
"     </b>",
"     Oral: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Leprosy:",
"     </b>",
"     Oral: 100 mg/day, in combination with other antileprosy agents; duration of therapy is variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatitis herpetiformis:",
"     </b>",
"     Oral: Initial: 50 mg/day, increase to 300. mg/day, or higher to achieve full control. Reduce dosage to minimum level as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia caused by",
"     </b>",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii,",
"      </i>",
"     </b>",
"     <b>",
"      alternative therapy (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis (primary or secondary):",
"     </i>",
"     100 mg/day once daily or divided in 2 doses as monotherapy",
"     <b>",
"      or",
"     </b>",
"     50 mg daily in combination with weekly pyrimethamine and leucovorin (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     100 mg/day once daily in combination with trimethoprim  for 21 days (CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8015320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/20/39237?source=see_link\">",
"      see \"Dapsone (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Leprosy:",
"     </b>",
"     Oral: Children: 1-2 mg/kg/24 hours, up to a maximum of 100 mg/day, in combination with other antileprosy agents; duration of therapy is variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of",
"     </b>",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"     </b>",
"     <b>",
"      pneumonia, alternative therapy (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis (primary or secondary):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children: 2 mg/kg/day once daily (maximum dose: 100 mg/day) or 4 mg/kg/dose once weekly (maximum dose: 200 mg) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children: 2 mg/kg/day once daily (maximum dose: 100 mg/day) in combination with trimethoprim for 21 days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8015322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8015323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No guidelines are available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8015379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9490508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8015365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     May administer with meals if GI upset occurs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8015286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of leprosy (due to susceptible strains of",
"     <i>",
"      Mycobacterium leprae",
"     </i>",
"     ) and dermatitis herpetiformis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8015288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of toxoplasmosis in severely-immunocompromised patients; alternative agent for",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) prophylaxis (monotherapy) and treatment (in combination with trimethoprim); pemphigus vulgaris (oral), aphthous ulcers (severe), bullous systemic lupus erythematosus; all in consultation with patient&rsquo;s physician as significant monitoring required",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8015264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dapsone may be confused with Diprosone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8015298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Hematologic: Reticulocyte increase (2% to 12%), hemolysis (&gt;10%; dose related; seen in patients with and without G6PD deficiency), hemoglobin decrease (&gt;10%; 1-2 g/dL; almost all patients),  methemoglobinemia (&gt;10%), red cell life span shortened (&gt;10%), Agranulocytosis, anemia, leukopenia, pure red cell aplasia (case report)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever, headache, insomnia, psychosis, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Bullous and exfoliative dermatitis, erythema nodosum, exfoliative dermatitis, morbilliform and scarlatiniform reactions, phototoxicity, Stevens-Johnson syndrome, toxic epidural necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hypoalbuminemia (without proteinuria), male infertility",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, nausea, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Cholestatic jaundice, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Drug-induced lupus erythematosus, lower motor neuron toxicity (prolonged therapy), peripheral neuropathy (rare, nonleprosy patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular:  Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Albuminuria, nephrotic syndrome, renal papillary necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Interstitial pneumonitis, pulmonary eosinophilia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Infectious mononucleosis-like syndrome (rash, fever, lymphadenopathy, hepatic dysfunction)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8015294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dapsone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8015295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Aplastic anemia, agranulocytosis and other severe blood dyscrasias have resulted in death; monitor carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Serious dermatologic reactions (including toxic epidermal necrolysis) are rare but potential occurrences.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Motor loss and muscle weakness have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Use with caution in patients with hypersensitivity to other sulfonamides; sulfone reactions may also occur as potentially fatal hypersensitivity reactions, these, but not leprosy reactional states, require drug discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution in patients with severe anemia; treat prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemoglobin M deficiency: Use with caution in patients with hemoglobin M deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobin reductase deficiency: Use with caution in patients with methemoglobin reductase deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8015301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (major), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8015302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: Dapsone (Systemic) may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8015306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease dapsone levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8015289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8015290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because of adverse events observed in some animal studies, dapsone is classified as pregnancy category C. Per the manufacturer, dapsone has not shown an increased risk of congenital anomalies when given during all trimesters of pregnancy. Several reports have described adverse effects in the newborn after",
"     <i>",
"      in utero",
"     </i>",
"     exposure to dapsone, including neonatal hemolytic disease, methemoglobinemia, and hyperbilirubinemia. Dapsone is an alternative for prophylaxis and treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) in pregnant, HIV-infected patients. Dapsone is also recommended for pregnant women requiring maintenance therapy of either leprosy or dermatitis herpetiformis",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8015292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8015293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dapsone is excreted in breast milk and can be detected in the serum of nursing infants. Hemolytic anemia has been reported in a breast-fed infant. Breast-feeding is not recommended by the manufacturer due to the potential for carcinogenicity observed in animal studies and the potential for hemolysis in the neonate, especially if there is a family history of G6PD deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8015364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give with antacids, alkaline foods, or drugs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dapsone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $31.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $39.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8015367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Check G6PD levels (prior to initiation); CBC (weekly for first month, monthly for 6 months and semiannually thereafter); reticulocyte counts; liver function tests. Monitor patients for signs of jaundice and hemolysis.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Daps (AR);",
"     </li>",
"     <li>",
"      Dapson (DK, EG, NL, NO);",
"     </li>",
"     <li>",
"      Dapson-Fatol (DE);",
"     </li>",
"     <li>",
"      Dapsona (CO);",
"     </li>",
"     <li>",
"      Dapsone (AU);",
"     </li>",
"     <li>",
"      Disulone (FR);",
"     </li>",
"     <li>",
"      Dopsan (TH);",
"     </li>",
"     <li>",
"      Lennon-Dapsone (ZA);",
"     </li>",
"     <li>",
"      Pyrisone (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8015309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive antagonist of para-aminobenzoic acid (PABA) and prevents normal bacterial utilization of PABA for the synthesis of folic acid",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8015311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well-absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Dapsone: 70% to 90%; Metabolite: ~99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.5 L/kg; throughout total body water and present in all tissues, especially liver and kidney",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (acetylation and hydroxylation); forms multiple metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 30 hours (range: 10-50 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~85%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Azizi A and Lawaf S, &ldquo;The Management of Oral Pemphigus Vulgaris With Systemic Corticosteroids and Dapsone,&rdquo; Journal Of Dental Research, Dental Clinics, And Dental Prospects, 2008, 2(1):33-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borras-Blasco J, Conesa-Garcia V, Navarro-Ruiz A, et al, \"Pure Red Cell Aplasia Associated With Dapsone Therapy,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(6):1137-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/15870135/pubmed\" id=\"15870135\" target=\"_blank\">",
"        15870135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      El-Sadr WM, Murphy RL, Yurik TM, et al, &ldquo;Atovaquone Compared With Dapsone for the Prevention of",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      in Patients With HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(26):1889-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/9862944/pubmed\" id=\"9862944\" target=\"_blank\">",
"        9862944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fabbri P, Cardinali C, Giomi B, et al, &ldquo;Cutaneous Lupus Erythematosus: Diagnosis and Management,&rdquo;",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      , 2003, 4(7):449-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/12814335/pubmed\" id=\"12814335\" target=\"_blank\">",
"        12814335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents,&rdquo; June 18, 2008. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Letko E, Zafirakis P, Baltatzis S, et al, &ldquo;Relapsing Polychondritis: A Clinical Review,&rdquo;",
"      <i>",
"       Semin Arthritis Rheum",
"      </i>",
"      , 2002, 31(6):384-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/12077711/pubmed\" id=\"12077711\" target=\"_blank\">",
"        12077711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynde CB, Bruce AJ, and Rogers RS 3rd, &ldquo;Successful Treatement of Complex Aphthosis With Colchicine and Dapsone,&rdquo;",
"      <i>",
"       Arch Derm",
"      </i>",
"      , 2009, 145(3):273-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/19289756/pubmed\" id=\"19289756\" target=\"_blank\">",
"        19289756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Medina I, Mills J, Leoung G, et al, &ldquo;Oral Therapy for",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in the Acquired Immunodeficiency Syndrome. A Controlled Trial of Trimethoprim-Sulfamethoxazole Versus Trimethoprim-Dapsone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(12):776-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/2392131/pubmed\" id=\"2392131\" target=\"_blank\">",
"        2392131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirochnick M, Michaels M, Clarke D, et al, &ldquo;Pharmacokinetics of Dapsone in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 122(5 Pt 1):806-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/8496767/pubmed\" id=\"8496767\" target=\"_blank\">",
"        8496767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stavola JJ and Noel GJ, &ldquo;Efficacy and Safety of Dapsone Prophylaxis Against",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in Human Immunodeficiency Virus-Infected Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1993, 12(8):644-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/8414776/pubmed\" id=\"8414776\" target=\"_blank\">",
"        8414776",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Werth VP, Fivenson D, Pandya AG, et al, &ldquo;Multicenter Randomized, Double-Blind, Placebo, Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 2008, 144(1):25-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/18209165/pubmed\" id=\"18209165\" target=\"_blank\">",
"        18209165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zuidema J, Hilbers-Modderman ES, and Merkus FW, &ldquo;Clinical Pharmacokinetics of Dapsone,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1986, 11(4):299-315.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/7/29814/abstract-text/3530584/pubmed\" id=\"3530584\" target=\"_blank\">",
"        3530584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9096 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29814=[""].join("\n");
var outline_f29_7_29814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016738\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015321\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015320\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015322\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015323\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015379\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490508\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015365\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015286\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015288\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015264\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015298\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015294\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015295\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015301\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015302\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015306\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015289\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015290\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015292\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015293\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015364\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322077\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015367\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390227\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015309\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015311\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/22/9573?source=related_link\">",
"      Dapsone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/20/39237?source=related_link\">",
"      Dapsone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/34/44579?source=related_link\">",
"      Dapsone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/51/1844?source=related_link\">",
"      Dapsone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10883?source=related_link\">",
"      Dapsone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_7_29815="Rheumatoid nodules";
var content_f29_7_29815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rheumatoid nodules",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29815/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29815/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29815/contributors\">",
"     Carl Turesson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29815/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29815/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29815/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29815/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/7/29815/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rheumatoid nodule is the most common cutaneous manifestation of rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although nodules commonly are found on pressure points (such as the olecranon process), they may occur at other sites, including ones within internal organs of the body. Thus, bedridden patients can develop nodules on the occiput and ischial areas, and nodules occasionally form on the Achilles tendon and vocal cords [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/3\">",
"     3",
"    </a>",
"    ]. Rheumatoid \"nodulosis\" is characterized by multiple nodules on the hands and multiple subchondral bone cysts known as \"geodes\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/4\">",
"     4",
"    </a>",
"    ]. These nodules tend to occur on extensor surfaces adjacent to joints, elbows, and fingers, as well as the forearm, metacarpophalangeal and proximal interphalangeal joints, occiput, back, heel, and other areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical and histopathologic features, diagnosis, and treatment of rheumatoid nodules will be reviewed here. The articular features and an overview of the systemic and nonarticular manifestations of RA are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND CLINICAL SIGNIFICANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Subcutaneous nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpable nodules in the subcutaneous tissues have been reported at initial presentation in 7 percent of patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/6\">",
"     6",
"    </a>",
"    ] and are found at some time during the disease course in 30 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/7\">",
"     7",
"    </a>",
"    ]. The vast majority of nodule formers have positive tests for rheumatoid factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/1\">",
"     1",
"    </a>",
"    ]. Nodules are found in 75 percent of patients with RA-associated Felty&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/5\">",
"     5",
"    </a>",
"    ]. RA patients with nodules are also more likely to develop vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/8\">",
"     8",
"    </a>",
"    ]. Limited data suggest that many patients with rheumatoid nodules have a positive test for antibodies to citrulline containing peptides (eg, anti-CCP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/9\">",
"     9",
"    </a>",
"    ]. In general, patients with rheumatoid nodules tend to have a severe RA phenotype, with more rapid progression of joint destruction than other patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/10\">",
"     10",
"    </a>",
"    ]. Rheumatoid nodules have also been noted in occasional patients with systemic lupus erythematosus, ankylosing spondylitis, granuloma annulare, and chronic active hepatitis, and they have been associated with antiphospholipid antibodies in patients with RA, as well as in healthy children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The size of the nodules varies from 2 mm to 5 cm; they are firm, nontender, and moveable in subcutaneous tissue (",
"    <a class=\"graphic graphic_picture graphicRef74194 \" href=\"mobipreview.htm?28/4/28737\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, the nodules are neither symptomatic nor a cosmetic concern. However, rheumatoid nodules can be painful",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disfiguring, can interfere with function, and can cause compressive neuropathies. Some patients find the nodules more distressing than the arthritis. The nodules may also ulcerate and thus serve as a site for local infection or other distant infectious complications by hematogenous spread of bacteria.",
"   </p>",
"   <p>",
"    A poorly understood phenomenon is that some patients treated for RA with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    have a noticeable increase in the size and number of rheumatoid nodules. This is referred to as accelerated nodulosis and is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Nodulosis'",
"    </a>",
"    .) Nodulosis has also occasionally been associated in RA patients with treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and RA",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of pulmonary rheumatoid nodules in patients with RA depends in part on the methods used for detection. As an example, plain film radiographs of the chest revealed rheumatoid nodules in only 2 of 516 patients with RA in one clinical series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a study of open lung biopsies from 40 patients with suspected lung disease found rheumatoid nodules in 13 subjects (32 percent); in 8 of 13 patients, there were multiple nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/12\">",
"     12",
"    </a>",
"    ]. Accelerated pulmonary nodulosis has been reported to follow anti-tumor necrosis factor (anti-TNF) therapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. These can mimic infection or malignancy.",
"   </p>",
"   <p>",
"    Nodules are generally located in subpleural areas or in association with interlobular septa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/16\">",
"     16",
"    </a>",
"    ]. Pulmonary rheumatoid nodules are generally asymptomatic but can lead to complications including pleural effusion, pneumothorax, pyopneumothorax, bronchopleural fistula, and hemoptysis. These and other aspects of rheumatoid nodules in the lungs are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\", section on 'Rheumatoid nodules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphoid aggregates containing B lymphocytes and features characteristic of lymphoid follicles have been reported in pulmonary nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/17\">",
"     17",
"    </a>",
"    ]. This contrasts with the expected structure of subcutaneous nodules, from which B cells and lymphoid follicles are normally absent. Such B cell aggregates may also occur in diffuse RA-associated interstitial lung disease, such as nonspecific interstitial pneumonitis or usual interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with these histopathologic features, reduction in size or even disappearance of pulmonary rheumatoid nodules may sometimes be seen in patients with severe RA treated with the B-cell depleting agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiac nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules may develop in the pericardium, myocardium, and valvular structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/20\">",
"     20",
"    </a>",
"    ]. They may be noted on echocardiograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/21\">",
"     21",
"    </a>",
"    ]. Symptoms related to the presence of nodules are rare, but syncope or death due to heart block from a lesion situated in the conduction system can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/22\">",
"     22",
"    </a>",
"    ]. Stroke or other manifestations of arterial embolization may result from nodules on a heart valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Central nervous system nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules rarely may affect the central nervous system. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11129?source=see_link&amp;anchor=H8#H8\">",
"     \"Neurologic manifestations of rheumatoid arthritis\", section on 'Rheumatoid nodules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic appearance of a typical rheumatoid nodule includes a central area of necrosis surrounded in turn by palisading macrophages and then lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef69272 \" href=\"mobipreview.htm?29/13/29910\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. The fibroblasts produce large quantities of metalloproteases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/30\">",
"     30",
"    </a>",
"    ]. The lymphocytes can generate IgG and IgM rheumatoid factor. Histologic features of focal vasculitis with associated immunoglobulin, fibrin deposition, and complement activation can be found in one-third of all rheumatoid nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination for mRNA transcripts for cytokines revealed evidence for tumor necrosis factor alpha, interferon gamma, interleukin-1 beta (IL-1beta), interleukin-1 receptor antagonist, IL-10, IL-15, IL-18, and IL-12 (but not IL-2 or IL-4), as well as adhesion molecules E-selectin, intracellular adhesion molecule-1 (ICAM-1), PECAM, and VCAM. IL-17A is not found in rheumatoid nodules, in contrast to its presence in the rheumatoid synovial membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/31\">",
"     31",
"    </a>",
"    ], but most of the cytokine profile, together with the ability of the tissue to produce metalloproteinases, establishes the rheumatoid nodule as a Th1 granuloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deposits of rheumatoid factor and the terminal components of complement are also found on the endothelium of small vessels within nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/35\">",
"     35",
"    </a>",
"    ]. A meta-analysis of individual patient data from published studies showed no strong association between the presence of nodules and carriage of major histocompatibility complex (MHC) alleles (shared epitope) that are associated with RA per se. There was a very weak association with only the HLADR&beta;1*0401 shared epitope allele but not with other genotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/36\">",
"     36",
"    </a>",
"    ]. This contrasts with a similar analysis of studies of RA associated vasculitis, in which an association between vasculitis and a double dose of the shared epitope was found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/37\">",
"     37",
"    </a>",
"    ], suggesting that genetic factors may be less important for development of nodules than for other extra-articular disease features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, a complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy in some patients with RA is the increased formation of rheumatoid nodules, a pro-inflammatory effect that occurs even when synovial inflammation is suppressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/38\">",
"     38",
"    </a>",
"    ]. Among susceptible individuals, this complication may be due to the activation of adenosine A1 receptors by methotrexate, which leads to enhanced cellular fusion and the formation of multinucleated giant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Nodulosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cigarette smoking may increase the risk of developing rheumatoid nodules. This was illustrated in a study of 1589 patients with early RA in which those with nodules were compared with age and sex matched RA controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/6\">",
"     6",
"    </a>",
"    ]. Those with nodules were significantly more likely to have ever smoked cigarettes (odds ratio 7.3, 95% CI 2.3-24.6). Smoking is also associated with vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/40,41\">",
"     40,41",
"    </a>",
"    ] and other severe extra-articular manifestations of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with RA, a slowly developing, firm, painless, subcutaneous nodule located at a pressure point is almost certainly a rheumatoid nodule. These can be movable or bound down to underlying fascia or periosteum. In the absence of symptoms related to the presence of the nodule, no additional diagnostic testing is necessary.",
"   </p>",
"   <p>",
"    Rheumatoid nodules in viscera may be more difficult to diagnose with confidence. As an example, a rheumatoid nodule in the lung may not be definitively diagnosed until lung cancer has been excluded by biopsy or excision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\", section on 'Rheumatoid nodules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of a nodule with the histologic characteristics described above for rheumatoid nodules (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathology and pathogenesis'",
"    </a>",
"    above) is nearly pathognomonic of RA. However, nodules with a similar histologic appearance rarely occur in some patients with systemic lupus erythematosus and in otherwise healthy children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Subcutaneous nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of subcutaneous rheumatoid nodules should include fibromas caused by chronic trauma from shoes or repetitive use of hand tools, subcutaneous granuloma annulare (pseudo rheumatoid nodules), xanthomatosis, sarcoidosis, gouty tophi, pseudogout tophi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/49\">",
"     49",
"    </a>",
"    ], cutaneous extravascular necrotizing granulomas (Churg-Strauss granulomas), tumoral calcinosis, fibromas unrelated to chronic trauma, xanthomas, subcutaneous sarcoidosis, lupus panniculitis, nodular (keloidal) scleroderma, metastatic tumors, histoplasmosis, amyloidosis, ganglion cysts, foreign body granulomas, basal cell skin cancer, epidermoid cysts, synovial cysts, necrobiotic granulomas, and necrobiosis lipoidica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. However, the concurrent presence of active RA with high rheumatoid factor titers points strongly toward rheumatoid nodules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lung nodule or nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the most important diagnosis to exclude in a patient with RA and a pulmonary nodule is non-small cell lung cancer at a potentially curable stage. The approach to a patient with RA and an asymptomatic pulmonary nodule is similar to that for others with solitary nodules. If radiographic stability of the lesion cannot be demonstrated conclusively by review of prior chest radiographs, or if prior studies are unavailable, then consideration can be given to additional investigations; these include continued observation with serial imaging studies, biopsy of the lesion, and surgical excision. An approach to diagnosis of a solitary pulmonary nodule is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rheumatoid nodulosis is one of several benign and malignant diseases that are associated with the presence of multiple pulmonary nodules. A discussion of the causes of multiple pulmonary nodules and an approach to diagnosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=see_link\">",
"     \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Accelerated nodulosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the formation of rheumatoid nodules is suspected to be due to use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , discontinuing treatment with this agent can be considered. A decision to stop or continue methotrexate therapy depends on several factors, including the success with which RA disease activity other than nodulosis has been controlled by methotrexate, the availability of other disease modifying antirheumatic drugs (DMARDs) and biologic response modifying agents (eg, anti-tumor necrosis factor alpha agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ), safety of alternative drugs, and cost concerns. Discontinuation of methotrexate and a change to an alternative DMARD or biologic response modifier may be appropriate, while some patients and their clinicians may decide to continue methotrexate.",
"   </p>",
"   <p>",
"    Regression of nodules has been noted in patients who received various DMARDs or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ; however, a review in 2002 found insufficient evidence to conclude that any specific treatment was beneficial for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    associated nodulosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with symptomatic accelerated nodulosis in the setting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    treatment, for whom there are viable alternative treatments, we suggest the discontinuation of methotrexate and a change to an alternative DMARD or biologic response modifier. Patients whose articular disease activity is well-controlled and whose nodulosis is only a cosmetic concern may choose to continue methotrexate therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subcutaneous nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic nodules require no specific treatment. However, those that are painful, that interfere with function, or that cause nerve entrapment may require an intervention. Direct injection of the nodule with a mixture of glucocorticoids and local anesthetic may be beneficial and is recommended. Surgical excision may be necessary for nodules that are causing serious complications. One patient without RA, but with nodules consistent with rheumatoid nodulosis on biopsy, has been reported to respond to topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    after failing to respond to topical corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Glucocorticoid injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local glucocorticoid injection of rheumatoid nodules is often effective in decreasing their size. This was illustrated in a study of 24 nodules in 11 patients with RA. Patients were randomly assigned for each injection to receive either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or placebo, and assessment was blinded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/52\">",
"     52",
"    </a>",
"    ]. A &gt;50 percent loss in nodule volume occurred in a significantly greater proportion of those who received glucocorticoid injections when compared with placebo injections (9 of 12 versus 1 of 12, respectively). Similar findings were later reported in a study of 20 patients (one nodule each) of comparable design, but, instead of methylprednisolone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide was injected and was found to be superior to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A long-acting glucocorticoid (eg, 0.1 to 0.3 mL of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide 40",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    and local anesthetic (eg, 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) in a 1:1 mixture by volume are typically used for injection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgical excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for surgical treatment of rheumatoid nodules include skin erosion and infection, pain or neurologic dysfunction arising from pressure on a peripheral nerve, and limitation of motion because of the location of the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29815/abstract/48\">",
"     48",
"    </a>",
"    ]. Recurrence of nodules at the same site is frequently seen.",
"   </p>",
"   <p>",
"    As noted (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Lung nodule or nodules'",
"    </a>",
"    above), surgical resection of pulmonary nodules is sometimes indicated. Surgical or intravascular approaches to cardiac nodules should be undertaken only when there is firm evidence that the nodules are contributing to abnormal cardiac function, to rhythm disturbances, or to embolic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid nodules are a common extra-articular manifestation of RA, with subcutaneous nodules occurring at some time in 30 to 40 percent of patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Subcutaneous nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wherever rheumatoid nodules are found, they have a similar histologic appearance. Characteristic features include a central area of necrosis surrounded by concentric layers of palisading macrophages and lymphocytes. As is the case for the synovitis of RA, the pathogenesis is uncertain but involves multiple cytokines. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of subcutaneous lesions can be made from their proximity to pressure points, generally intact overlying skin, and firm to hard nature on palpation, often with fixation to the underlying periosteum. Although the histopathologic features are nearly pathognomonic, biopsy is rarely necessary for diagnosis of rheumatoid nodules located in or beneath the skin. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rheumatoid pulmonary nodules present a more difficult diagnostic challenge. When an asymptomatic single lung nodule is discovered, we recommend a thorough evaluation to exclude a potentially resectable lung cancer. An approach to diagnosis in this setting is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link\">",
"       \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatoid nodules in the myocardium can cause heart block; lesions located on or near the heart valves may cause regurgitation or embolic events. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cardiac nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of multiple pulmonary nodules requires thorough evaluation to exclude treatable infectious and potentially curable neoplastic diseases. The differential diagnosis and evaluation of such patients is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=see_link\">",
"       \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For an asymptomatic subcutaneous nodule, targeted therapy is not necessary. For symptomatic nodules, we recommend local injection of glucocorticoids and a local anesthetic as the initial treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Glucocorticoid injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complication of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      therapy in some patients with RA is the increased formation of rheumatoid nodules. In patients for whom there are viable alternative treatments, we suggest discontinuation of methotrexate and a change to an alternative DMARD or biologic response modifier (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients whose articular disease activity is well-controlled and whose nodulosis is only a cosmetic concern may choose to continue methotrexate therapy.",
"     </li>",
"     <li>",
"      For patients with symptomatic subcutaneous nodules that have resulted in complications (eg, skin ulceration, nerve compression) and that either are not appropriate for steroid injection or have not responded to local injection, surgical excision may be necessary. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgical excision'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/1\">",
"      Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005; 53:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/2\">",
"      Highton J, Hessian PA, Stamp L. The Rheumatoid nodule: peripheral or central to rheumatoid arthritis? Rheumatology (Oxford) 2007; 46:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/3\">",
"      Ylitalo R, Heimb&uuml;rger M, Lindestad PA. Vocal fold deposits in autoimmune disease--an unusual cause of hoarseness. Clin Otolaryngol Allied Sci 2003; 28:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/4\">",
"      Ginsberg MH, Genant HK, Y&uuml; TF, McCarty DJ. Rheumatoid nodulosis: an unusual variant of rheumatoid disease. Arthritis Rheum 1975; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/5\">",
"      Garc&iacute;a-Patos V. Rheumatoid nodule. Semin Cutan Med Surg 2007; 26:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/6\">",
"      Nyh&auml;ll-W&aring;hlin BM, Jacobsson LT, Petersson IF, et al. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 2006; 65:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/7\">",
"      Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/8\">",
"      Turesson C, McClelland RL, Christianson T, Matteson E. Clustering of extraarticular manifestations in patients with rheumatoid arthritis. J Rheumatol 2008; 35:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/9\">",
"      Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J Rheumatol 2008; 35:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/10\">",
"      Nyh&auml;ll-W&aring;hlin BM, Turesson C, Jacobsson LT, et al. The presence of rheumatoid nodules at early rheumatoid arthritis diagnosis is a sign of extra-articular disease and predicts radiographic progression of joint destruction over 5 years. Scand J Rheumatol 2011; 40:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/11\">",
"      Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine (Baltimore) 1968; 47:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/12\">",
"      Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985; 131:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/13\">",
"      Watson P, Simler N, Screaton N, Lillicrap M. Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/14\">",
"      Horvath IF, Szanto A, Csiki Z, et al. Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide. Pathol Oncol Res 2008; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/15\">",
"      Rozin A, Yigla M, Guralnik L, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006; 25:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/16\">",
"      Walters MN, Ojeda VJ. Pleuropulmonary necrobiotic rheumatoid nodules. A review and clinicopathological study of six patients. Med J Aust 1986; 144:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/17\">",
"      Highton J, Hung N, Hessian P, Wilsher M. Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. Rheumatology (Oxford) 2007; 46:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/18\">",
"      Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006; 54:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/19\">",
"      Glace B, Gottenberg JE, Mariette X, et al. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). Ann Rheum Dis 2012; 71:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/20\">",
"      Kitas G, Banks MJ, Bacon PA. Cardiac involvement in rheumatoid disease. Clin Med 2001; 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/21\">",
"      Wisowska M, Sypua S, Kowalik I. Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int 1999; 18:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/22\">",
"      Ahern M, Lever JV, Cosh J. Complete heart block in rheumatoid arthritis. Ann Rheum Dis 1983; 42:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/23\">",
"      Chatzis A, Giannopoulos N, Baharakakis S, et al. Unusual cause of a stroke in a patient with seronegative rheumatoid arthritis. Cardiovasc Surg 1999; 7:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/24\">",
"      Mounet FS, Soula P, Concina P, Cerene A. A rare case of embolizing cardiac tumor: rheumatoid nodule of the mitral valve. J Heart Valve Dis 1997; 6:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/25\">",
"      Kang H, Baron M. Embolic complications of a mitral valve rheumatoid nodule. J Rheumatol 2004; 31:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/26\">",
"      Palmer DG, Hogg N, Highton J, et al. Macrophage migration and maturation within rheumatoid nodules. Arthritis Rheum 1987; 30:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/27\">",
"      Athanasou NA, Quinn J, Woods CG, Mcgee JO. Immunohistology of rheumatoid nodules and rheumatoid synovium. Ann Rheum Dis 1988; 47:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/28\">",
"      Miyasaka N, Sato K, Yamamoto K, et al. Immunological and immunohistochemical analysis of rheumatoid nodules. Ann Rheum Dis 1989; 48:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/29\">",
"      Wikaningrum R, Highton J, Parker A, et al. Pathogenic mechanisms in the rheumatoid nodule: comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum 1998; 41:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/30\">",
"      Harris ED Jr. A collagenolytic system produced by primary cultures of rheumatoid nodule tissue. J Clin Invest 1972; 51:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/31\">",
"      Stamp LK, Easson A, Lehnigk U, et al. Different T cell subsets in the nodule and synovial membrane: absence of interleukin-17A in rheumatoid nodules. Arthritis Rheum 2008; 58:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/32\">",
"      Hessian PA, Highton J, Kean A, et al. Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 2003; 48:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/33\">",
"      Edwards JC, Wilkinson LS, Pitsillides AA. Palisading cells of rheumatoid nodules: comparison with synovial intimal cells. Ann Rheum Dis 1993; 52:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/34\">",
"      Elewaut D, De Keyser F, De Wever N, et al. A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis 1998; 57:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/35\">",
"      Kato H, Yamakawa M, Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol 2000; 27:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/36\">",
"      Gorman JD, David-Vaudey E, Pai M, et al. Lack of association of the HLA-DRB1 shared epitope with rheumatoid nodules: an individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis. Arthritis Rheum 2004; 50:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/37\">",
"      Gorman JD, David-Vaudey E, Pai M, et al. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 2004; 50:3476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/38\">",
"      Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991; 88:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/39\">",
"      Merrill JT, Shen C, Schreibman D, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 1997; 40:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/40\">",
"      Struthers GR, Scott DL, Delamere JP, et al. Smoking and rheumatoid vasculitis. Rheumatol Int 1981; 1:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/41\">",
"      Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/42\">",
"      Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/43\">",
"      Nyh&auml;ll-W&aring;hlin BM, Petersson IF, Nilsson JA, et al. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/44\">",
"      Schofield JK, Cerio R, Grice K. Systemic lupus erythematosus presenting with 'rheumatoid nodules'. Clin Exp Dermatol 1992; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/45\">",
"      Hassikou H, Le Guilchard F, Lespessailles E, et al. Rheumatoid nodules in systemic lupus erythematosus: a case report. Joint Bone Spine 2003; 70:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/46\">",
"      Simons FE, Schaller JG. Benign rheumatoid nodules. Pediatrics 1975; 56:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/47\">",
"      Mastboom WJ, van der Staak FH, Festen C, Postma MH. Subcutaneous rheumatoid nodules. Arch Dis Child 1988; 63:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/48\">",
"      McGrath MH, Fleischer A. The subcutaneous rheumatoid nodule. Hand Clin 1989; 5:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/49\">",
"      Sander O, Scherer A. Mimicry of a rheumatoid nodule by tophaceous pseudogout at the elbow. J Rheumatol 2008; 35:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/50\">",
"      Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy 2002; 22:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/51\">",
"      Garrido-R&iacute;os A, S&aacute;nchez-Velicia L, Sanz-Mu&ntilde;oz C, et al. Rheumatoid nodulosis: successful response to topical tacrolimus. Clin Rheumatol 2009; 28:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/52\">",
"      Ching DW, Petrie JP, Klemp P, Jones JG. Injection therapy of superficial rheumatoid nodules. Br J Rheumatol 1992; 31:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29815/abstract/53\">",
"      Baan H, Haagsma CJ, van de Laar MA. Corticosteroid injections reduce size of rheumatoid nodules. Clin Rheumatol 2006; 25:21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7523 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-C33EB2799F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29815=[""].join("\n");
var outline_f29_7_29815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Subcutaneous nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiac nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Central nervous system nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Subcutaneous nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lung nodule or nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Accelerated nodulosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subcutaneous nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Glucocorticoid injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgical excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7523\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7523|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/4/28737\" title=\"picture 1\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/13/29910\" title=\"picture 2\">",
"      Rheumatoid nodule Low",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11129?source=related_link\">",
"      Neurologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_7_29816="Hepatic hemangioma";
var content_f29_7_29816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic hemangioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29816/contributors\">",
"     Michael P Curry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29816/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29816/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29816/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/7/29816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic hemangiomas (also referred to as cavernous hemangiomas because of the cavernous vascular space seen histologically) are the most common benign mesenchymal hepatic tumors. In one series of 549 patients referred for MRI for evaluation of focal hepatic lesion(s), 585 of 805 lesions (72 percent) were hemangiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemangiomas are often solitary, but multiple lesions may be present in both the right and left lobe of the liver in up to 40 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/2\">",
"     2",
"    </a>",
"    ]. They range in size from a few millimeters to over 20 cm. The majority are small (&lt;5 cm). Those larger than 5 cm have been referred to as giant hemangiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with hepatic hemangiomas are asymptomatic and have an excellent prognosis. Symptoms are more likely with large lesions. The diagnosis is often considered in patients found to have a focal liver lesion in whom hemangiomas need to be distinguished from other tumors. An approach to such patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of hepatic hemangiomas have ranged from 0.4 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The highest estimates have been derived from autopsy studies suggesting that these lesions are common in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. This observation is confirmed by the increasing recognition of hemangiomas in asymptomatic patients undergoing radiologic imaging tests of the abdomen for other reasons.",
"   </p>",
"   <p>",
"    Although they can be diagnosed at any age, 60 to 80 percent of cases are diagnosed in patients who are between the ages of 30 and 50 years. In adults, hemangiomas occur more frequently in women with a ratio of 3:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Lesions responsible for symptoms are more likely in young women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of hepatic hemangiomas is incompletely understood. They are considered to be vascular malformations or hamartomas of congenital origin that enlarge by ectasia rather than by hyperplasia or hypertrophy.",
"   </p>",
"   <p>",
"    Hormonal influence over tumor growth is suggested by enlargement during pregnancy and estrogen and progesterone therapy and regression after withdrawal of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In one report, enlargement occurred over time in 23 percent of patients receiving estrogen hormone therapy as compared to only 10 percent of controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/15\">",
"     15",
"    </a>",
"    ]. However, estrogen receptors have not been demonstrated in all tumors and tumor growth has been demonstrated in the absence of estrogen therapy and in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, cavernous hemangiomas vary in size from a few millimeters to many centimeters. The larger lesion may be pedunculated and on gross examination appear as cystic lesions with a dark color. They can be found in both lobes of the liver but are more often found in the right lobe. Lesions are well circumscribed and often surrounded by a thin capsule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/18\">",
"     18",
"    </a>",
"    ]. The cut surfaces exhibit a red-brown appearance with a spongy consistency that may show hemorrhage, scarring, or calcification (",
"    <a class=\"graphic graphic_picture graphicRef53994 \" href=\"mobipreview.htm?10/62/11235\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Microscopically, the tumor is composed of cavernous vascular spaces of varying sizes lined by a single layer of flat endothelium and filled with blood. The vascular compartments are separated by thin fibrous septae and may contain thrombi (",
"    <a class=\"graphic graphic_picture graphicRef65735 \" href=\"mobipreview.htm?23/37/24149\">",
"     picture 2",
"    </a>",
"    ). Large hemangiomas may develop a collagenous scar or fibrous nodule as thrombosis occurs. Rarely, there may be focal stromal calcification and ossification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/7\">",
"     7",
"    </a>",
"    ]. Cavernous hemangiomas of the liver may be associated with hemangiomas in other organs, bile duct hamartomas, and focal nodular hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangiomas are typically discovered incidentally at laparotomy, autopsy, or during an imaging test performed for unrelated conditions. Lesions &gt;4 cm are more likely to cause symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptoms are abdominal pain and right upper quadrant discomfort or fullness. However, the relationship of the hemangioma to symptoms is not always clear. In one report, for example, abdominal pain was due to other causes in 54 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/10\">",
"     10",
"    </a>",
"    ]. Less common symptoms include nausea, anorexia, and early satiety, which may develop with large hemangiomas due to compression of adjacent organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. Acute abdominal pain can result from thrombosis or bleeding within the tumor and associated stretching and inflammation of Glisson's capsule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/2\">",
"     2",
"    </a>",
"    ]. Discomfort from an acute thrombosis can last up to three weeks and be associated with fever and abnormal liver function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Giant hemangiomas in children have been associated with high output cardiac failure and hypothyroidism. High output cardiac failure is reported in numerous case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In one series of 16 infants presenting with hepatic hemangiomas within four months of birth, 58 percent were diagnosed with high output cardiac failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/26\">",
"     26",
"    </a>",
"    ]. Hypothyroidism is due to the presence of high levels of 3 iodothyronine deiodinase activity in the hemangioma tissue, which catalyzes the conversion of thyroxine and triiodothyronine to biologically inactive hormones, reverse triiodothyronine, and 3,3'-diiodothyronine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous hemangiomas in children may be a marker for hepatic hemangiomas. In one report, hepatic hemangiomas were detected by ultrasound in 23 percent of infants. In a recent study of infants presenting to a dermatology clinic with numerous (&gt;6) or one large (&gt;5 cm) cutaneous hemangioma(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/28\">",
"     28",
"    </a>",
"    ], the presence of a single large cutaneous hemangioma was generally associated with a single hepatic hemangioma while multiple or miliary cutaneous hemangiomas were associated with the presence of multiple hepatic hemangiomas.",
"   </p>",
"   <p>",
"    The Kasabach-Merritt syndrome is a consumptive coagulopathy in children that has been described in association with giant hemangiomas. Patients have severe thrombocytopenia, hypofibrinogenemia, elevated fibrin degradation products, and fragmentation of red blood cells. However, the association with hemangiomas has been questioned since detailed evaluation of affected patients has suggested that the associated tumor may actually be a kaposiform hemangioendothelioma (a rare malignant tumor), which can resemble a giant hemangioma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rare presentations include the development of hemobilia following rupture into the biliary tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/29\">",
"     29",
"    </a>",
"    ] and steroid resistant polymyalgia rheumatica, which can be cured by resection of the hemangioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic hemangiomatosis, the presence of innumerable hemangiomas, is rare in adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/16,31\">",
"     16,31",
"    </a>",
"    ]. The etiology is unknown, although an association with hereditary hemorrhagic telangiectasia and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    have been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=see_link&amp;anchor=H14#H14\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Hepatic involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical findings are usually unremarkable but occasionally reveal a palpable liver or mass. A bruit is seldom heard over the hemangioma.",
"   </p>",
"   <p>",
"    Liver function tests are usually normal, unless there has been a complication such as thrombosis, bleeding, or compression of the biliary tree. Alpha fetoprotein is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of hepatic hemangiomas is incompletely understood. However, several studies describing clinical and radiologic follow-up have reported that the majority remain stable over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/6,10,34-36\">",
"     6,10,34-36",
"    </a>",
"    ]. In one study that followed the progress of 68 hemangiomas in 47 patients over one to six years, 56 hemangiomas (82 percent) remained unchanged in size, three lesions could not be found, seven were less obvious, one smaller and only one lesion was found to have increased in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/37\">",
"     37",
"    </a>",
"    ]. Significant growth has been demonstrated in occasional patients with resultant symptoms and need for surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/17,38,39\">",
"     17,38,39",
"    </a>",
"    ]. Development of spontaneous rupture is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/8,10,40-43\">",
"     8,10,40-43",
"    </a>",
"    ]. It usually occurs in large hemangiomas that are peripherally located, however, follow-up of giant hemangiomas (tumors &gt;5 cm in size) has shown that even these rarely enlarge or rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/44\">",
"     44",
"    </a>",
"    ]. Traumatic rupture of cavernous hemangioma following blunt trauma to the abdomen is also rare but highlights that traumatic rupture of the liver may be associated with underlying liver pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/45\">",
"     45",
"    </a>",
"    ]. Iatrogenic rupture or intratumoral bleeding has been described following liver biopsy or fine needle aspiration, which has resulted in a reluctance of most clinicians to perform such tests in patients with known or suspected hemangiomas. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Percutaneous needle biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic hemangiomas have characteristics that can suggest the diagnosis on ultrasound, CT, or MRI. A minority of lesions are atypical and may require multiple imaging tests to achieve a confident diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Plain radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain abdominal radiographs may show calcification within the tumor. However calcification is not specific for hemangiomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound typically reveals a well-demarcated homogeneous hyperechoic mass. The hemangioma may be hypoechoic in patients with fatty infiltration of the liver due to the bright signal from the surrounding parenchyma. Blood flow within the hemangioma can be demonstrated by color Doppler in only 10 to 50 percent of hemangiomas, and thus color Doppler does not improve the accuracy of ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Sonographic findings also depend upon the size of the hemangioma. One study characterized 158 hemangiomas as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions &lt;2 cm had an echogenic pattern",
"     </li>",
"     <li>",
"      Lesions between 2 and 5 cm were mainly echogenic (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77575 \" href=\"mobipreview.htm?2/28/2499\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lesions &gt;5 cm had mixed echogenicity probably because of intratumoral thrombosis and fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, some malignant liver lesions have similar acoustic patterns and therefore other imaging modalities are usually required for confirmation. On the other hand, the diagnosis can be strongly suggested by ultrasound in approximately 80 percent of patients with lesions &lt;6 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Possible hemangioma on ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting recommendations regarding the appropriate follow-up for patients with \"typical\" ultrasound appearance of a hepatic hemangioma ranging from confirmatory cross sectional contrast enhanced imaging to repeat ultrasound after a time interval. As noted above, the radiological appearances of a hemangioma on ultrasound overlap with those of HCC and hepatic metastases. As a result, the follow-up care of patients with an ultrasound diagnosis of a hemangioma depends upon their risk of primary or secondary hepatic malignancy.",
"   </p>",
"   <p>",
"    All patients with a history of liver disease or known or suspected extrahepatic malignancy should undergo a confirmatory examination such as a contrast enhanced CT or MRI. In patients with no evidence of liver disease or extrahepatic malignancy and \"typical\" appearances of hemangioma on ultrasound, an acceptable alternative is to repeat the ultrasound at three to six months to document stability. In a study of 213 \"typical\" hepatic hemangiomas, one lesion (0.47 percent) classified as a hemangioma was later diagnosed as a neuroendocrine hepatic metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, one patient had a coexistent lung mass on chest x-ray on the same day he was diagnosed with a liver lesion that was a \"typical\" hemangioma but was subsequently diagnosed with a hepatic metastasis from a lung cancer. Thus, patients with a possible hepatic hemangioma who subsequently develop liver disease or extrahepatic malignancy require further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Contrast enhanced ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound contrast agents consist of gas filled echogenic microbubbles that enhance the ultrasound signal produced by flowing blood. Contrast agents may improve the detection of focal liver lesions and tumor vascularity. Hepatic hemangiomas have a peripheral globular contrast pooling in the early phase that become larger and more numerous in later phases. In one study of 58 patients with histologically proven hemangiomas, 74 percent of patients had the typical peripheral nodular enhancement while 10 percent of cases were indeterminate and 16 percent had dense homogenous arterial enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/51\">",
"     51",
"    </a>",
"    ]. In a separate study of the time related changes of enhancement appearance, the use of a diffuse and partial enhancement pattern in the early phase had sensitivity and specificity for the diagnosis of hemangioma of 79 and 100 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A non-contrast enhanced CT scan of a hemangioma usually demonstrates a well-demarcated hypodense mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70560 \" href=\"mobipreview.htm?42/1/43027\">",
"     image 2",
"    </a>",
"    ). Calcifications are seen in approximately 10 percent of cases. Similar to ultrasound, the lesions may appear as hyperdense relative to the surrounding parenchyma in patients with fatty infiltration of the surrounding liver.",
"   </p>",
"   <p>",
"    The administration of contrast results in a peripheral nodular enhancement in the early phase, followed by a centripetal pattern or \"filling in\" during the late phase. Peripheral nodular or globular enhancement representing venous lakes is seen in up to 94 percent of hemangiomas &gt;4 cm in size. A pattern of globular enhancement isodense to the aorta is seen in 67 percent of hemangiomas, a feature that helps distinguish them from hepatic metastases.",
"   </p>",
"   <p>",
"    The lesions classically opacify after a delay of three or more minutes and remain isodense or hyperdense on delayed scans (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70560 \" href=\"mobipreview.htm?42/1/43027\">",
"     image 2",
"    </a>",
"    ). Possible exceptions are hemangiomas &gt;4 cm, in which the center of the lesion may not opacify completely. Variations in vascular enhancement among hemangiomas may be due to differences in the size of the vascular spaces, the presence of cystic spaces, and the amount of scar tissue within hemangiomas. Absence of enhancement is seen in hemangiomas with large cystic areas or scar tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has emerged as a highly accurate, non-invasive technique for diagnosing hemangiomas with a sensitivity of approximately 90 percent and a specificity of 91 to 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The typical MRI appearance is a smooth, well-demarcated homogeneous mass that has low signal intensity on T1-weighted images and is hyperintense on T2-weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77870 \" href=\"mobipreview.htm?15/42/16035\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/53,55\">",
"     53,55",
"    </a>",
"    ]. The presence of intratumoral fibrosis results in areas of low intensity on T2-weighted images.",
"   </p>",
"   <p>",
"    Administration of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) results in early peripheral discontinuous nodular or globular enhancement on arterial phase imaging with progressive centripetal enhancement or \"filling-in\" on delayed scans similar to that seen on CT scanning. This enhancement pattern is typical of most hemangiomas &gt;2 cm; tumors &lt;2 cm show a homogeneous enhancement on early phase images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/56\">",
"     56",
"    </a>",
"    ]. Small hemangiomas that demonstrate rapid uniform enhancement are sometimes indistinguishable from hypervascular metastases of hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Technetium-99m pertechnetate-labeled red blood cell pool study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technetium-99m pertechnetate-labeled red blood cell pool studies (99mTc-RBC pool studies) show initial hypoperfusion during arterial flow, which is followed by gradual increase of tracer peaking 30 to 50 minutes after the injection. Retention of the isotope within the lesion remains on delayed images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79488 \" href=\"mobipreview.htm?18/31/18928\">",
"     image 4",
"    </a>",
"    ). Sensitivity for lesions &gt;2 cm in size varies from 69 to 92 percent. Specificity approximates 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. False negatives can occur due to the presence of fibrosis or thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/62\">",
"     62",
"    </a>",
"    ]. False positive tests are rare but include lesions such as hypervascular malignancies and angiosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single-photon emission CT (SPECT) using 99mTc-RBC increases the spatial resolution of planar scintigraphy, providing sensitivity and accuracy close to that of MRI for lesions &gt;1 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/63\">",
"     63",
"    </a>",
"    ]. The best use of 99mTc-RBC SPECT is for lesions &gt;2 cm to confirm a suspected hemangioma seen as a hyperechoic lesion in ultrasound and to clarify the diagnosis when CT findings are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography is rarely used for diagnosis. It is reserved for atypical tumors that cannot be diagnosed definitively after multiple non-invasive imaging tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/64\">",
"     64",
"    </a>",
"    ]. Classical features include a large feeding vessel with displacement and diffuse pooling of contrast that produces a characteristic \"cotton wool\" appearance that persists during the venous phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging in patients with cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a hepatic hemangioma can frequently be made confidently with ultrasound in patients without a prior history of malignancy or chronic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/50\">",
"     50",
"    </a>",
"    ]. In contrast, the hyperechoic metastases and hepatocellular carcinoma (HCC) may have similar sonographic characteristics and are more likely in such patients. As a result, multiple imaging modalities and serum AFP determination may be required to differentiate a benign hemangioma from a malignant lesion in these settings. This was illustrated in a study that included 1982 patients with cirrhosis of whom 166 (8 percent) had a focal lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/65\">",
"     65",
"    </a>",
"    ]. Of these 166 patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ultrasound showed the presence of a hemangioma-like lesion in 44 patients with a normal AFP",
"     </li>",
"     <li>",
"      Contrast-enhanced CT confirmed hemangioma in 12 of the 44 patients",
"     </li>",
"     <li>",
"      99mTc-RBC confirmed hemangioma in 10 of the remaining 32 patients",
"     </li>",
"     <li>",
"      Fine needle aspiration biopsy (FNAB) confirmed the presence of HCC in the remaining 22 patients",
"     </li>",
"     <li>",
"      During follow-up a further 26 hemangioma-like lesions were identified on US, 22 of which were confirmed as HCC and four as dysplastic nodules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another group performed a retrospective analysis of 17 patients with cirrhosis in whom there were a total of 21 hemangiomas identified by histology from an explanted liver, during autopsy, or with strict radiologic criteria with follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/66\">",
"     66",
"    </a>",
"    ]. All patients had undergone a contrast-enhanced CT scan. Five of the lesions were not seen on CT (all were less than 2.5 cm). A confident diagnosis of hemangioma could only be made in 11 of the 16 identified lesions; three required further evaluation while two were incorrectly labeled as \"suggestive of HCC.\" Follow-up revealed that seven hemangiomas became smaller in size and five subcapsular lesions developed overlying scar retraction, a feature previously associated with malignant hepatic neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS NEEDLE BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of percutaneous fine needle aspiration biopsy (FNAB) of a suspected hemangioma is still being debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/68-74\">",
"     68-74",
"    </a>",
"    ]. The procedure has been associated with fatal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]; large superficial lesions in subcapsular locations appear to pose the greatest risk. In addition, there is a low diagnostic yield from FNABs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In one report, for example, FNAB was performed in 36 patients, 18 of whom had inconclusive radiological findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/73\">",
"     73",
"    </a>",
"    ]. Diagnostic material was obtained from only 21 individuals, one of whom developed significant bleeding requiring transfusion. We do not recommend use of needle aspiration or biopsy in the evaluation of a possible hemangioma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients, particularly those with lesions &lt;1.5 cm, can be reassured and observed. As discussed above, long-term follow-up of hemangiomas in such patients has confirmed that most do not grow or develop complications. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Natural history'",
"    </a>",
"    above.) On the other hand rapid growth of a hemangioma has been reported, justifying close radiologic follow-up of patients with lesions &gt;5 cm, particularly those in a sub capsular location. In the absence of symptoms, the risk of bleeding is too low to justify prophylactic resection.",
"   </p>",
"   <p>",
"    Patients who have pain or symptoms suggestive of extrinsic compression of adjacent structures should be considered for surgical resection. However, it is important that all other causes of pain have been evaluated and excluded prior to surgery. This approach is supported in one report in which 25 percent of patients had persistence of symptoms after surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/10\">",
"     10",
"    </a>",
"    ]. Overall, indications for surgical intervention have decreased to approximately 2 percent and include the development of complications such as rupture and intraperitoneal bleeding, which has a 20 percent mortality, incapacitating symptoms due to large hemangiomas, or failure to exclude a malignancy by radiologic studies. Giant hemangiomas only rarely turn out to be malignant vascular tumors when resected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four surgical methods are available for the treatment of hemangiomas: liver resection, enucleation, hepatic artery ligation, and liver transplantation. Mortality from surgical resection is negligible in specialized hepatobiliary centers. However, some studies suggest enucleation is associated with less blood loss and transfusion requirements compared with resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]. However, one study that included 40 patients who underwent surgery for hemangiomas (28 liver resections and 12 enucleations) found no difference between the procedures with regard to mortality, morbidity, or transfusion requirement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/36\">",
"     36",
"    </a>",
"    ]. Some authors advocate routinely performing complete extrahepatic ligation of the main arterial supply before attempting enucleation of a hemangioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orthotopic liver transplantation has also been used successfully to treat symptomatic patients with unresectable giant hemangiomas and hemangiomas associated with Kasabach-Merritt syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Non-surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-surgical techniques include hepatic artery embolization, radiotherapy, and interferon alpha-2a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/83-86\">",
"     83-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial embolization has been used to control acute bleeding and symptoms, but it may be complicated by abscess formation, and there is no evidence of long-term efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiotherapy is generally reserved for treatment of childhood hemangiomas associated with Kasabach-Merritt syndrome. It is rarely considered a first line therapy because of its known effects on growth and the risk of secondary malignancy. It may provide some beneficial effects in reducing tumor size in settings in which resection is not technically feasible because of tumor location [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interferon alpha-2a has been used in infants with life-threatening hemangiomas in extrahepatic sites, although success has not been uniform [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/83\">",
"       83",
"      </a>",
"      ]. Its efficacy for hepatic hemangiomas has not been well studied. Interferon probably works as an",
"      <span class=\"nowrap\">",
"       antiproliferative/antiangiogenic",
"      </span>",
"      agent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Recommendations regarding OCPs and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks associated with use of oral contraceptives or pregnancy are not well understood. There is insufficient evidence to conclusively link estrogens to the development or growth of hemangiomas. As a result, controversy exists as to whether patients with hemangiomas should be advised against pregnancy. Full-term pregnancies without complications have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest reviews included 27 pregnancies in patients with hepatic hemangiomas ranging in size from 2.4 to 61 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29816/abstract/88\">",
"     88",
"    </a>",
"    ]. Enlargement occurred in 12 cases and spontaneous rupture was reported in one case with a hemangioma that was 10 cm in size. Intra-tumor hemorrhage occurred in one case and was successfully treated with arterial embolization. Maternal outcome was good in 23 cases and not mentioned in three cases. One patient died. Fetal outcome was good in 16 cases, not mentioned in five, and there were two fetal deaths and four terminations. The authors conclude hemangiomas can be managed conservatively during pregnancy and vaginal delivery is acceptable as complications from lesions under 10 cm are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimates of the prevalence of hepatic hemangiomas have ranged from 0.4 to 20 percent. The highest estimates have been derived from autopsy studies suggesting that these lesions are common in the general population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemangiomas are typically discovered incidentally at laparotomy, autopsy, or during an imaging test performed for unrelated conditions. Lesions &gt;4 cm are more likely to cause symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic hemangiomas have characteristics that can suggest the diagnosis on ultrasound, CT, or MRI. A minority of lesions are atypical and may require multiple imaging tests to achieve a confident diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic patients, particularly those with lesions &lt;1.5 cm but including those &le;5 cm, can be reassured and observed. On the other hand rapid growth of a hemangioma has been reported, justifying close radiologic follow-up of patients with lesions &gt;5 cm, particularly those in a subcapsular location. In the absence of symptoms, the risk of bleeding is too low to justify prophylactic resection.",
"     </li>",
"     <li>",
"      Patients who have pain or symptoms suggestive of extrinsic compression of adjacent structures should be considered for surgical resection. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/1\">",
"      John TG, Greig JD, Crosbie JL, et al. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann Surg 1994; 220:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/2\">",
"      Tait N, Richardson AJ, Muguti G, Little JM. Hepatic cavernous haemangioma: a 10 year review. Aust N Z J Surg 1992; 62:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/3\">",
"      Adam YG, Huvos AG, Fortner JG. Giant hemangiomas of the liver. Ann Surg 1970; 172:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/4\">",
"      Grieco MB, Miscall BG. Giant hemangiomas of the liver. Surg Gynecol Obstet 1978; 147:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/5\">",
"      Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986; 39:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/6\">",
"      Gandolfi L, Leo P, Solmi L, et al. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut 1991; 32:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/7\">",
"      Ishak KG, Rabin L. Benign tumors of the liver. Med Clin North Am 1975; 59:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/8\">",
"      Gilon D, Slater PE, Benbassat J. Can decision analysis help in the management of giant hemangioma of the liver? J Clin Gastroenterol 1991; 13:255.",
"     </a>",
"    </li>",
"    <li>",
"     Edmondson H. Tumors of the liver and intrahepatic bile ducts. Vol. Fascicle 25, Atlas of tumor pathology, Washington, DC: Armed Forces Institute of Pathology, 1958.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/10\">",
"      Farges O, Daradkeh S, Bismuth H. Cavernous hemangiomas of the liver: are there any indications for resection? World J Surg 1995; 19:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/11\">",
"      Saegusa T, Ito K, Oba N, et al. Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy. Intern Med 1995; 34:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/12\">",
"      Graham E, Cohen AW, Soulen M, Faye R. Symptomatic liver hemangioma with intra-tumor hemorrhage treated by angiography and embolization during pregnancy. Obstet Gynecol 1993; 81:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/13\">",
"      Winkfield B, Vuillemin E, Rousselet MC, et al. [Progression of a hepatic hemangioma under progestins]. Gastroenterol Clin Biol 2001; 25:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/14\">",
"      Conter RL, Longmire WP Jr. Recurrent hepatic hemangiomas. Possible association with estrogen therapy. Ann Surg 1988; 207:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/15\">",
"      Glinkova V, Shevah O, Boaz M, et al. Hepatic haemangiomas: possible association with female sex hormones. Gut 2004; 53:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/16\">",
"      Lehmann FS, Beglinger C, Schnabel K, Terracciano L. Progressive development of diffuse liver hemangiomatosis. J Hepatol 1999; 30:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/17\">",
"      DuPre CT, Fincher RM. Case report: cavernous hemangioma of the liver. Am J Med Sci 1992; 303:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/18\">",
"      Baer HU, Dennison AR, Mouton W, et al. Enucleation of giant hemangiomas of the liver. Technical and pathologic aspects of a neglected procedure. Ann Surg 1992; 216:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/19\">",
"      Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D. Association of focal nodular hyperplasia and hepatic hemangioma. Gastroenterology 1989; 97:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/20\">",
"      Toshikuni N, Kawaguchi K, Miki H, et al. Focal nodular hyperplasia coexistent with hemangioma and multiple cysts of the liver. J Gastroenterol 2001; 36:206.",
"     </a>",
"    </li>",
"    <li>",
"     Goodman Z. Benign Tumors of the Liver. In: Neoplasms of the liver, Okuda K, Iskah E (Eds), Springer-Verlag, Tokyo 1987. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/22\">",
"      Kuo PC, Lewis WD, Jenkins RL. Treatment of giant hemangiomas of the liver by enucleation. J Am Coll Surg 1994; 178:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/23\">",
"      Pateron D, Babany G, Belghiti J, et al. Giant hemangioma of the liver with pain, fever, and abnormal liver tests. Report of two cases. Dig Dis Sci 1991; 36:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/24\">",
"      Kristidis P, de Silva M, Howman-Giles R, Gaskin KJ. Infantile hepatic haemangioma: investigation and treatment. J Paediatr Child Health 1991; 27:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/25\">",
"      Bruce S, Downe L, Devonald K, Ellwood D. Noninvasive investigation of infantile hepatic hemangioma: a case study. Pediatrics 1995; 95:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/26\">",
"      Luks FI, Yazbeck S, Brandt ML, et al. Benign liver tumors in children: a 25-year experience. J Pediatr Surg 1991; 26:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/27\">",
"      Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000; 343:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/28\">",
"      Hughes JA, Hill V, Patel K, et al. Cutaneous haemangioma: prevalence and sonographic characteristics of associated hepatic haemangioma. Clin Radiol 2004; 59:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/29\">",
"      Mikami T, Hirata K, Oikawa I, et al. Hemobilia caused by a giant benign hemangioma of the liver: report of a case. Surg Today 1998; 28:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/30\">",
"      Kadry Z, Mentha G, Cereda JM. Polymyalgia rheumatica as a manifestation of a large hepatic cavernous hemangioma. J Hepatol 2000; 32:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/31\">",
"      Moon WS, Yu HC, Lee JM, Kang MJ. Diffuse hepatic hemangiomatosis in an adult. J Korean Med Sci 2000; 15:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/32\">",
"      Haitjema T, Westermann CJ, Overtoom TT, et al. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. Arch Intern Med 1996; 156:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/33\">",
"      Feurle GE. Arteriovenous shunting and cholestasis in hepatic hemangiomatosis associated with metoclopramide. Gastroenterology 1990; 99:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/34\">",
"      Mungovan JA, Cronan JJ, Vacarro J. Hepatic cavernous hemangiomas: lack of enlargement over time. Radiology 1994; 191:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/35\">",
"      Yamagata M, Kanematsu T, Matsumata T, et al. Management of haemangioma of the liver: comparison of results between surgery and observation. Br J Surg 1991; 78:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/36\">",
"      Giuliante F, Ardito F, Vellone M, et al. Reappraisal of surgical indications and approach for liver hemangioma: single-center experience on 74 patients. Am J Surg 2011; 201:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/37\">",
"      Gibney RG, Hendin AP, Cooperberg PL. Sonographically detected hepatic hemangiomas: absence of change over time. AJR Am J Roentgenol 1987; 149:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/38\">",
"      Nghiem HV, Bogost GA, Ryan JA, et al. Cavernous hemangiomas of the liver: enlargement over time. AJR Am J Roentgenol 1997; 169:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/39\">",
"      Yoshida J, Yamasaki S, Yamamoto J, et al. Growing cavernous haemangioma of the liver: 11-fold increase in volume in a decade. J Gastroenterol Hepatol 1991; 6:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/40\">",
"      Scribano E, Loria G, Ascenti G, et al. Spontaneous hemoperitoneum from a giant multicystic hemangioma of the liver: a case report. Abdom Imaging 1996; 21:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/41\">",
"      Yamamoto T, Kawarada Y, Yano T, et al. Spontaneous rupture of hemangioma of the liver: treatment with transcatheter hepatic arterial embolization. Am J Gastroenterol 1991; 86:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/42\">",
"      Mazziotti A, Jovine E, Grazi GL, et al. Spontaneous subcapsular rupture of hepatic haemangioma. Eur J Surg 1995; 161:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/43\">",
"      Trastek VF, van Heerden JA, Sheedy PF 2nd, Adson MA. Cavernous hemangiomas of the liver: resect or observe? Am J Surg 1983; 145:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/44\">",
"      Pietrabissa A, Giulianotti P, Campatelli A, et al. Management and follow-up of 78 giant haemangiomas of the liver. Br J Surg 1996; 83:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/45\">",
"      Hotokezaka M, Kojima M, Nakamura K, et al. Traumatic rupture of hepatic hemangioma. J Clin Gastroenterol 1996; 23:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/46\">",
"      Perkins AB, Imam K, Smith WJ, Cronan JJ. Color and power Doppler sonography of liver hemangiomas: a dream unfulfilled? J Clin Ultrasound 2000; 28:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/47\">",
"      Tanaka S, Kitamura T, Fujita M, et al. Color Doppler flow imaging of liver tumors. AJR Am J Roentgenol 1990; 154:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/48\">",
"      Yasuhara K, Kimura K, Ohto M, et al. Pulsed Doppler in the diagnosis of small liver tumours. Br J Radiol 1988; 61:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/49\">",
"      Ohnishi K, Nomura F. Ultrasonic Doppler studies of hepatocellular carcinoma and comparison with other hepatic focal lesions. Gastroenterology 1989; 97:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/50\">",
"      Leifer DM, Middleton WD, Teefey SA, et al. Follow-up of patients at low risk for hepatic malignancy with a characteristic hemangioma at US. Radiology 2000; 214:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/51\">",
"      Dietrich CF, Mertens JC, Braden B, et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007; 45:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/52\">",
"      Yamashita Y, Ogata I, Urata J, Takahashi M. Cavernous hemangioma of the liver: pathologic correlation with dynamic CT findings. Radiology 1997; 203:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/53\">",
"      McFarland EG, Mayo-Smith WW, Saini S, et al. Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. Radiology 1994; 193:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/54\">",
"      Lee MG, Baker ME, Sostman HD, et al. The diagnostic accuracy/efficacy of MRI in differentiating hepatic hemangiomas from metastatic colorectal/breast carcinoma: a multiple reader ROC analysis using a jackknife technique. J Comput Assist Tomogr 1996; 20:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/55\">",
"      Goshima S, Kanematsu M, Kondo H, et al. Hepatic hemangioma: correlation of enhancement types with diffusion-weighted MR findings and apparent diffusion coefficients. Eur J Radiol 2009; 70:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/56\">",
"      Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994; 192:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/57\">",
"      Kim T, Federle MP, Baron RL, et al. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology 2001; 219:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/58\">",
"      Tamm EP, Rabushka LS, Fishman EK, et al. Intrahepatic, extramedullary hematopoiesis mimicking hemangioma on technetium-99m red blood cell SPECT examination. Clin Imaging 1995; 19:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/59\">",
"      Isla C, Ceballos C, C&oacute;rdoba E, et al. Cavernous hemangioma of the liver. Diagnostic value of 99mTc-labeled red cell scintigraphy: results in 28 patients. Rev Esp Enferm Dig 1997; 89:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/60\">",
"      Moinuddin M, Allison JR, Montgomery JH, et al. Scintigraphic diagnosis of hepatic hemangioma: its role in the management of hepatic mass lesions. AJR Am J Roentgenol 1985; 145:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/61\">",
"      Farlow DC, Chapman PR, Gruenewald SM, et al. Investigation of focal hepatic lesions: is tomographic red blood cell imaging useful? World J Surg 1990; 14:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/62\">",
"      Salvatori M, Meduri G, Manfredi R, et al. [A false negative scintigram in hepatic cavernous hemangioma with extensive thrombotic fibrosis. A case report]. Radiol Med 1994; 88:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/63\">",
"      el-Desouki M, Mohamadiyeh M, al-Rashed R, et al. Features of hepatic cavernous hemangioma on planar and SPECT Tc-99m-labeled red blood cell scintigraphy. Clin Nucl Med 1999; 24:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/64\">",
"      Belli L, De Carlis L, Beati C, et al. Surgical treatment of symptomatic giant hemangiomas of the liver. Surg Gynecol Obstet 1992; 174:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/65\">",
"      Caturelli E, Pompili M, Bartolucci F, et al. Hemangioma-like lesions in chronic liver disease: diagnostic evaluation in patients. Radiology 2001; 220:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/66\">",
"      Brancatelli G, Federle MP, Blachar A, Grazioli L. Hemangioma in the cirrhotic liver: diagnosis and natural history. Radiology 2001; 219:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/67\">",
"      Soyer P, Bluemke DA, Vissuzaine C, et al. CT of hepatic tumors: prevalence and specificity of retraction of the adjacent liver capsule. AJR Am J Roentgenol 1994; 162:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/68\">",
"      Terriff BA, Gibney RG, Scudamore CH. Fatality from fine-needle aspiration biopsy of a hepatic hemangioma. AJR Am J Roentgenol 1990; 154:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/69\">",
"      Davies R. Haemorrhage after fine-needle aspiration biopsy of an hepatic haemangioma. Med J Aust 1993; 158:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/70\">",
"      Caturelli E, Rapaccini GL, Sabelli C, et al. Ultrasound-guided fine-needle aspiration biopsy in the diagnosis of hepatic hemangioma. Liver 1986; 6:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/71\">",
"      Heilo A, Stenwig AE. Liver hemangioma: US-guided 18-gauge core-needle biopsy. Radiology 1997; 204:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/72\">",
"      Solbiati L, Livraghi T, De Pra L, et al. Fine-needle biopsy of hepatic hemangioma with sonographic guidance. AJR Am J Roentgenol 1985; 144:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/73\">",
"      Taavitsainen M, Airaksinen T, Kreula J, P&auml;iv&auml;nsalo M. Fine-needle aspiration biopsy of liver hemangioma. Acta Radiol 1990; 31:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/74\">",
"      Brambs HJ, Spamer C, Volk B, et al. Histological diagnosis of liver hemangiomas using ultrasound-guided fine needle biopsy. Hepatogastroenterology 1985; 32:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/75\">",
"      Gedaly R, Pomposelli JJ, Pomfret EA, et al. Cavernous hemangioma of the liver: anatomic resection vs. enucleation. Arch Surg 1999; 134:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/76\">",
"      Ozden I, Emre A, Alper A, et al. Long-term results of surgery for liver hemangiomas. Arch Surg 2000; 135:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/77\">",
"      Popescu I, Ciurea S, Brasoveanu V, et al. Liver hemangioma revisited: current surgical indications, technical aspects, results. Hepatogastroenterology 2001; 48:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/78\">",
"      Lerner SM, Hiatt JR, Salamandra J, et al. Giant cavernous liver hemangiomas: effect of operative approach on outcome. Arch Surg 2004; 139:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/79\">",
"      Fu XH, Lai EC, Yao XP, et al. Enucleation of liver hemangiomas: is there a difference in surgical outcomes for centrally or peripherally located lesions? Am J Surg 2009; 198:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/80\">",
"      Longeville JH, de la Hall P, Dolan P, et al. Treatment of a giant haemangioma of the liver with Kasabach-Merritt syndrome by orthotopic liver transplant a case report. HPB Surg 1997; 10:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/81\">",
"      Tepetes K, Selby R, Webb M, et al. Orthotopic liver transplantation for benign hepatic neoplasms. Arch Surg 1995; 130:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/82\">",
"      Russo MW, Johnson MW, Fair JH, Brown RS Jr. Orthotopic liver transplantation for giant hepatic hemangioma. Am J Gastroenterol 1997; 92:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/83\">",
"      Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/84\">",
"      Gaspar L, Mascarenhas F, da Costa MS, et al. Radiation therapy in the unresectable cavernous hemangioma of the liver. Radiother Oncol 1993; 29:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/85\">",
"      Reading NG, Forbes A, Nunnerley HB, Williams R. Hepatic haemangioma: a critical review of diagnosis and management. Q J Med 1988; 67:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/86\">",
"      Deutsch GS, Yeh KA, Bates WB 3rd, Tannehill WB. Embolization for management of hepatic hemangiomas. Am Surg 2001; 67:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/87\">",
"      Marques R, Taborda F, Jorge CS, et al. Successful outcome in a pregnancy complicated by large hepatic hemangioma. Acta Obstet Gynecol Scand 1997; 76:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29816/abstract/88\">",
"      Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 2004; 187:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3594 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-77.94.48.4-CAB5F750F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29816=[""].join("\n");
var outline_f29_7_29816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Possible hemangioma on ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Contrast enhanced ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Technetium-99m pertechnetate-labeled red blood cell pool study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PERCUTANEOUS NEEDLE BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Non-surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Recommendations regarding OCPs and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3594|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/28/2499\" title=\"diagnostic image 1\">",
"      Hepatic hemangioma US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/1/43027\" title=\"diagnostic image 2\">",
"      Hepatic hemangioma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/42/16035\" title=\"diagnostic image 3\">",
"      Cavernous hemangioma MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/31/18928\" title=\"diagnostic image 4\">",
"      Hemangioma blood pool scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3594|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/62/11235\" title=\"picture 1\">",
"      Hepatic hemangioma Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/37/24149\" title=\"picture 2\">",
"      Hepatic hemangioma Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36888?source=related_link\">",
"      Approach to the patient with a focal liver lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_7_29817="Proton plan EFT paranas sinus";
var content_f29_7_29817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80047%7EONC%2F80490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80047%7EONC%2F80490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proton beam radiation treatment plan for a young man with a Ewing's sarcoma involving the left paranasal sinuses and infratemporal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The much higher degree of conformality and normal tissue sparing with protons can be seen by comparing this treatment plan to the corresponding photon beam treatment plan in Figure 1B.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John A Jackson, Medical Dosimetrist, Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Conformal photon beam radiation treatment plans for a young man with a Ewing's sarcoma involving the left paranasal sinuses and infratemporal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast this treatment plan with the proton beam treatment plan illustrated in Figure 1A to see the much higher degree of conformality and normal tissue sparing with protons.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John A Jackson, Medical Dosimetrist, Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29817=[""].join("\n");
var outline_f29_7_29817=null;
var title_f29_7_29818="Pregnancy in women with congenital heart disease: General principles";
var content_f29_7_29818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy in women with congenital heart disease: General principles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Joseph K Perloff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Carol A Waksmonski, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Michael R Foley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/7/29818/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/7/29818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until the latter half of the twentieth century, females with congenital heart disease often died before reaching a reproductive age or died during pregnancy, labor, or the puerperium. Improved techniques of surgical repair have resulted in larger proportions of women with congenital heart disease surviving to bear children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general principles of management during and after pregnancy in women who have unoperated or repaired congenital malformations of the heart or circulation will be reviewed here as well as the role of contraception. Pregnancy in women with specific congenital cardiac anomalies, and the management of heart failure and arrhythmias during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/21/35159?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful cardiac surgery improves fertility and reduces the risk of pregnancy in women with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As a result, women who had previously been unable to bear children or who would not have reached reproductive age are now presenting for obstetric and cardiologic care after reparative cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these advances, congenital heart disease remains an important cause of maternal mortality and morbidity during pregnancy. The magnitude of risk is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of maternal deaths from 2000 to 2002 in the United Kingdom, cardiac disease was the second most common cause, with congenital heart disease accounting for 20 percent of the cardiac deaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maternal morbidity was evaluated in a review of mostly retrospective reports published from 1985 to 2006 that described the outcomes of 2491 pregnancies in women with structural congenital heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/5\">",
"       5",
"      </a>",
"      ]. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cardiac complications were documented in 11 percent of completed pregnancies, with the most common being heart failure (5 percent) and arrhythmias (4.5 percent).",
"     </li>",
"     <li>",
"      Cardiovascular events such as myocardial infarction, stroke, and cardiovascular mortality were reported primarily in Eisenmenger patients and those with palliated or unrepaired cyanotic heart disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"       \"Medical management of Eisenmenger syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertensive disorders related to pregnancy were reported in 9 percent of pregnancies, which is comparable to the rate expected in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/6\">",
"       6",
"      </a>",
"      ], but were more frequent in patients with transposition of the great arteries, aortic coarctation, pulmonic valve stenosis, or aortic stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that a woman's impaired cardiac reserve is cumulative with each pregnancy adding to the deficit. However, with few exceptions, this is not the case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/7\">",
"     7",
"    </a>",
"    ]. Gravidas with congenital heart disease may be at higher risk during an individual pregnancy but, if they survive, the long-term ill effects are generally not cumulative or significant. Thus, successive pregnancies generally entail the same but not greater risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiac reserve in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal alterations in circulatory and respiratory physiology during pregnancy can have deleterious effects on the mother with congenital heart disease and on her developing fetus. There are two major hemodynamic changes: (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure typically falls early in gestation and is usually 10 mmHg below baseline in the second trimester, declining to a mean of",
"      <span class=\"nowrap\">",
"       105/60",
"      </span>",
"      mmHg. This response is induced by a reduction in systemic vascular resistance which serves to increase flow across right-to-left shunts.",
"     </li>",
"     <li>",
"      A 30 to 50 percent increase in intravascular volume and cardiac output occurs in normal pregnancy by the early to mid third trimester. In patients whose cardiac output is limited by myocardial dysfunction or valvular lesions, volume overload is poorly tolerated and may lead to congestive failure. Pregnancy may also result in ascending aortic aneurysm formation or dissection in patients with an anatomic predisposition (eg, Marfan syndrome, coarctation of the aorta, or bicuspid aortic valve). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20262?source=see_link\">",
"       \"Pregnancy and Marfan syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Marked fluctuations in cardiac output occur during normal labor and delivery. Cardiac output increases progressively from the first stage of labor, sometimes reaching an additional 50 percent by the late second stage. The potential for dramatic volume shifts is heightened at the time of delivery in response to the physiologic transfusion which occurs with release of vena caval obstruction and blood from the now contracted uterus; postpartum hemorrhage may exacerbate these volume shifts, which are tolerated poorly by women whose cardiac output is highly dependent upon adequate preload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7775297\">",
"    <span class=\"h2\">",
"     Risk of thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the normal hemodynamic changes of pregnancy, cardiac reserve can be impaired by thromboembolism. Pregnancy is associated with an increased thromboembolic risk due to lower extremity venous stasis resulting from inferior vena caval compression by the gravid uterus, and to a hypercoagulable state due to an increase in vitamin K dependent clotting factors and a reduction in free protein S. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link&amp;anchor=H3#H3\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\", section on 'Pathogenesis and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with congenital heart disease, a review cited above found a 2 percent incidence of thromboembolic events in 688 completed pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/5\">",
"     5",
"    </a>",
"    ] compared to an expected rate of 0.05 to 0.10 percent during uncomplicated pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/8\">",
"     8",
"    </a>",
"    ]. Potential risk factors for thromboembolism were not evaluated.",
"   </p>",
"   <p>",
"    The issue of hypercoagulability is of particular concern in women with risk for thrombosis related to prosthetic heart valves, atrial fibrillation, or previous thromboembolic events. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Management guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cardiac reserve of a pregnant woman with congenital heart disease is reduced, appropriate treatment can minimize encroachment on reserve and on the risk of aggravating maternal heart disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anxiety is a special concern in the primigravida as she anticipates her first gestational experience. The expectant mother should be told what to expect during pregnancy, labor, and puerperium in order to decrease, if not eliminate, fear of the unknown. As term approaches, the gravida should be reassured that the pain of labor and delivery will be safely ameliorated.",
"     </li>",
"     <li>",
"      The pregnant woman should be urged to get adequate rest. We suggest an afternoon nap in addition to eight hours of sleep at night.",
"     </li>",
"     <li>",
"      The normal physiologic edema of pregnancy is harmless, and is due to an increase in total exchangeable sodium and water and inferior vena caval compression. Diuretics are not indicated and sodium restriction is not helpful. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=see_link\">",
"       \"Renal and urinary tract physiology in normal pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise encroaches upon the limited reserve of the pregnant woman with heart disease. As a result, strenuous physical activity should be avoided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/30/7657?source=see_link\">",
"       \"Recommendations for exercise during pregnancy and the postpartum period\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/29/4568?source=see_link\">",
"       \"Anatomical and physiological changes of pregnancy and exercise\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heat and humidity add to the hemodynamic burden of pregnancy and can aggravate heart failure in a marginally compensated gravida. A cool, dry environment promotes dissipation of heat, improves regulation of body temperature, and is therefore therapeutic.",
"     </li>",
"     <li>",
"      Anemia in pregnancy is defined as a hemoglobin concentration less than 10.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      during the second trimester and less than 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in the first and third trimesters. Routine administration of iron supplements beyond that in standard prenatal multivitamins should be avoided, particularly in cyanotic patients. Furthermore, patients with right-to-left shunts are erythrocytotic because of a hypoxia-driven increase in erythropoietin production. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39478?source=see_link&amp;anchor=H4#H4\">",
"       \"Medical management of cyanotic congenital heart disease in adults\", section on 'Erythrocytosis and anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asymptomatic bacteriuria can lead to pyelonephritis. Thus, screening for asymptomatic bacteriuria should be a standard practice at the first prenatal visit. Rescreening is generally not performed in low risk women, but should be considered in women at high risk for infection (eg, presence of urinary tract anomalies, hemoglobin S, or preterm labor). Asymptomatic bacteriuria should be promptly treated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/40/43657?source=see_link\">",
"       \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The thromboembolic risk can be reduced by meticulous leg care. Attention should also be paid to posture. Lying in a lateral decubitus position is desirable. The supine position, passive standing, and sitting with knees flexed and legs dependent should be minimized to reduce inferior vena caval compression. Support hose are useful, and ambulation should begin as soon as practical after delivery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Hypercoagulability is of particular concern for women at risk for thrombosis related to prosthetic heart valves, atrial fibrillation, or previous thromboembolic events. Such patients are candidates for anticoagulation. Considerations in choosing an anticoagulation regimen should include adverse fetal effects (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      embryopathy) in the first trimester, bleeding risk, and the risk of thrombosis on the prosthetic valve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MAJOR MATERNAL CARDIAC RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following risks and predictors in women with congenital heart disease for maternal or fetal complications during pregnancy have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/2,3,9,10\">",
"     2,3,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary hypertension (pulmonary vascular disease)",
"     </li>",
"     <li>",
"      Maternal cyanosis",
"     </li>",
"     <li>",
"      Poor maternal functional class",
"     </li>",
"     <li>",
"      History of arrhythmia",
"     </li>",
"     <li>",
"      Maternal anticoagulants",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious risk to the mother is pulmonary hypertension, particularly Eisenmenger syndrome, which includes the additional risk of maternal cyanosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/1\">",
"     1",
"    </a>",
"    ]. Pulmonary hypertension, more specifically pulmonary vascular disease, limits or precludes appropriate adaptive responses to the circulatory changes of pregnancy and to the volatile changes during labor, delivery, and the postpartum period. Women with Eisenmenger syndrome, even when cyanosis is mild, can develop severe and potentially fatal hypoxemia during pregnancy or the postpartum period.",
"   </p>",
"   <p>",
"    The maternal mortality in women with Eisenmenger syndrome is as high as 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/11\">",
"     11",
"    </a>",
"    ]. Eisenmenger patients poorly tolerate the hemodynamic changes associated with pregnancy and delivery, and are particularly susceptible to complications such as preeclampsia and postpartum hemorrhage. In addition, there is appreciable fetal morbidity and mortality. Preterm delivery and fetal growth retardation occur in at least 50 percent of cases, with only 15 to 25 percent of pregnancies progressing to term. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the presence of pulmonary vascular disease and a reversed shunt through a nonrestrictive ventricular septal defect, the gestational fall in systemic vascular resistance augments the right-to-left shunt. A sudden fall in systemic resistance can precipitate intense cyanosis, whereas a sudden rise in resistance, which occurs with bearing down during labor, may abruptly depress cardiac output and provoke fatal syncope. Accordingly, the majority of maternal deaths occur during delivery or in the first week postpartum.",
"   </p>",
"   <p>",
"    Pregnancy is contraindicated in women with Eisenmenger syndrome because of the high maternal mortality risk, appreciable fetal risks, and increased risk of thromboembolism. When pregnancy occurs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been recommended beginning at 20 weeks, but this approach is not appropriate because of the greater risks of hemorrhage, hypovolemia, and death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arterial oxygen saturation before pregnancy is one of the most important predictors of poor fetal and maternal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/3,9,12,13\">",
"     3,9,12,13",
"    </a>",
"    ]. The impact of maternal oxygen saturation was illustrated in a series of 96 pregnancies in 44 women with cyanotic congenital heart disease; only 41 (43 percent) of the pregnancies resulted in a live birth, 15 of which were premature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/2\">",
"     2",
"    </a>",
"    ]. The likelihood of a live birth was much lower in women with a resting arterial oxygen saturation below 85 percent (12 versus 63 percent in those with higher oxygen saturations).",
"   </p>",
"   <p>",
"    Adverse maternal outcomes were also reported in a series of 104 pregnancies in 74 women: 90 percent of mothers with cyanotic lesions had significant postpartum cardiac complications compared to 19 percent in mothers with acyanotic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/3\">",
"     3",
"    </a>",
"    ]. Arterial oxygen saturation above 80 percent reduces this risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related problem in patients with cyanotic congenital heart disease is erythrocytosis. Phlebotomy is not indicated except in women with hematocrits &ge;65 percent and intrusive symptoms of hyperviscosity, such as headache, loss of concentration, fatigue, and myalgias. Care must be taken to avoid an excessive reduction in hematocrit, which results in iron deficiency. A single isovolumetric phlebotomy usually suffices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39478?source=see_link&amp;anchor=H4#H4\">",
"     \"Medical management of cyanotic congenital heart disease in adults\", section on 'Erythrocytosis and anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oxygen administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of antepartum oxygen in cyanotic women is unproven. There is little convincing evidence that oxygen benefits the mother, and there is no evidence that a favorable effect is exerted on a growth-retarded fetus, even though administration of high levels of inspired oxygen may raise the arterial oxygen saturation by increasing the partial pressure of alveolar oxygen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/14\">",
"     14",
"    </a>",
"    ]. Antepartum oxygen administration is not recommended.",
"   </p>",
"   <p>",
"    Other aspects of management of cyanotic congenital heart disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39478?source=see_link\">",
"     \"Medical management of cyanotic congenital heart disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Maternal functional class",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal morbidity and mortality vary directly with the New York Heart Association (NYHA) functional classification (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/9,15,16\">",
"     9,15,16",
"    </a>",
"    ]. In one series of 405 women with heart disease who had 519 pregnancies between 1970 and 1983, 60 percent had rheumatic heart disease (which is now much less common in developed countries), 31 percent had congenital heart disease, and the remaining patients had arrhythmias, cardiomyopathy, or ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/15\">",
"     15",
"    </a>",
"    ]. Eighty-six percent were NYHA class I or II: the three maternal deaths occurred in women who were NYHA class III or IV.",
"   </p>",
"   <p>",
"    Application of the NYHA classification is problematic in women with cyanotic malformations and pulmonary vascular disease with or without venoarterial mixing. Shortness of breath with exertion is primarily due to an exercise-induced fall in systemic vascular resistance that increases right-to-left shunting and induces hypercapnia that stimulates hyperventilation. True cardiac dyspnea, culminating in pulmonary edema, is a major maternal risk, but is more commonly seen in acquired heart disease involving the left ventricle or mitral valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias and conduction disturbances that occur during pregnancy must be distinguished from electrophysiologic abnormalities in gravidas with unoperated and postoperative congenital heart disease. These abnormalities can jeopardize the life of both the mother and the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When arrhythmias are infrequent and well tolerated, and when patients are minimally symptomatic, conservative management is advised. When arrhythmias cause intrusive symptoms or hemodynamic compromise, antiarrhythmic therapy is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/18\">",
"     18",
"    </a>",
"    ]. Although no antiarrhythmic drug is completely safe during pregnancy, most are acceptable and can be given with relatively low risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/19\">",
"     19",
"    </a>",
"    ]. Physiologic changes during pregnancy may alter the pharmacokinetics of antiarrhythmic drugs so serum drug concentrations and patient response must be closely monitored. Rarely, radiofrequency ablation is required during pregnancy for recurrent symptoms that are not responsive to medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrical cardioversion can be performed with relative safety during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     CARPREG risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend using a composite risk score to quantify the risk of cardiac events during pregnancy. A retrospective study examined the risks and predictors of pregnancy-related cardiac complications in women with heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/9\">",
"     9",
"    </a>",
"    ]. The findings were then applied by the Cardiac Disease in Pregnancy (CARPREG) investigators in a prospective study of 562 women with congenital or acquired cardiac disease or arrhythmias who had 617 pregnancies; 74 percent of the pregnancies occurred in women with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four predictors of cardiac events were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor functional class (NYHA class III or IV) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) or cyanosis",
"     </li>",
"     <li>",
"      Previous cardiac events (eg, heart failure, transient ischemic attack, stroke) or arrhythmia",
"     </li>",
"     <li>",
"      Left heart obstruction (mitral valve area of &lt;2 cm2, aortic valve area of &lt;1.5 cm2, or peak left ventricular outflow gradient &gt;30 mmHg)",
"     </li>",
"     <li>",
"      Left ventricular systolic dysfunction (ejection fraction &lt;40 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One point was assigned to each finding. The actual rate of primary cardiac events (pulmonary edema, arrhythmia requiring treatment, stroke, cardiac arrest or death) was 13 percent overall, with 55 percent occurring antepartum. There was high agreement between the rates that were observed in the two studies and those predicted by the CARPREG risk index: 0 points (4 versus 5 percent); 1 point (26 versus 27 percent); and &ge;2 points (62 versus 75 percent).",
"   </p>",
"   <p>",
"    The predictive value of the CARPREG risk index in women with congenital heart disease was subsequently evaluated in 53 such women who had 90 pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/21\">",
"     21",
"    </a>",
"    ]. Adverse cardiac events occurred in 25 percent of pregnancies; the events included heart failure with pulmonary edema, symptomatic arrhythmias, and the need for urgent invasive intervention. There were no significant differences between the observed rates of adverse cardiac events and those predicted by the CARPREG risk index: 0 points (12 versus 5 percent); 1 point (30 versus 27 percent); and &ge;2 points (100 versus 75 percent). Overall risk assessment was improved, primarily in patients with 1 point, by incorporating the presence (high risk) or absence (low risk) of subpulmonary ventricular dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe pulmonary regurgitation.",
"   </p>",
"   <p>",
"    Neither of these studies included patients with Eisenmenger syndrome which, as noted above, is associated with a high maternal mortality. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pulmonary hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk to the fetus among women with congenital heart disease is described below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Fetal risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2802124\">",
"    <span class=\"h2\">",
"     BNP levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma brain natriuretic peptide (BNP) and N-terminal probrain natriuretic peptide (NT-proBNP) levels are well-recognized markers of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .) These markers may also be helpful in monitoring women with cardiovascular disease during pregnancy.",
"   </p>",
"   <p>",
"    A longitudinal study found that BNP levels during uncomplicated pregnancy were approximately twice as high as nonpregnant levels (median 19 [10-143] versus 10 [10-37]",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among pregnant women with heart disease, the presence of a markedly elevated BNP level is associated with adverse maternal cardiac events, as reported by a study comparing BNP levels during pregnancy in 66 women with heart disease and 12 healthy women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/23\">",
"     23",
"    </a>",
"    ]. An elevated BNP",
"    <span class=\"nowrap\">",
"     (&gt;100pg/mL)",
"    </span>",
"    was found in all eight women who developed adverse cardiac events (defined as sustained arrhythmia requiring treatment, stroke, cardiac arrest or cardiac death, pulmonary edema, decline in NYHA function class by at least 2 classes, or need for urgent invasive cardiac procedures during pregnancy or within six months after delivery). Elevated BNP level detection preceded the adverse event in four women. One third of women with BNP",
"    <span class=\"nowrap\">",
"     &gt;100pg/mL",
"    </span>",
"    had an adverse cardiac event. &nbsp;",
"   </p>",
"   <p>",
"    Marked elevations in BNP or NT pro-BNP levels are also observed with preeclampsia. A greater than five-fold elevation in median NT-proBNP was observed in women with preeclampsia (median 430",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    versus 74",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in normotensive pregnant women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, a greater than fivefold elevation in median BNP levels was observed in women with severe preeclampsia (101",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    versus 17.8",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in normotensive pregnant women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    and the 2007 European Society of Cardiology (ESC) guidelines on the management of valvular heart disease identified \ the following maternal valve lesions as posing high maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal risk during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe aortic stenosis with or without symptoms (",
"      <a class=\"graphic graphic_table graphicRef65280 \" href=\"mobipreview.htm?17/33/17948\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Symptomatic mitral stenosis (NYHA class II to IV) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aortic or mitral regurgitation with NYHA class III to IV symptoms",
"     </li>",
"     <li>",
"      Aortic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mitral valve disease with severe left ventricular dysfunction (defined as a left ventricular ejection fraction less than 40 percent) or severe pulmonary hypertension (defined as pulmonary artery pressure &gt;75 percent of systemic pressure)",
"     </li>",
"     <li>",
"      Marfan syndrome with or without aortic regurgitation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mechanical prosthetic valve requiring anticoagulation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of pregnant women with prosthetic heart valves\", section on 'Anticoagulation during pregnancy for women with mechanical heart valves'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6306545\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study of cardiopulmonary exercise testing and outcomes in 89 pregnancies in 83 women suggested that a blunted heart rate response to exercise is a risk factor for adverse pregnancy outcomes in women with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/28\">",
"     28",
"    </a>",
"    ]. Higher peak heart rate, percentage of maximum age predicted heart rate, and chronotropic index were each associated with lower risk of adverse cardiac events (OR 0.71, 95% CI 0.53 to 0.94; OR 0.93; 95% CI 0.88 to 0.98; and OR 0.65; 95% CI 0.47 to 0.90, respectively). (Chronotropic index [CRI] = [peak heart rate &ndash; resting heart",
"    <span class=\"nowrap\">",
"     rate]/[220",
"    </span>",
"    &ndash; age &minus; resting heart rate]). Each of these parameters was also associated with a lower risk of adverse neonatal events, primarily preterm birth before 37 weeks of gestation (OR 0.75, 95% CI 0.58 to 0.98; OR 0.94; 95% CI 0.89-0.99; and OR 0.73; 95% CI 0.54 to 0.98).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARDIAC SURGERY DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the best ways to simplify medical management of the gravida is to perform reparative cardiac surgery before conception. Successful cardiac surgery improves fertility, enables the mother to better tolerate the physiologic changes associated with pregnancy, eliminates the fetal risk from maternal cyanosis, and benefits the subsequent health of mother and, in turn, the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac surgery during pregnancy should be minimized or avoided in women with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. The maternal risks are about the same as those in nonpregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], but cardiopulmonary bypass during pregnancy incurs risk for the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Fetal risks are related to nonpulsatile blood flow and reduced uteroplacental flow during cardiopulmonary bypass, to deep hypothermia, and to preterm labor and delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/31,34-36\">",
"     31,34-36",
"    </a>",
"    ]. If cardiopulmonary bypass is needed, high blood flow (2.5",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m2) and mean arterial blood pressure greater than 70 mmHg are recommended to maximize placental perfusion.",
"   </p>",
"   <p>",
"    The following maternal and fetal outcomes were noted after surgery involving cardiopulmonary bypass during pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 59 women in one report, three died (5 percent) but none of the deaths was directly related to elective surgery (one due to endocarditis and two due to emergency surgery for an aortic dissection) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/30\">",
"       30",
"      </a>",
"      ]. A lower mortality rate (3 percent) was noted in another review; this rate was similar to that in nonpregnant women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Fetal/neonatal",
"      </span>",
"      mortality in these two series was 29 and 19 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a woman presents early in pregnancy with one of the high risk valve lesions described above, we recommend termination of pregnancy followed by reparative surgery before another attempt at pregnancy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Major society guidelines'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Pregnancy termination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the mother declines termination, we manage the patient medically and operate only for refractory NYHA class III or IV symptoms as recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/26\">",
"     26",
"    </a>",
"    ]. It is preferable to delay surgery, if possible, until the fetus is viable; a cesarean delivery can then be performed as part of a combined procedure.",
"   </p>",
"   <p>",
"    During surgery, foam wedges should be placed under the mother's right side to displace the uterus and minimize aortocaval compression. The fetal heart rate should be monitored continuously. Fetal bradycardia often responds to an increase in pump flow rate. In viable fetuses, prolonged bradycardia (less than 80 beats per minute) that is unresponsive to increased pump flow rates is an indication for cesarean delivery if the fetus is at a viable gestational age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies and case reports in pregnant women suggest that hypothermia to 25&ordm;C does not adversely affect the fetus. However, rewarming may increase both uterine activity and the risk of preterm labor. Although moderate hypothermia (32&ordm;C) is probably safe, its effects on the fetus have not been well studied.",
"   </p>",
"   <p>",
"    Cesarean delivery has been successfully performed while the mother was on cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/37\">",
"     37",
"    </a>",
"    ]. When confronted with the catastrophe of sudden maternal death, immediate postmortem caesarean delivery is an important option. About 150 postmortem caesarean deliveries have been reported, with an infant survival of approximately 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/38\">",
"     38",
"    </a>",
"    ]. For the best outcome, cesarean delivery should be performed within four minutes of maternal cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/39\">",
"     39",
"    </a>",
"    ]. The resulting decompression of the gravid uterus aids maternal resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREGNANCY TERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The option of pregnancy termination should be discussed with women in whom gestation represents a major maternal or fetal risk. The first trimester is the safest time for elective pregnancy termination, which should be performed in-hospital, rather than in an outpatient facility, so that all emergency support services are available. The general principles to consider when a termination procedure is planned include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient's cardiologist, an anesthesiologist, and the",
"      <span class=\"nowrap\">",
"       obstetrician/gynecologist",
"      </span>",
"      who will perform the procedure should confer prior to the termination.",
"     </li>",
"     <li>",
"      Endocarditis prophylaxis is not consistently recommended [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/41\">",
"       41",
"      </a>",
"      ], but treatment should be individualized. Gynecologists routinely advise antibiotic prophylaxis to prevent postabortal endometritis, which occurs in 5 to 20 percent of women not given antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dilatation and evacuation is the safest procedure in both the first and second trimesters.",
"     </li>",
"     <li>",
"      If surgical evacuation is not feasible in the second trimester, prostaglandins E1, E2, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      , a synthetic prostaglandin structurally related to prostaglandin E1, can be administered to evacuate the uterus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/44\">",
"       44",
"      </a>",
"      ]. These drugs are absorbed into the systemic circulation and can lower systemic vascular resistance and blood pressure, and increase heart rate, effects that are greater with E2 than E1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link\">",
"       \"Overview of pregnancy termination\"",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Up to seven weeks gestation,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      is an alternative to surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link\">",
"       \"Overview of pregnancy termination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When prostaglandin E compounds are given, systemic arterial oxygen saturation should be monitored with a transcutaneous pulse oximeter and norepinephrine infused at a rate that supports the diastolic blood pressure, which reflects systemic vascular resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostaglandin F compounds should be avoided because they can significantly increase pulmonary artery pressure and may decrease coronary perfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Saline abortion should be avoided because saline absorption can cause expansion of the intravascular volume, heart failure, and clotting abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF LABOR, DELIVERY, AND THE POSTPARTUM PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with functionally mild unrepaired congenital heart disease, and in women who have undergone successful cardiac surgery, the management of labor and delivery is the same as for normal pregnant women, except for potential increase in risk of infective endocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of endocarditis was evaluated in a review of mostly retrospective reports published from 1985 to 2006 that described the outcomes of 2491 pregnancies in women with structural congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/5\">",
"     5",
"    </a>",
"    ]. The rate of endocarditis was 0.5 percent during 1372 completed pregnancies among women with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/5\">",
"     5",
"    </a>",
"    ]. However, other puerperal infections and antibiotic prophylaxis for this population were not disclosed.",
"   </p>",
"   <p>",
"    High rates of both maternal and fetal mortality (22 and 15 percent, respectively, in a review of 67 cases) have been reported for endocarditis during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/46\">",
"     46",
"    </a>",
"    ]. However, most of the data came from individual case reports and are subject to selection bias.",
"   </p>",
"   <p>",
"    Guidelines for endocarditis prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link&amp;anchor=H15#H15\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Vaginal or cesarean delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with unrepaired or postoperative congenital heart disease who are considered functionally normal are allowed to go into spontaneous labor. However, when there are concerns about the functional adequacy of the heart and circulation, labor should be induced under controlled conditions if there are no obstetrical contraindications to vaginal delivery. The timing of induction is individualized, taking into account the gravida's cardiac status, inducibility of the cervix, and fetal lung maturity as determined by amniocentesis. Long inductions in women with an unfavorable cervix should be avoided.",
"   </p>",
"   <p>",
"    Induction of labor in gravidas with a favorable cervix usually requires only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration and artificial rupture of the membranes. An unfavorable cervix can be ripened by a variety of methods. The softened, dilated cervix is more responsive to the subsequent induction of labor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=see_link\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The method of choice for cervical ripening may vary with the clinical setting. One option is to use a mechanical method, such as a Foley catheter, due to concerns for potential adverse effects from pharmacologic agents for cervical ripening. However, there is a theoretical risk of infection from introduction of a foreign body. While there is no categorical contraindication to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    , there is a theoretical risk of coronary vasospasm and a low risk of arrhythmias. Dinoprostone appears to have more profound effects on blood pressure and is contraindicated in active cardiovascular disease. Mechanical methods would be preferable in the patient with cyanosis where a drop in systemic vascular resistance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood pressure would be detrimental.",
"   </p>",
"   <p>",
"    Once in labor, the gravida should be placed in a lateral decubitus position to minimize uterine compression of the abdominal aorta and inferior vena cava, and thus to attenuate the hemodynamic fluctuations associated with major uterine contractions in the supine position. The fetal head should be allowed to descend to the perineum in response to the forces of labor, unassisted by maternal pushing, in order to avoid the undesirable circulatory effects of the Valsalva maneuver. Delivery can then be assisted by low forceps or vacuum extraction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular or intravenous opiates relieve pain and apprehension. Lumbar epidural anesthesia is effective in controlling labor pain, and lowers pain-induced elevations in sympathetic activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38633?source=see_link\">",
"     \"Pharmacologic management of pain during labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because venous return can be reduced by epidural anesthesia, this method should be used cautiously and monitored carefully in patients in whom cardiac output is likely to be sensitive to reductions in preload. Intravenous fluid administration must be monitored carefully to avoid volume expansion or volume depletion.",
"   </p>",
"   <p>",
"    Continuous lumbar epidural analgesia with local anesthetics or opiates, or continuous opioid spinal anesthesia can be safely administered. If Cesarean delivery is required for obstetrical reasons, it can be performed under general anesthesia or appropriate regional anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic arterial pressure is monitored during labor because lumbar epidural anesthetics may cause hypotension. A Swan-Ganz catheter for hemodynamic monitoring should not be routinely employed. In cyanotic congenital heart disease, hemostatic defects increase the risk of bleeding during percutaneous insertion of these catheters and withdrawal of the catheter has been accompanied by pulmonary or systemic (paradoxical) embolization and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with Eisenmenger's syndrome, all essential hemodynamic information is provided by monitoring systemic arterial pressure with an intraarterial line, and by monitoring systemic arterial oxygen saturation by transcutaneous fingertip pulse oximetry, which varies directly with systemic vascular resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Fetal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reductions in uterine blood flow and placental oxygen delivery typically occur during uterine contractions, but the fetus usually extracts enough oxygen to meet its needs. Complications of labor, such as abruptio placentae, cord compression, or maternal hemodynamic instability, may subject the fetus to decreased oxygenation and lead to fetal acidosis or death. A growth retarded fetus is especially vulnerable to hypoxia during labor. For this reason, continuous electronic fetal heart rate monitoring and monitoring of uterine contractions are recommended during labor to permit timely intervention if an undesirable fetal heart rate patterns occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Preterm labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm labor is a major concern, especially in a cyanotic pregnant woman whose fetus is likely to be immature. Pharmacologic inhibition of uterine contractions (tocolytic therapy) usually involves",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , ritodrine or other beta adrenergic agonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , or, when available, atosiban, an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    receptor antagonist. Potential complications of beta adrenergic agonist therapy include volume expansion and increased maternal heart rate, which can lead to heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/49\">",
"     49",
"    </a>",
"    ]. Nifedipine, indomethacin, and magnesium sulfate are generally the preferred agents. However, nifedipine may be harmful in patients with significant aortic stenosis or cyanotic heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Role of cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the pregnant woman with a functionally significant congenital cardiac malformation, regardless of whether or not there has been surgical repair, the anticipation and management of labor, delivery, and the puerperium are crucial if risk is to be minimized. There is a virtual consensus that cesarean delivery should be reserved for obstetrical indications, namely: cephalopelvic disproportion, placenta previa, or preterm labor in a gravida on oral anticoagulants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=see_link&amp;anchor=H4#H4\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Indications and contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks of cesarean delivery in such women include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General anesthesia which incurs the risk of hemodynamic instability associated with intubation and the anesthetic agent",
"     </li>",
"     <li>",
"      Blood loss is at least twice as great as with vaginal delivery",
"     </li>",
"     <li>",
"      Increased risks of wound and uterine infections and postoperative thrombophlebitis",
"     </li>",
"     <li>",
"      Incisional bleeding is frequent in patients on anticoagulants and in cyanotic gravidas who have inherent coagulation defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Oxygen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen is often intuitively administered during labor, especially in cyanotic women. However, maternal benefit has not been demonstrated, and it is not clear to what extent, if any, maternal oxygen administration increases fetal PaO2. Transcutaneous fingertip oximetry is usually sufficient to monitor maternal oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Postpartum care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After expulsion of the placenta, bleeding is reduced by uterine massage and administration of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , which should be infused slowly (less than 2",
"    <span class=\"nowrap\">",
"     U/min)",
"    </span>",
"    to avoid hypotension. In the postpartum period, meticulous leg care, elastic support stockings, and early ambulation are important preventive measures that reduce the risk of thromboembolism.",
"   </p>",
"   <p>",
"    In cyanotic gravidas,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    reinforces the intrinsic hemostatic defect(s) and may result in dangerous and even fatal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/1\">",
"     1",
"    </a>",
"    ]. Accordingly, heparin should be avoided. This does not apply to patients with prosthetic heart valves in whom anticoagulation is required to prevent valve thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of pregnant women with prosthetic heart valves\", section on 'Anticoagulation during pregnancy for women with mechanical heart valves'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding a newborn is fatiguing and associated with a low risk of mastitis with bacteremia. As a result, some women with symptomatic congenital heart disease who might otherwise prefer breastfeeding may choose to bottle feed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     FETAL RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The functional class of the mother, maternal cyanosis, and maternal medications expose the fetus to risks that threaten normal intrauterine growth and development. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall fetal outcomes in mothers with congenital heart disease have been assessed in a number of studies. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review cited above of mostly retrospective reports of 2491 pregnancies in women with structural congenital heart disease, miscarriage occurred in 15 percent and 5 percent of women chose to terminate their pregnancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/5\">",
"       5",
"      </a>",
"      ]. Fetal mortality was 1.7 percent and perinatal mortality was 2.3 percent (compared to an expectation of less than 0.5 percent in the general population), The relatively high rate of premature births (16 percent) and the recurrence of congenital heart disease in the offspring are important variables. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Inheritance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The prospective CARPREG study evaluated 562 women with congenital or acquired cardiac disease or arrhythmias who had 617 pregnancies; 74 percent of the pregnancies occurred in women with congenital heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/20\">",
"       20",
"      </a>",
"      ]. Neonatal complications occurred in 122 pregnancies (20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The major complications were premature birth in 105 pregnancies (17 percent), one-half of which were due to preterm labor, and small for gestational age in 22 pregnancies (4 percent). Less common complications included respiratory distress syndrome or intraventricular (cerebral) hemorrhage as complications of premature birth in 17 pregnancies (3 percent overall, but 16 percent of premature births) and fetal or neonatal death (1 percent each). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=see_link\">",
"       \"Management and complications of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors for adverse outcomes included NYHA class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) or cyanosis at the baseline prenatal visit, left heart obstruction (aortic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mitral stenosis), smoking, multiple gestations, and the use of anticoagulants throughout pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the series of 90 pregnancies in women with congenital heart disease, spontaneous abortion occurred in 12.2 percent of clinically recognized pregnancies, a rate that was not different from the 12 to 15 percent rate in women without heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/21\">",
"       21",
"      </a>",
"      ]. There were adverse neonatal outcomes in 28 percent of pregnancies, including preterm delivery (21 percent), small for gestational age (8 percent), intrauterine fetal demise (3 percent), intraventricular hemorrhage and neonatal death (1.4 percent each). An adverse neonatal outcome was independently predicted by a basal left ventricular outflow gradient &gt;30 mmHg (odds ratio 7.5).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to survival of premature infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Maternal functional class",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) is a major determinant of fetal mortality, with incremental risk ranging from virtually zero for gravidas who are asymptomatic at all levels of activity to about 30 percent for gravidas with symptoms that curtail virtually all average everyday activity, and are present at rest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/1\">",
"     1",
"    </a>",
"    ]. In pregnant women with the Eisenmenger syndrome, for example, only 15 to 25 percent of pregnancies progress to term. Spontaneous abortion is common, and there is appreciable fetal mortality associated with prematurity and fetal growth retardation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Maternal cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cyanotic congenital heart disease and no pulmonary hypertension can go through pregnancy with a relatively low maternal risk, although fetal risk is increased.",
"   </p>",
"   <p>",
"    Maternal cyanosis compromises fetal growth and increases prematurity and fetal wastage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Fetal outcomes were reported in a review of 96 pregnancies in women with cyanotic congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/12\">",
"     12",
"    </a>",
"    ]. The following findings were commented on:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only 43 percent of pregnancies resulted in a live birth, 37 percent of which were premature.",
"     </li>",
"     <li>",
"      The rate of spontaneous abortion increased roughly in parallel with maternal hypoxemia.",
"     </li>",
"     <li>",
"      The mean birth weight of full term infants was 2575 grams compared to a normal term birthweight of 3500 grams.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even when pre-gestational cyanosis is mild, the incidence of fetal wastage is not insignificant because right-to-left shunts tend to increase during the course of pregnancy in response to the fall in systemic vascular resistance.",
"   </p>",
"   <p>",
"    We suggest that antepartum fetal monitoring begin at 28 weeks of gestation because of the increased risk of fetal growth retardation and fetal wastage in cyanotic gravida.",
"   </p>",
"   <p>",
"    We also suggest obstetrical ultrasound examinations at 28 and 34 weeks of gestation to screen for fetal growth retardation, with additional assessment if growth delay is diagnosed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=see_link&amp;anchor=H9#H9\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Antepartum FHR monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Effects of cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgical repair during pregnancy eliminates cyanosis and substantially improves maternal functional class. As noted above, pregnant women who require cardiac surgery usually tolerate cardiopulmonary bypass as well as nonpregnant women, but the reported",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    mortality associated with procedures involving cardiopulmonary bypass is 19 to 29 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Cardiac surgery during pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Offspring of women with congenital heart disease are at increased risk of congenital heart defects. The largest experience comes from a referral series of 6640 pregnancies in which one parent or sibling had congenital heart disease. Recurrence in the fetus was detected by echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/52\">",
"     52",
"    </a>",
"    ] and was diagnosed in 178 (2.7 percent), with concordance (recurrence of the same parental or sibling defect) in approximately one-third. The incidence was similar whether the affected index case was the father, the mother, or a sibling.",
"   </p>",
"   <p>",
"    These results are qualified because only pregnant women referred for fetal echocardiography were included. Thus, the overall recurrence estimates may not be the same as those obtained from population-based studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based survey of 427 probands with congenital heart disease and their 837 children, the risk of a cardiac anomaly in the offspring was 10.7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a collaborative study from Britain that evaluated 393 children of 727 parents, recurrence occurred in 4.1 percent of offspring and 2.1 percent of siblings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/54\">",
"       54",
"      </a>",
"      ]. The risk of recurrence was greater if the mother rather than the father had congenital heart disease (5.7 versus 2.2 percent).",
"     </li>",
"     <li>",
"      Similar findings were found in the prospective CARPREG report cited above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/20\">",
"       20",
"      </a>",
"      ]. There were 432 live births in mothers with congenital heart disease but no recognized genetic syndrome. Congenital heart disease was present in 7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of recurrent congenital heart disease varies with the specific parental defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/5,54\">",
"     5,54",
"    </a>",
"    ]. The data according to defect are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/21/35159?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There also appears to be variation among lesions in the rate of concordance (recurrence of the same lesion in the parent or sibling) depending upon the specific defect. In the referral series cited above, the following were the three most frequent recurrent lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular septal defect &mdash; 55 percent concordance (17 of 31 recurrences).",
"     </li>",
"     <li>",
"      Coarctation of the aorta &mdash; 13 percent (two of 15 recurrences).",
"     </li>",
"     <li>",
"      Hypoplastic left heart syndrome &mdash; 33 percent (four of 12 recurrences).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also familial syndromes associated with specific disorders, such as atrial septal defect in the Holt-Oram syndrome, and a high rate of heritability with bicuspid aortic valve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26201?source=see_link&amp;anchor=H5#H5\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Genetic disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main fertility issues in women with congenital heart disease: menstrual patterns and contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Ovarian function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian function in women with congenital heart disease is an important concern. Whether ovarian function varies with the type of heart defect, and how reparative surgery affects ovarian function remain largely unknown. In a report of 98 women (mean age 33), those who were cyanotic had a delay in onset of menstruation (by about one year) and an increased incidence of abnormally short or long cycle lengths; women with acyanotic congenital heart disease had menstrual patterns similar to normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These abnormal menstrual patterns in cyanotic women are believed to represent a chronic anovulatory state related to dysfunction of the hypopituitary-ovarian axis or abnormal uterine hemostasis in response to chronic hypoxemia and erythrocytosis. It is not known if there is an age beyond which reparative cardiac surgery is unlikely to be followed by normal ovarian function, especially in cyanotic women.",
"   </p>",
"   <p>",
"    Chronic anovulation, if not treated, predisposes women to endometrial hyperplasia and carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link&amp;anchor=H6#H6\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Chronic anovulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with congenital heart disease are often not given information about contraception and the potential risks associated with pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/56\">",
"     56",
"    </a>",
"    ]. The same contraceptive methods available to normal healthy women are generally applicable to those with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/57\">",
"     57",
"    </a>",
"    ]. However, women with congenital heart disease often do not know the most appropriate method of contraception or are given incorrect advice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/58\">",
"     58",
"    </a>",
"    ]. Factors to consider are whether a reversible contraceptive method or sterilization is desired, the efficacy of various methods (perfect use failure rate), patient specific factors that will affect compliance (typical use failure rate) (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"mobipreview.htm?12/56/13197\">",
"     table 3",
"    </a>",
"    ), and medical issues that affect the risk-to-benefit profile of various methods. The World Health Organization and the Centers for Disease Control have published guidelines for estimating the risk versus benefit of use of contraception in women with medical disorders (",
"    <a class=\"graphic graphic_table graphicRef65586 \" href=\"mobipreview.htm?39/25/40350\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Barrier methods include condoms (which are available for use by males or by females) and the diaphragm with spermicide. Although these methods are generally less effective than other techniques, they pose virtually no risk of complications. In women needing to avoid pregnancy due to their cardiac status, these methods should be avoided due to their high typical use failure rate (18 percent for male condom).",
"     </li>",
"     <li>",
"      An intrauterine device (IUD) is an option for acyanotic or mildly cyanotic women who want a reversible method of contraception and are at low risk of acquiring a sexually transmitted infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"       \"Overview of intrauterine contraception\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The levonorgestrel-releasing intrauterine device (Mirena&reg;) has the advantage of reducing menstrual blood loss by 40 to 50 percent and may induce amenorrhea, which may be important with certain conditions.",
"     </li>",
"     <li>",
"      A copper containing IUD has the advantage of lasting for at least ten years. Less need to change the IUD minimizes infection risk. It will not interfere with any medication metabolism and causes no hormonal side effects, having few contraindications related to medical conditions. It is not recommended in anemic women or cyanotic women with hematocrit levels above 55 percent because intrinsic hemostatic defects increase the risk of excessive menstrual bleeding, which is more common with the copper containing IUD than the levonorgestrel-releasing IUD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination estrogen-progestin contraceptives (pill, patch, ring) can be used in women who are at low risk for thromboembolic complications, ie, no pulmonary hypertension and no surgical baffles, such as those with uncomplicated valvular disease (",
"      <a class=\"graphic graphic_table graphicRef65586 \" href=\"mobipreview.htm?39/25/40350\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"       table 5",
"      </a>",
"      ). The usual dose is 30 to 35 mcg. The lowest estrogen-containing oral contraceptive contains 20 mcg of ethinyl estradiol, which theoretically has fewer thromboembolic complications and higher failure rates, although these differences have not been proven. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"       \"Overview of the use of estrogen-progestin contraceptives\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progestin-only contraception can be given, using the levonorgestrel-releasing intrauterine device (IUD), injections of depot medroxyprogesterone (eg, Depo-Provera), pills (eg, Micronor tablets, Nor-QD, or generics), or the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=see_link\">",
"       etonogestrel",
"      </a>",
"      implant (Implanon&reg;). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"       \"Overview of contraception\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tubal occlusion is not reversible but can usually be accomplished safely, even in relatively high-risk women. The risk may be even lower with the minimally invasive hysteroscopic technique [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12665?source=see_link\">",
"       \"Hysteroscopic sterilization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15018?source=see_link\">",
"       \"Surgical sterilization of women\"",
"      </a>",
"      .) Vasectomy for the male partner is an equally efficacious option that incurs no maternal risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for the appropriate contraception for women with heart disease including congenital heart disease are reviewed in an AHA guideline statement on best practices in managing the transition to adulthood for adolescents with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal ligation or an IUD is the safest and most effective contraceptive and can be used in women with cyanotic congenital heart disease and pulmonary vascular disease. Depo-Provera is inappropriate for patients with heart failure because of its tendency to cause fluid retention. Oral contraceptives containing 20 to 35 mcg of ethinyl estradiol are considered safe in patients with a low thrombogenic potential and a low failure rate, provided that no dose is missed and the patient does not smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/7/29818/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9687643\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved techniques of surgical repair have resulted in larger proportions of women with congenital heart disease surviving to bear children. Despite these advances, congenital heart disease remains an important cause of maternal mortality and morbidity during pregnancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women with congenital heart disease may be at higher risk during an individual pregnancy but, if they survive, the long-term ill effects are generally not cumulative or significant. Thus, successive pregnancies generally confront the same but not greater risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal alterations in circulatory and respiratory physiology during pregnancy can have deleterious effects on the mother with congenital heart disease and on her developing fetus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiac reserve in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal physiologic edema of pregnancy is harmless, and is due to an increase in total exchangeable sodium and water and inferior vena caval compression. Diuretics are not indicated and sodium restriction is not helpful. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anemia in pregnancy is defined as a hemoglobin concentration less than 10.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      during the second trimester and less than 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in the first and third trimesters. Routine administration of iron supplements beyond that in standard prenatal multivitamins should be avoided, particularly in cyanotic patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypercoagulability is a particular concern in women at risk for thrombosis related to prosthetic heart valves, atrial fibrillation, or previous thromboembolic events. Such patients are candidates for anticoagulation. Considerations in choosing an anticoagulation regimen should include adverse fetal effects (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      embryopathy) in the first trimester, bleeding risk, and the risk of thrombosis on the prosthetic valve. (See",
"      <a class=\"local\" href=\"#H7775297\">",
"       'Risk of thromboembolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Management guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risks in women with congenital heart disease for maternal or fetal complications during pregnancy include maternal pulmonary hypertension (pulmonary vascular disease), cyanosis, poor functional class, history of arrhythmia, and use of anticoagulants.",
"     </li>",
"     <li>",
"      We recommend using the CARPREG risk index to quantify the risk of cardiac events during pregnancy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'CARPREG risk index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following maternal valve lesions pose high maternal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal risk during pregnancy: severe aortic stenosis with or without symptoms, symptomatic mitral stenosis (NYHA class II to IV), aortic or mitral regurgitation with NYHA class III to IV symptoms, aortic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mitral valve disease with severe left ventricular dysfunction (defined as a left ventricular ejection fraction less than 40 percent) or severe pulmonary hypertension (defined as pulmonary artery pressure &gt;75 percent of systemic pressure), Marfan syndrome, mechanical prosthetic valve requiring anticoagulation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Major society guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Counseling regarding contraception should include consideration of whether a reversible contraceptive method or sterilization is desired, the efficacy of various methods (perfect use failure rate), patient specific factors that will affect compliance (typical use failure rate), and medical issues that affect the risk-to-benefit profile of various methods. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Contraception'",
"      </a>",
"      above.) Women who must not get pregnant, eg, Eisenmenger&rsquo;s syndrome should not use less effective methods such as condoms.",
"     </li>",
"     <li>",
"      Cardiac surgery during pregnancy should be avoided, if possible, due to the risk for the fetus. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cardiac surgery during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The option of pregnancy termination should be discussed with women in whom gestation represents a major maternal or fetal risk. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pregnancy termination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with functionally mild unrepaired congenital heart disease, and in women who have undergone successful cardiac surgery, the management of labor and delivery is the same as for normal pregnant women, except for potential increase in risk of infective endocarditis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management of labor, delivery, and the postpartum period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cesarean delivery should be reserved for obstetrical indications, namely: cephalopelvic disproportion, placenta previa, or preterm labor in a gravida on oral anticoagulants. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Role of cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impaired maternal functional class, maternal cyanosis, and maternal medications expose the fetus to risks that threaten normal intrauterine growth and development. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Fetal risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Offspring of women with congenital heart disease are at increased risk of congenital heart defects. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Inheritance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Child, JS.. Management of Pregnancy and contraception in Congenital Heart Disease. In: Congenital Heart Disease in Adults, 3rd ed, Perloff, JK, Child, JS, Aboulhosn, J (Eds), Saunders/Elsevier, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/2\">",
"      Whittemore R, Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol 1982; 50:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/3\">",
"      Shime J, Mocarski EJ, Hastings D, et al. Congenital heart disease in pregnancy: short- and long-term implications. Am J Obstet Gynecol 1987; 156:313.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis G, Drife JO. Why mothers die 2000-2002&mdash;The sixth report of confidential enquiries into maternal deaths in the United Kingdom. London: RCOG Press, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/5\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/6\">",
"      Roberts JM, Pearson GD, Cutler JA, et al. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertens Pregnancy 2003; 22:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/7\">",
"      Chesley LC. Rheumatic cardiac disease in pregnancy. Long-term followup. Obstet Gynecol 1975; 46:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/8\">",
"      Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/9\">",
"      Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/10\">",
"      Siu S, Chitayat D, Webb G. Pregnancy in women with congenital heart defects: what are the risks? Heart 1999; 81:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/11\">",
"      Kahn ML. Eisenmenger's syndrome in pregnancy. N Engl J Med 1993; 329:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/12\">",
"      Presbitero P, Somerville J, Stone S, et al. Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation 1994; 89:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/13\">",
"      Weiss BM, Atanassoff PG. Cyanotic congenital heart disease and pregnancy: natural selection, pulmonary hypertension, and anesthesia. J Clin Anesth 1993; 5:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/14\">",
"      Willcourt RJ, King JC, Queenan JT. Maternal oxygenation administration and the fetal transcutaneous PO2. Am J Obstet Gynecol 1983; 146:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/15\">",
"      McFaul PB, Dornan JC, Lamki H, Boyle D. Pregnancy complicated by maternal heart disease. A review of 519 women. Br J Obstet Gynaecol 1988; 95:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/16\">",
"      Selzer A. Risks of pregnancy in women with cardiac disease. JAMA 1977; 238:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/17\">",
"      Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/18\">",
"      Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol 1998; 82:58I.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/19\">",
"      Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995; 130:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/20\">",
"      Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/21\">",
"      Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation 2006; 113:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/22\">",
"      Hameed AB, Chan K, Ghamsary M, Elkayam U. Longitudinal changes in the B-type natriuretic peptide levels in normal pregnancy and postpartum. Clin Cardiol 2009; 32:E60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/23\">",
"      Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/24\">",
"      Kale A, Kale E, Yalinkaya A, et al. The comparison of amino-terminal probrain natriuretic peptide levels in preeclampsia and normotensive pregnancy. J Perinat Med 2005; 33:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/25\">",
"      Resnik JL, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005; 193:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/26\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/27\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/28\">",
"      Lui GK, Silversides CK, Khairy P, et al. Heart rate response during exercise and pregnancy outcome in women with congenital heart disease. Circulation 2011; 123:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/29\">",
"      John AS, Gurley F, Schaff HV, et al. Cardiopulmonary bypass during pregnancy. Ann Thorac Surg 2011; 91:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/30\">",
"      Weiss BM, von Segesser LK, Alon E, et al. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996. Am J Obstet Gynecol 1998; 179:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/31\">",
"      Parry AJ, Westaby S. Cardiopulmonary bypass during pregnancy. Ann Thorac Surg 1996; 61:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/32\">",
"      Strickland RA, Oliver WC Jr, Chantigian RC, et al. Anesthesia, cardiopulmonary bypass, and the pregnant patient. Mayo Clin Proc 1991; 66:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/33\">",
"      Chambers CE, Clark SL. Cardiac surgery during pregnancy. Clin Obstet Gynecol 1994; 37:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/34\">",
"      Tripp HF, Stiegel RM, Coyle JP. The use of pulsatile perfusion during aortic valve replacement in pregnancy. Ann Thorac Surg 1999; 67:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/35\">",
"      Goldstein I, Jakobi P, Gutterman E, Milo S. Umbilical artery flow velocity during maternal cardiopulmonary bypass. Ann Thorac Surg 1995; 60:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/36\">",
"      Pomini F, Mercogliano D, Cavalletti C, et al. Cardiopulmonary bypass in pregnancy. Ann Thorac Surg 1996; 61:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/37\">",
"      Martin MC, Pernoll ML, Boruszak AN, et al. Cesarean section while on cardiac bypass: report of a case. Obstet Gynecol 1981; 57:41S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/38\">",
"      Weber CE. Postmortem cesarean section: review of the literature and case reports. Am J Obstet Gynecol 1971; 110:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/39\">",
"      Katz VL, Dotters DJ, Droegemueller W. Perimortem cesarean delivery. Obstet Gynecol 1986; 68:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/40\">",
"      Dildy GA, Clark SL. Cardiac arrest during pregnancy. Obstet Gynecol Clin North Am 1995; 22:303.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/42\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 74. Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2006; 108:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/43\">",
"      Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol 1996; 87:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/44\">",
"      Jain JK, Mishell DR Jr. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med 1994; 331:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/45\">",
"      Secher NJ, Thayssen P, Arnsbo P, Olsen J. Effect of prostaglandin E2 and F2alpha on the systemic and pulmonary circulation in pregnant anesthetized women. Acta Obstet Gynecol Scand 1982; 61:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/46\">",
"      Campuzano K, Roqu&eacute; H, Bolnick A, et al. Bacterial endocarditis complicating pregnancy: case report and systematic review of the literature. Arch Gynecol Obstet 2003; 268:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/47\">",
"      Devitt JH, Noble WH, Byrick RJ. A Swan-Ganz catheter related complication in a patient with Eisenmenger's syndrome. Anesthesiology 1982; 57:335.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Fetal heart rate patterns: Monitoring, interpretation, and management. ACOG technical bulletin 207. Washington, DC. 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/49\">",
"      Armson BA, Samuels P, Miller F, et al. Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. Am J Obstet Gynecol 1992; 167:758.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff, JK. The Clinical Recognition of Congenital Heart Disease, 6th ed, Elsevier/Saunders, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/51\">",
"      Schmaltz AA, Neudorf U, Winkler UH. Outcome of pregnancy in women with congenital heart disease. Cardiol Young 1999; 9:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/52\">",
"      Gill HK, Splitt M, Sharland GK, Simpson JM. Patterns of recurrence of congenital heart disease: an analysis of 6,640 consecutive pregnancies evaluated by detailed fetal echocardiography. J Am Coll Cardiol 2003; 42:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/53\">",
"      Whittemore R, Wells JA, Castellsague X. A second-generation study of 427 probands with congenital heart defects and their 837 children. J Am Coll Cardiol 1994; 23:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/54\">",
"      Burn J, Brennan P, Little J, et al. Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. Lancet 1998; 351:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/55\">",
"      Canobbio MM, Rapkin AJ, Perloff JK, et al. Menstrual patterns in women with congenital heart disease. Pediatr Cardiol 1995; 16:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/56\">",
"      Kovacs AH, Harrison JL, Colman JM, et al. Pregnancy and contraception in congenital heart disease: what women are not told. J Am Coll Cardiol 2008; 52:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/57\">",
"      Sciscione AC, Callan NA. Congenital heart disease in adolescents and adults. Pregnancy and contraception. Cardiol Clin 1993; 11:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/58\">",
"      Leonard H, O'Sullivan JJ, Hunter S. Family planning requirements in the adult congenital heart disease clinic. Heart 1996; 76:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/59\">",
"      Famuyide AO, Hopkins MR, El-Nashar SA, et al. Hysteroscopic sterilization in women with severe cardiac disease: experience at a tertiary center. Mayo Clin Proc 2008; 83:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/60\">",
"      Sable C, Foster E, Uzark K, et al. Best practices in managing transition to adulthood for adolescents with congenital heart disease: the transition process and medical and psychosocial issues: a scientific statement from the American Heart Association. Circulation 2011; 123:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/7/29818/abstract/61\">",
"      Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation 1997; 96:358.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1422 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29818=[""].join("\n");
var outline_f29_7_29818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9687643\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiac reserve in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7775297\">",
"      Risk of thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MAJOR MATERNAL CARDIAC RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cyanosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oxygen administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Maternal functional class",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CARPREG risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2802124\">",
"      BNP levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6306545\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARDIAC SURGERY DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREGNANCY TERMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT OF LABOR, DELIVERY, AND THE POSTPARTUM PERIOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Labor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Preterm labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Role of cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Postpartum care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      FETAL RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Maternal functional class",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Maternal cyanosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Effects of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Ovarian function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9687643\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1422\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1422|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/33/17948\" title=\"table 2\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/56/13197\" title=\"table 3\">",
"      Pregnancy rate during first year of contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/25/40350\" title=\"table 4\">",
"      WHO criteria for contraceptive use in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 5\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/29/4568?source=related_link\">",
"      Anatomical and physiological changes of pregnancy and exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12665?source=related_link\">",
"      Hysteroscopic sterilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39478?source=related_link\">",
"      Medical management of cyanotic congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20262?source=related_link\">",
"      Pregnancy and Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/21/35159?source=related_link\">",
"      Pregnancy in women with congenital heart disease: Specific lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/30/7657?source=related_link\">",
"      Recommendations for exercise during pregnancy and the postpartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15018?source=related_link\">",
"      Surgical sterilization of women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_7_29819="EB-specific monoclonal antibodies";
var content_f29_7_29819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    EB-specific monoclonal antibodies and corresponding proteins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antibody*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Target protein (antigen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb D5/16B4",
"       </td>",
"       <td>",
"        Keratin 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb LL002",
"       </td>",
"       <td>",
"        Keratin 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb HD121",
"       </td>",
"       <td>",
"        Plectin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb 123",
"       </td>",
"       <td>",
"        Collagen 17 (BP180)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb GoH3",
"       </td>",
"       <td>",
"        Alpha-6-integrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb 3E1",
"       </td>",
"       <td>",
"        Beta-4 integrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb K140",
"       </td>",
"       <td>",
"        Laminin-332 beta 3 chain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb GB3",
"       </td>",
"       <td>",
"        Laminin-332 gamma 2 chain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb BM165",
"       </td>",
"       <td>",
"        Laminin-332 alpha 3 chain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb AE2",
"       </td>",
"       <td>",
"        Type IV collagen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mAb LH 7-2",
"       </td>",
"       <td>",
"        Type VII collagen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Monoclonal antibodies can be obtained from several sources and may have different names.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29819=[""].join("\n");
var outline_f29_7_29819=null;
var title_f29_7_29820="DSM-IV criteria PMDD";
var content_f29_7_29820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F87069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F87069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV criteria for premenstrual dysphoric disorder (PMDD)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        A. In most menstrual cycles during the past year, five (or more) of the following symptoms were present for most of the time during the last week of the luteal phase, began to remit within a few days after the onset of the follicular phase, and were absent in the week postmenses, with at least one of the symptoms being either (1), (2), (3), or (4):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Marked anxiety, tension, feelings of being \"keyed up\" or \"on edge\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Marked affective lability (eg, feeling suddenly sad or tearful or increased sensitivity to rejection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Persistent and marked anger or irritability or increased interpersonal conflicts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Decreased interest in usual activities (eg, work, school, friends, hobbies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. Subjective sense of difficulty in concentrating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. Lethargy, easy fatigability, or marked lack of energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8. Marked change in appetite, overeating, or specific food cravings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9. Hypersomnia or insomnia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10. A subjective sense of being overwhelmed or out of control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a sensation of \"bloating\", weight gain",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Note:",
"        </strong>",
"        In menstruating females, the luteal phase corresponds to the period between ovulation and the onset of menses, and the follicular phase begins with menses. In nonmenstruating females (eg, those who have had a hysterectomy), the timing of luteal and follicular phases may require measurement of circulating reproductive hormones.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        B. The disturbance markedly interferes with work or school or with usual social activities and relationships with others (eg, avoidance of social activities, decreased productivity and efficiency at work or school).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        C. The disturbance is not merely an exacerbation of the symptoms of another disorder, such as Major Depressive Disorder, Panic Disorder, Dysthymic Disorder, or a Personality Disorder (although it may be superimposed on any of these disorders).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Criteria A, B, and C must be confirmed by prospective daily ratings during at least two consecutive symptomatic cycles. (The diagnosis may be made provisionally prior to this confirmation.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright &copy; 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29820=[""].join("\n");
var outline_f29_7_29820=null;
var title_f29_7_29821="Weaver curve";
var content_f29_7_29821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Weaver curve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plotted above is an example of the use of the Weaver curve. The child's OFC was 49.5 cm at the age of 9 months, placing him well above the 97th percentile on Nellhaus's head circumference chart. His standard score (SS) was calculated to be +2.93. The father had an OFC of 59.5 cm, and the mother's was 59.0 cm with SS of +2.65 and +2.90, respectively. Their average parental SD was +2.78. When plotted, the intercept (A) of lines from the SS falls below the +2 SD regression line. Thus, the child's head size in relationship to that of his parents is judged to be normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weaver DD, Christian JC. J Pediatr 1980; 96:993. Copyright &copy; 1980 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29821=[""].join("\n");
var outline_f29_7_29821=null;
var title_f29_7_29822="APR ventilation";
var content_f29_7_29822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Airway pressure release ventilation (APRV)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: Continuous flow positive airway pressure (CPAP). B: During exhalation with CPAP, the CPAP valve opens and the airway pressure release (APR) valve closes. C: During airway pressure release from the preset CPAP level to ambient pressure, the CPAP valve closes and the APR valve opens. After closure of the APR valve, functional residual capacity (FRC) is re-established.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Downs JB, Stock MC, Crit Care Med 1987; 15:459.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29822=[""].join("\n");
var outline_f29_7_29822=null;
var title_f29_7_29823="Thomas test";
var content_f29_7_29823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thomas test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 348px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFcAYkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0v9oXxjqehWOlaP4a1F9P1nUGln+0JAZzHFFGTgqFbG9zGgOO5ruPhp4mTxh4E0bXFI8y6tx56j+CZflkX8HDVuHTrI6mNSNnbnURD9nF15S+aIs7tm/GduecZxnmk0zTLDSrdoNLsrWygZ2kaO3iWNS7dWIUAZPc0AW6KKKACiiigAoorg/FurX2r6pNoOjXL2NlbKH1bVUODCuM+TEf+ehXkt/CPcjCbtqwSud5RXzl4U1jW9Y0O0dNa8aX8SJtKadaKojUcKDM+DIxABJBPWt37L4lndJdA1DxVYPAwea48Qzotuijkgx4LPx6YA9alzSK5T3CivJ08X+KrCyXV4rM69osas9xNtjtWeMf8tIEJyVAz98/Nxj1r1DTb231LTrW+spBLa3MSzROOjIwBU/iCKpNPYTVixRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcb451TUpdQs/DegSi1vr6J5574jJtLdSFLKO8jFsLngcntVnR9LtdH02GwsUKwRj+I7mcnqzH+JieST1rO1Q+T8WLfd/y86JIifVJ1J/RhW9XPVetjSC0AYChQAFHAA6CsXxNYQXECTz6dd6oYmG2zinCo56gurMqEA+ucdga2qo63q9hoenve6rcpb26nGW5LMeiqByzHsBzWaKOP8QySxJE2rxjWtbdlNnoFo5WBDnhpB/Eq9S7jaMcDpWl8Hrq7iGv6Tq91Zve2l7vEFrLuigWRFYRpnnAOeP5VTWx1bxbJJPcpN4e0WcAPDHhL69UdPNccxJj+EfN7itGbwB4Wkt44k0a3gMQxHNblopV9xIpDZ75zWkZcpLVz0MHPSivOY7TxV4cO7RNRGu2I62OqSbZl/65zgc/Rx+NbegeO9J1S9XTrvztJ1k9dPv18qQ/7h+7IPdSa1jNSIcbHV0UUVYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOG8cDyPGvgy6j/ANZJNc2jD1R4Sx/IxrW7XO3r/wBs/E3KndaaBaFCexuZ8ZH1WNR/33XRVz1X7xrHYGZUVmdgqKCzMewHU15Xb6ZqmvwW3jy2L3OqRzPNp+nTEGI2WSojUHhZHUbw/XJA6V2HxEu5LbwleR2+Tc3hSyhAOCWlcJx+DE/hXQ28EVpBFb26hYYUEcajoFAwP0FQnYe5S8P6zZ6/pUWoadIXhfKsrDDxOPvI69VYHgitCuU1zQr6y1WXX/CnlrqEgH2ywkO2G/Udyf4JQOj9+hrS8NeI7HX45VtvMgvbf5bmxuF2T27ejL6ejDg9jQ11QGzVLWNJ0/WrJrTVrOC8tzzslXOD6g9Qfcc1dopDOVg03xH4bbd4c1P+1NPXppmrSEso9I7j7w9g4Ye4rc8P+N9O1S9Gm3sc+ka1/wA+F8Ajv7xt92Qe6k/hV6qGu6NYa7YGz1W2S4hzuXPDRt2ZGHKsPUVpGq1uQ4o6uivOoo/Fvhv/AJBl5H4j01elrqDiK6QeizAbX/4GAfetXS/iFotxdJZaobjRNSY4FrqaeSWP+w/3H/4CTWymmQ00dhRSKQygqQQeQR3paoQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWP4u12Hw54fu9SmUytEoWKFfvTSscJGPdmIFbFedTTHxb43MqndoXh6UpH/duL7GGb3EQOP95j6UpOyuNK5f8AB2jy6LoiRXriXU7h2ur6Ufxzucv+A+6PZRW1RRXI3fU2OU8Uf6b4x8J6YDlY5ZtTlX2iTYh/77kH5V1deT+P5p08WarrtjcPFd+G7G3W2UcpPJK7F4GHcOu0exwe1ei+G9at9f0iG/tVePdlJYJBh4JBw0bDsQabWiYkzTrD8R+GbLXJIblmmstUtx/o+oWrbJ4vbPRl9VbIrcopbDOM/t/WvDQ2eLLI31gvA1fTYiwA9ZoRlk9yuR9K6jStSsdXsku9Lu4Lu1f7ssLhh+nQ+xq5XM6p4M0u7vHv7E3Gkaq3JvNOfynY/wC2v3X/AOBA09GI6WivNNW0Xx5bXzTrrt3qdjtCmPT3itJwB3CurIx+jLmm2fiPU7O5js49dH2lm2rYeKbI2krH0W4jGxj6cGmoX2Yr2PTagv7K01G0e11C2gurZ+GinjDqfwNc6/iy40wlfE/h/VNLAxm4iT7Xb/8AfceSP+BKK2NH13SdbRm0jU7O9C8sIZQzL9V6j8RScWtx3uYsfgmCwYnw7q+r6IhOTBa3G+H8I5AwH4YqddO8W2h3WPi1boDpFqWnxup+rRlG/nXSUU1OSCyOfXxL4r0041fw1DqEQ6z6Pcgn6+VJtP5E1btPiR4ZklWG+vX0m5PHk6nC9qfzcBT+BrVps0Uc8ZjnjSWM9UdQwP4GrVV9SXA07LUrC+x9ivba4yM/upVfj14NW64G+8DeHL1T/wASa1tps7kuLKMW8yN/eV0wQaTwhq+o6Z4qbwpqt+urj7M11bXfH2iNFYKUuAOM/MNrcZwcjNXGopaEuNjv6KKK0JCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorE8R+KtE8OWclxq+pW0ARciMuDI/sqdWJ9AKAMv4ha5dWdtbaLobga/qxMVu3X7PGP9ZO3sgPHqxAqXQtKtdE0i102wUrbWyBFzyWPUsT3JOST6msXwdY3dzcXfibXImj1bVAAkD9bO2HMcPsf4m/2j7CuormqSu7GsVYKUc8UlYvjXWE0Dwnqupu4jMEDeWScfO3yr+pFQUcXPBHqGoaRECrNr/iBryQDndBbAhT9P3af99V1XjKyuPDWrv4q0qF5rCRQus2ca5LIOlygH8aD7w/iX3Fcz4Bv9CuvH8KW2rWEtromkRWdsRcofMkkOXZRnnhQDXsoKuvBDA+nNdMY+7ZmTepz9pcQ3lrDc2kqTW8yCSORDlXU8gg1LXJ39k3w+nnvLYPJ4Snl8yaBFJOmux5kQD/liTyy/wAOcjjNdVDLHPDHNBIksMihkdG3KwPQg9xWEouLNE7jqKKKgYVBqFla6lZyWmoW8V1ayDa8UyB1YfQ1PRTA4+2vrr4fXcUV3LNd+DZWCLPKxeXS2PAVm6tCTwGPKd+Ol74k6JHDYxeKNEto11fSWF1uhQBrmAf62JiPvApkj3ArfuIYriCSC4jSWGVSjxuMqykYII9K5zwZdSeGtZHhDUpGlsJkaTRp5OS0Y+/bMe7IOR6r9K3hLm0Zm1bVHQ2dzDe2kF1aSCS3njWWNx0ZWGQfyNTDk1ysWieIfCc0tr4esbbV9Bd2kt7Z7nyJrPccmMFgVaPJOOhA454px0DxP4lHk+IJbfRNJbiW00+Yy3E4/utNgBFPfaMn1FR7J3K5kZPh+78Y69f6p/ZOq6NPptnL5KXcunuqTSDO9UxJyE4BboTkdq2n03x7cj7O134eskY/NeQRyySKO+2Nvlz7k/ga7bTrG20ywgstPgjt7WBBHFFGuFRR0AFWa19miOZnEQ/DPQXiB1V9T1S6PMlxc6hMDIfdUYKB7AYrotA8O6P4eheLRdOtrJZDlzEmGc/7TdT+JrVoq7WJuFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVe+JFucccirFV77/j2b8KmWzGtzhrjwRol1czTXqX92ZXLsk9/O0YJOeE3AAe1XtK8MaDpMgk0zRrC2lHIlSBd/8A30ef1rXorluzWwtJRRSGFeFftFeJ0mltPDNnKD5TLdXm09GH+rQ+/wDER/u13Xxf8af8Ih4d22Uif2zekxWqnkoP4pSPRR098V8uMWeR5JXeSWRi7yOcs7HqSe5NXFdTmxFXlXKtyN4Y35eNGPuoNWrC8vNNkV9NvryyZeht53j/AEBxUNFXc4VJrZnYWHxQ8bWIITxBLcoRgpeQpMpHpyM/rVvwn8UNX8O6lI8dlavpUoJfToXaKJZCc748hvL75Vfl56VwlFDbejNI1px6ns0/x6uypFv4bhR/WW9LD8ggqqfjrrfbR9L+haT/ABryOtfwl4a1PxZrC6bo8amQDdNPJny4E/vMR+g6mlZFqvUk7I9DX4762pzJoulFfaWRf15q1aftATOwSXw5DMw6/Z70nH4bDXZ+Fvg94Y0ZI5NQgOs3w5aW85jB/wBmP7oH1zXoFrZWlpGsdra28Ma8BY41UD8hSvHsdUY1PtM8jtfjvpxH+m+HtXhHcx7XA/PbTNe+KngzxRpTWwvb3TdRhdZ7O4ktjmC4XlGyM8dj6gmvZgAOir+Qqre6bY3y7b2xtbhfSWFW/mKV49jSzL3hDVpda8OWF9dwC3u5YgZoQwbY/cZHbuPYitivPJfAPhlpDLBpaWU3USWMj2zD/v2RS/8ACNalaHdo/i7XLcj+C7ZLxD/38G78mrVVV1JcD0KiuAXUPHWnf6yHQ9biHUxs9nKR9DvXP4ipk+IS2i/8VD4e1zSsfelFv9phH/A4i36gVammTys7misHRfGHh3W22aXrNjcS94hKA4+qnkflW9VCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqC+GbZqnqrqk0dtp9xNMwSKNCzMegA6mlLZjW5m0vbPYV5D4t+N2l2Ek1r4cs5NUuUO3z5D5duD9fvN+A/GvHvEfjfxP4kDpq2rS/ZWP8Ax6237mLHoQOW/E1yqITrwifRPir4n+FvDjPDPfi9vV4+y2Q81wfRiPlX8TXk3iL42eINQLR6HaW2kwHpJIBPMfz+Ufka8sRFRdqKFX0AxT6pJI5Z4mT20Jb+7u9RvpL3Urqe8vJPvzzvuYj09h7CoqKKZg23qwooooEFFFFADJGKoSq7m7Adz2FfXHw08KxeEfCdrY7Qb6QCa8k7vMRz+A+6PpXy14ZRJfFOhRygGJ9RtlcHoQZVzX2eepqZbHbhY6OQlFFFQdYUUUUAFFFFABSgkHIJB9qSigDL1jw7outD/ibaVZXbdQ8sKlgfXd1/WsqLwcNPwfD+u63pO3lY0uftEOf+ucoYY9hiupoqlJrYVjn0vPHGmnaP7F16EdGJaxm/H76E/TFSDxzf23/IV8Ia3ABwXtfLul/Da279K3KWr9qyeRGOvxM8MKQt9d3OnSf3b6zmgx+LLj9a29M8UaBqsiR6brWm3UjdEhukZj+AOaYeRg1k6n4c0TVInj1DSLCdW6loFDA+oYcg+4NUqvdC5DsaK85i0zxD4aYP4a1FtTsFPOl6rKWIHpFcfeU+gfcPpXU+FfE1n4ign8lJbW+tW8u7sbgbZrd8dGHoezDIPY1pGSlsS1Y3aKKKoQUUUUAFFFFABRRRQAUUUUAFFBooAKKKzte1vTdAsGvdYvIbS2XjdI2Nx9FHVj7DmgDRrmvE/jTStAnSzczX2qyDMenWSebO3uVH3V/2mwKwZ9Z8SeKht0WGTw9o79b+7jBu5l9YojxGP9p+f9mtPw9oGnaBbNFp0JDyHfPcSNvmuH7tI55Y/wCRWcqiWxSiZkh8X+IgTe3MfhrT26W9mRNeMPRpSNkf/AQT71e+G8tzBc+I9Huby5vY9OvVW3luZDJIIniRwrMeTgluvbFbQGSAKw/hiftMninUV5ju9YlEZ9ViVIv5oamnJyeo5JJHb0UUVsQFc18Sbr7H4C12cAEi0defcY/rXS1w3xuJX4Ya5g4/dqP/AB4UnsTLZnx4vCge1OpKWsDgCiiigAooooAKKKKACiiigAV3idJYTiWNg6H0YHIP5gV9k+FNcg8SeHLDV7UjZdRBmUfwP0ZT9DkV8bV3fwo8fv4M1J7fUN8mg3bhplXk279PNUdx/eH40mrnTh6ii+V9T6joqKzuoL21iurOaOe2lUPHLGwZXB7gipag7wooopAFFFFABRRRQAUUUUAFFFFABRRRQAVh694ZstXuY71Zbmw1aJdkWoWT+XMg/uns6/7LAityimnbYRzcOreMdEIjvrK28R2g4FxZsLa5A/2o2Oxv+AsPpVsePXXibwl4oQ99trG4z/wGQ/nWzRWiqsXIjHHxCs1/4+ND8TQDpl9KlIz6ZUGj/hZvhlR+/n1CA4yRNptymPxMeK2aUO46M350/asXIjLg+JPg6Ygf8JDYxE9p2MX/AKEBXSWOo2V+gexvLa5QjIMMquD+RrLniiuARcRRTA9RIgbP51zt34E8LXTs76FYxyk5MkCeU35rg01V8hch6BRXnS+CbK3GNN1TX9PHpBqcpH5OWFSDQ/ENuMWPjXU1XsLu1guP12qf1qvaoXIz0GiuCC+OYRsi1zQbkf37jTpEb64WTFRyaHr99n+1vGGobDz5WnQR2ij/AIFhn/8AHqftIhys76WWOFC80ixoOrMcCsHVvGvhrSRi/wBcsI3xkRrMHc/RVyT+Arm08AeHC/mX1lJqUp6vqFxJck++HYj9K2tN0XStL/5BmmWNoc5zBAqH8wKh1V0HyGdL441DVFKeEvD15cbuFvdSU2lsPRgG/eOPYKPrTNG8LRwXqarrtw2sa8Rzdzj5Ic/wwR9I1+nJ7mukJyck5NJUSqORSikL1PNJRTZpY4IXlmkSOKNSzu7AKoHUknoKzKKHiTVY9D0DUNTm5W1gaUDP3mA+VR7k4H41c+H+kS6H4N0qwuf+PpIQ9wT1Mrku+f8AgTGuV01JvH+qWt0qNF4RsZluImkUhtTmQ5VgD0hU4IP8RA7Dn0uumnGy1MpO4UUUVoSFYHjzw4PFfhW+0Y3LWpuVAEyru2EEEHHfpW/RQDVz5xl/Zy1IEeT4tjPr5lj/AINUD/s6a5/B4qsj9bIj/wBmr6VopcqI9nHsfL11+z74thUG21rRrk91aOSL9eazn+CPjhGK/ZtNk/2ku+P1UGvrKilyoXsodj5L/wCFKeOP+fKx/wDAsf4Uf8KU8cf8+Vj/AOBY/wAK+tKKORB7GHY+TP8AhSnjj/nzsf8AwLH+FTWvwL8azk+adJtQP787MT+AWvq2ijlQeyh2PmIfs++J++s6T/37etbS/wBne6a1J1XxKsdxk4W2tQyAduWOa+h6KfKh+zj2PmfW/wBn/X7VDJo2sWWoY/5ZTxGBj9CCR/KuJ1H4aeN9OYifw1dy4/itXSYfoa+zqKTghOlF9D428I+IPF/w+uGMGl6mNOdt01jd2kvkk9yrAfI3uOPUGvd/D/xO8M6rpUF1d6jb6XO4O+1vJArxkHHXoQeoPcV6kQCMHkVE9tBIBvgibHqgNS6aZpC8dDg5PH3hKMkHxDpzsP4YpPMP5KDTF8daTMcWVtrN6eg+z6ZOwP4lQK76G1t4QBDBFGB/cQCpqXskXzs89TxFq1zxY+Dddcnobgw26/jufP6VIsnje6GINA0ix/2rzUWk/wDHY0/rXfUVXs4i5mcE3/Cc2wzLo2hXw9LW/kiP5PGR+tQv4l1Sz/5C3hDW4AOWktRHdIB/wBt36V6HRQ6cQ5mecr8QfDGMT6mbV+8dzbSxOPwK0p+IPhYn93qolHrFbysB+IWvRCqnqAfrQAB0AH0qfZIfOec/8LA0Bv8AVNqUvYeXptwwb6HZzTv+E60vBK2Ovso6sNInwPr8tei0UeyQc557B4+8LyuscmsQWsrcCO8VrdvycCugtLu2vY99lcwXKf3oZFkH5gmt24toLlClzDFMhGCsiBgfzrmr74eeEr2TzJNBsopc58y2T7O+fXdHtNJ0uzDnL9JWI3w/FuCdH8S+IbA9FVroXKAem2UN/OozoHjS24tvEml3aDp9r00qx+pRx/KpdJj50b9Fc+Y/HcP3tO8N3YHeO7mhJ/Aowph1TxVEP3/guWTHU22pwPn6BtpqfZyHzI6OiuZbxVdRcXXhLxPER1KWqTD/AMcc/wAqY3jrTIuLuz1y1PpNpNwPr0Q0uV9h3R1NFcqPH2hPkQnU5j6RaZct+H3Kd/wmds3EOi+JZj3CaTNx+YFHK+wXOoormP8AhLmPKeGPFTD1/s0r+hYGl/4Si+bAi8H+Jyx6B4IUH5mXijlYXR01Fc0Ne11z+58Eay2OvmXFtH/OTml/tTxZJgQ+C3QnvcapCoH12hqfJILo6SiudB8dvyNF8PRez6hKx/SMUkl140s0Ml34a068iXll0/UT5mPZZEAP03UezkLmR0dFcqnj/QEcR6lNc6TcfxRalayQFfqSNv5E0svj/wAOZCWF82qXDfct9Nia4kc+gCjA/EgUuV9h3NnXdZsNC02S+1ScQwKQoABZpGPREUcsx7AVi2HhzUfGEsV94whaz0dSJLfQt2S57PdEfePpGPlHfJ6XvCvh26v9UHiXxVbqmoDIsLBmDrp8X4cGVurN26Dgc9xW8KdtWZuXYRFVFVEUKqjAAGABS0UVoSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACOqupV1DKexGaSONIgRGioD2UYp1FABQc4460UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBFPcwW+37RNHFu6b3C5/OpQcjI6V4T+0hoF1rfifwOyafe3Onwx6kl1Nb6Q+pCDfFGELRKOSWHyk4wRkfdr0H4LW2o2Xws8N2utWD6ffwWoiktnYsyBSQpOeQSoBx2zjtQB2tFFFABUM93b27Ks9xFEzHCh3AJPtmuJ8S6zqes69N4c8N3X2KO1UNqepqoZoSwysMQPHmEcknO0Y4yRXG6p4c0qfV20Hw3YJPq6hX1HW7zNzLZIeRh3zmZh90D7vXjioc0tClG503jb4g3lhNeJ4atLe8g0qRBqd1OSI0JdV8iPH3pcNk9l4zknFRXfivxHHdvbS6v4IspkJyklxI7/AIrlcVpTeD9Em8MR+HntX/spCrGJZGVpGU7suw5Yk8k9zU9r4V8PWtqttBoWlrAvIQ2qN+JJBJPuazdUrlMPTPiLqBmu7T7JZ+ILyLGDoZcQR+vmyyYRcexJ68Vc8F/E601zxC+g6lBFY6oV8y3MU/nQXSgZIjkwMsO4x2OM4rO1GNLa1tbLxDNYwWhwYNB0mMh7k54UjOXUEcgBV/vHFZnjy9mgtrC41t/sl7HKJ9H0mwi86dp4+VMjjgqOjKuFwSCTTVR3E4o9oorI8I6rJrnhjS9TmjWKa6t0lkjXOFYjkc+hzWvWxAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQTgE0UUAec/DFd/hKO/c7rjUrm4vZmPUs0rD9AAPoKPAOPM8Us3+uOtz7yepASPb+lL4D/0D+29Bk4l0vUJdgPeGU+bGR7Ycj/gJpvhn/RfHHi+yPSZ7bUE9MPHsP6x1yy3Zqjq6KKpa5qdvoujXup3pItrSJpnx1IA6D3JwB9akolv7q00+2kvtQmgt7eBcvPMwVUH1NcBpdpqOuX0l5oQn061lBV9d1BPMvLiMnO23jbiKP0JAz12nrWrpHh251qe21rxkVnuRiW20wc21lnkZH/LSQd2PQ9AK7MnPWnsI47TdD8SeFLGO38M6zHqFlADs0/VIgMjk4WZMEHk8sDW/oXjrTr69XTdUjm0XWTx9ivsKZPeN/uyD/dOfYVo1T1fS7DWbJrPVrOC8tm/5ZzIGAPqPQ+4q41WtyXFHUUV5tDpniTwuM+GNQGq6cv/ADC9VkJZB6RXHJHsHDD3Fbmh+PNMv7xNO1KOfRdYb/ly1BQjP/1zf7sg/wB0mtlNMhpo62ijrRVCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDhfGtncaR4isfFGnwSzwsosNTghXc7Qlv3coA6mNic/7LN6VR8IN/aXiXxRrQwYHnTTrdh0ZIAQx/77Zh+FdF8Qtcm0Tw8/9ngPq17ItnYRn+Kd+Afooyx9lNQeHNJh0HQrHS7Zi0drEE3nq7dWY+5JJP1rGrZGkDRrjPiSZ706HolnEk817efaHhd9geOAeaQW5wCwQdO9dnXKWv8Ap/xOv5DzHpOnR26+0k7F2I99qIPxrJFMt+HvFllq872Vwj6brcf+u027wsq+69nX0Zc/hXQ1m63oWla7AsOsafb3iLynmplk91bqp+hFYX/CL6rpfzeGfEV1FGOlnqY+2Q49AxIkX/vo0aAddRXInxNrGl8eJPDlwsQ+9eaU32qL6lMCRR+Bra0LxFo+vITpGo290y/ejVsSIfRkOGB+opWC5qVT1fS7DWLJrPVbOC8tm5McyBhn1Hofcc1dpKBnJ2+ia/4dP/FKawLiz/6B2sM0qL/uTD51+h3Cr6+Ob3TxjxL4Y1OzUdbixxew/mnzj8VrdpQccgkGrjUaJcUyPRPGXh3W3EemazZTTZx5PmBZAfQo2G/St+uR1fQNI1lcarplleehmhViPocZH4VkJ4F0iEFbKfWbGL/nlaarcRoPoN9aKqupPIei0V54NA13T/m0HxbqCgdINURbyM/8C+V//Hqnh8T+KNNO3XPDa38Q/wCXnRpg59swybWH4FqpVIsTizvKK4z/AIT5B9/wz4qU/wDYNLf+gk0n/CeseU8J+KmT+99iRf8Ax1pA36VXMhWZ2lFYfhjxLa+IReLBb3lpc2cgjntryLy5YyVDKSMngg5BzW5TEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVw/wARtTubl7Xwpo0rR6lqik3E6dbS0HEknsx+4vuc9qTdtQWpn6VOfFni648Qk7tJ00vZaX6SP0mnH1I2KfQE966yoNPs7fTrC3srKJYbW3jWKKNeiqBgCp65ZS5nc2SsKBkgetcn8Pz9qPiPU+17q8+w/wCzHiIf+gGug1e9TTdJvb6XiO2geZvoqk/0rnPhLcWtx8PdINrKJXEZ+08YZZyxaRWB5ByT1o6AddRRRUjFBwcjrWLrvhbRNdYSappsE1wPu3CgpKv0kXDD862aKYHJDw7r2mc6B4lmkiHS11iP7Sn0EgxIB9S1V73xdq+gxI3ibw4yxM6xLdafdxyxM7HCjDlWBJrtahvrS2v7SW1vreK5tZV2yQyqGVx6EGnfuI59/GljbAnVtO1zSlHWS706Qxj/AIGm5f1rT0nxDo2sf8gvVLK7OMlYplZh9VzkVjQtq3gYZshc6z4XXlrUkyXdgvrGessY/un5gOhOMVq6poPhfx9oD3dnHYXD3MRNvqMMa+bE+OGDD5gynsfTBrX2cZbMjma3NeisPwbq8ur6GjXyiPVLV2tL6IfwTx8N+B4YezCtysWrOxYUoBPQVzGr6jf6trR8OeGJhDdoofUNQKb1sYz0VR0Mrdh2HJ7Vd/4V7byjF74h8TXf+/qLJn/vgLVxptq4nJI1L25gsbaW4vZo7eCJS7ySttCqBkk5rmLfVvEXidQ3hXTo7HTH+7qmqKR5g/vRQDDEehYqPrWxbfDbwrFMks+mfbpUOQ99NJc4P0diK7AAKAAMAdhWipJbkuZg+EvDieH7a6Ml3Nf6heS+fd3kwAaV8BRhRwqgAAKOgreqOaeGHHnSxx55+dgKz5/EWiW+ftGsadFjn57pF/ma0INSiuYuviB4Rtf9f4l0kH0W6Rv5GqbfE7wjyItWE5HaC3lkP/jqmmFjs6K4k/EnSG/49rDX7k9vK0qbn/vpRUlr8Q9LN7DbatZ6nopuG228upW/lRyn0D5IB9mwaV0OzOyooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqtqZuF0+4Ni0SXWw+U0ylkDdiwHJH0rivsnjK4A+0+KrK29RZaWP5yO38qlyS3Gk2dX4l1u08O6HdapflvJgXO1RlpGPCoo7sxIAHqa5TwdpV3bx3Wr62FOvaqwmugDkQKPuQKf7qDj3JJpLbwnE2oW99rGqaprNzbv5sIvZh5UbjoyxIFQEdiQcV0lYznzaIuMbCUUUVkWcr8R83Wi2mixkiXWr2GxwOvllt0pH0jVvzq14s0K70bUpPE/he382baBqWmx4AvYlHDJ6TKOn94fKe1cXr/wAQfD2l/FZF1qecQaLaskYhhaQG5lxuJx0KoAP+BGt4/HXwT/z8ah/4BP8A4V0QS5bMxlJXOq0bVLPWdMt9Q02YTWk67kYcfUEdiDwQeQauV4sfid4S03xa+o6Fd3sWnX7FtRs3spNhkxxPH6OTgMOhznqOdx/jf4QVcqNXf2Wz5/VqylBp6FqpHuem0V41dfHvTFJFp4f1KUdmkljT9Oaz7j4+T8/ZvDK+3m3mPzwtLlYvaw7nutKAScAZNeEWfxc8Z+IGMHhjwnazTZxuR5J1X/ePyqPxata38HfETxKm7xX4oGl279bWx6gemE2j8y1PktuUpX2PTtZ8QaPocZfWNVsbED/nvOqn8s5rzy48QWtjrA8QeALPWLwyyKdRtrXT5Da3iE4LgkACUdQy9ehz1rT0H4PeDtKcT3Gntqt53n1FzKSf937v6V6DGqxxJHGAkaKFVV4CgdAB6UJqL0C19zhhd6ifEl7rWheFNZQ38KJcQX80NrE8i/dlxuZw23KnA5GPSr+7xzdn7vh3S09cy3Tj/wBAFdXRQ5XdxpWOM0zwhq9qLknxXc232qZriddPs4oQ8jfeYlgzZPHftxVw+CbCb/kIajr+oA9VudUl2n/gKFRXT0UudhZHL/8ACvvCZHzaFauf7zl2b/vosTSH4e+FT10aIg9QZpSD/wCPV1NFHM+4WOZj8AeEo87fD2mnP96IN/OrsPhTw7BzDoGkx85+WzjHP5Vs0UrsLFa30+ythi3s7aIYx8kSr/IVZUBfugD6CiigY4sx6sfzqvf2dtqFnNaX9vFc2sy7ZIpVDK49wamooA4+C41H4fuCXuNT8IZAYMTJcaYPUHrJCP8AvpfcV6Pa3EN3bRXFtKk0Eqh45EbKsp5BBHUVknnIIyD61yieFJ9IkaXwfq9xowLFzZOvn2bE9f3Tcpn/AGCPpWsKnRkOPY9Gorgo/FniLSBjxH4ca7hHW70V/OB9zC2HH0G6tzQPGfh/X5DFpuqQPdD71tITFMv1jbDfpWyknsRZo6GiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijv1ooAiu/+PaT6VkVr3f/AB7SfSsiueruaQ2Ciis3Xte0rQLb7RrWo21lF285wC30HU/hWZZpV558YPHjeEdNhtNNZDrV6pMRYbhBGODIR3OeAPX6VzviT46WEG+Lw1pk19J0FxdfuYvrt++fyFeK69rF9r+rTalq0/n3k2AzYwqgdFUdlHpVKPc56tdRWj1KDu8kkkk0jyyyMXeRzlnYnJJPqTRRRVHn76hRRTHbYhbBOOw6mgCxY2lzqF/BY6dbyXV7O22KCIZZj/QDuTwK988AfBqw0+JLzxesWpagcEWoJNvD7Y/jPuePQd63vhF4Fh8JaIl1eRq2u3qB7mQjmIHkRL6Ad/U/hXf1LlbY9ClQUFd7jLeGK2gSG2ijhhQYWONAqqPYDgU+iipOgKKKKQBRRRQAUUUUAFFFFABRRRQAUUUoBJwASaAEoqi+s6ZHqiaa+pWa6g43LbGZfMI/3c5q+eDzTASiiikAVm63oGka7GE1jTbW8x91pYxvX6N1H4GtKimBy8XhvU9IwfDPiO+to16Wmof6ZB9PmIdfwarA8Xa9pA/4qTw489uvW90Z/tCY9TEcSL+G6ugpenSrVRolxTHeH/E+i+IYi+j6jb3JXh41bEiH0ZD8yn6itmuJ1zwroutyibULCM3S/cuoSYp0+ki4b9aoR6X4q0X/AJAPiJdQt16WmtR7zj0EyYb8SGrRVV1JcD0WiuEj8eXenLjxT4b1KwUfeurMfbLf65T51/Fa6LQvFGh68pOj6rZ3bDqkco3r9V6j8RWikmTaxs0UUUxBRRRQAUUVDd3UFlbSXF5NHBbxjc8krBVUepJ6UATUVwc/j99ULReCtKn1jnH26Q+RZr7+Ywy//AAfrVN/Duta38/izxBO0R62GlE20P0Z8+Y/5jPpUSmkUo3Oi8QeOdA0O4+y3F79o1A/dsrNDPOf+ALkj8cViPq3i/X2UWNpH4YsM5M92FuLt/QCIHag92JPtWrouiaZodv5Gj2FtZRnqIUALe5PUn3JrQrJ1X0KUUZXg7WNUGt33h/xFLDc3kEKXdteRR+WLiBiVJZMkK6sMHHByDXY1wll+8+LSbf+WOhkP/wO4GB/46a7utoO6uyHuRXIzbyfSvMvFnxP8MeGy8Mt4b69Xj7LZYkYH0Y/dX8Tn2rt/GxdfB2tmFtsn2OXB/4Aa+HkUKgVQFA6ADFRUSbM51vZ6JHpXif4yeI9X3xaUkWi2p4BjIknI93Iwv4DPvXnNxLLc3LXF3NLcXL/AHppnLufxPNNoqDknVlPdiUtFFBAUUUUAFa/gy3juvGWgQzgGFtQg3g9CN4OPxOB+NZFPtp5ra5huLZ9k8LrJG3oysGX9QKCoO0k2fbh5NJWX4W1u28R+HrHVrIjyrmMMVzyj9GQ+4ORWpWZ6wUUUUgCiiigAooooAKKKKACigkKpJOAOST2rmLzxrpxuXs9Diude1BeDBpqCRUP+3LwifiaaTewr2OoFYWu+KdO0i5WyzLfas4/dadZr5k7/gPuj/abAqtH4e8U+IBnXtSTQrButjpT7p2Ho9wRx/wAD611Xhvw1pHhu2aHRrKO3DnMknLSSn1dzlmP1NaxpdyXPscrHaeOdWGSuk+HoG6Bs3k4HvjagP51ZX4fJdr/AMVDr+t6qD96L7R9mhP/AACIL+pNdxRWqgkQ5M5j/hAfCn9lyacNA08WshDMBEAxYdG3/e3D+9nPvWDNpXiPwjl9OebxHoa9bWZx9ut1/wCmbniUD+62G9zXotFNxT3BOxyOga7p2v2rT6XcCURnbLGwKSwt/ddDyp9jWlVPxN4MsdZu11K1lm0vXIxiPUbMhZMf3XHSRf8AZYH2xXOP4j1Hw1Ktt45tVigJ2prNopNrJ/10XrCfrlfesJU2tjRSudfRUVpcwXlus9nPFcQPyskTh1P0I4qWsygooopAFFFFACgkHIJB9qxNa8K6FrT+ZqWlWs0w6TBNkq/R1ww/OtqimBy8XhnUtN/5F/xVq1qg6QXu29iHsN/zgfRqsDUvHVnhXs/D+qr/AH4p5LRv++WDj9a6CiqVSSJ5UYX/AAlPilRl/BqsB1EeqRkn6ZUUq+N9TjOLzwXrkfvC8Eo/SStyiq9qw5EYE3jDxDd/u9H8H3cbN0m1O5igjX6hSzH8qqQ+E31O6S/8Z3g1q8Q7o7baUs7c/wCxEfvH/afJ+ldVRSdRsFFIFAVVVQFVRgADAA9AKKKKzKClqrqWoWmmWpuL+dIYshQW6sx6Ko6knsBWHFo2ueKruQ6znSvDWCq2MbEXN4D3mYf6tP8AYU5Pc9qqMXLYTdix4DkXV/EfiDX7dlfT38rT7WUdJRFuLsp7rvcgHvtNdzUNnawWVpDa2cMcFvCoSOONdqoo6AAVNXUlZWMm7mL41/5FDWv+vOX/ANANfDw6V9w+NBnwhrQAz/ocv/oBr4eHQVFQ5MRuhaKKKzMAooooAKKKKACiiigDt/hZ4/m8Fai8F2rzaDdOGnjUZaB+nmoO/wDtL36jmvqDT7211GyhvLC4jubSZQ8csTblYeoNfE9dD4O8Y6z4RuTJo9wPIc7pbSUFoZD64/hP+0OfrSaudVGvy+7I+vqK8z8L/GXw9qiJHrG/Rrs8HzjuhJ9pB0/4EBXo9ldW9/As1jPDcxMMq8LhwR9RUNNHapJ6olookIjQvIQiDksxwB+Ncvc+OtFFw1rpb3GtXq8GDS4TcEH/AGnHyL+LUJXGdRWbrmvaVoUKy6vfwWofhFdvnkPoqjlj9BWVHb+NtdxthsvDNm38UhF3d49lH7tT+LV0HhzwdpeiXMl6BNf6tL/rdQvW82dh6BsYVR/dUAVpGk3uQ5HPR+INa1X/AJFvwxeSxn7t3qbfY4cdiFIMjD/gIqwvhrxZqOG1XxPDpyHrBpFooI9vMk3E/kK7yitVTiiXJnED4baTcMP7ZvtY1mMHIhv71miz7ou0H8Qa6+wsrXT7VLawtoba3QYWKFAir9AOKsUVSVibhRRRTAKKKKACiiigApsiJIjJIodGGCrDIIp1FAHH3vw48OyzPcWFtPpF0xyZtLna2J+oU7T+INVG8NeLdPOdL8TQahGP+WOrWYLH28yLaR/3ya7uik4p7juzz59U8VafxqvhNrlB96bSbtJgfpHJsb+dQjx/oUL+Xqkl5pEvddRtJIAP+BEbf1r0emyIkiFJFV1PUMMg1DpIfOzmNO1fTdTQNpuo2d2p6eROr/oDV5gVPzAj61X1LwP4X1JzJe6Bpryn/loIFV/++hg/rWf/AMK60mHjTL7XNNH9211OYL/3yzMP0qfY+ZXOa9FYw+H6HJfxR4qd+zf2jtx+CqAfxBpjeCtXt/8AkG+NNXQf3byGG5H57VP61PsmHOjcornn0/x3ZkmO48Paqg6LJHLaufxBcfpTG1rxFZ/8hPwdfMo6yaddRXC/gpKt+lJ05D5kdJRXLv440u3AbU7TWdLiztM1/pssUan0L4Kj65xXSWtxBd2yXFpNFPbyDKSxOHVh7EcGpcWtx3JKKKKkYVzmseIZ/wC1v7E8N2a6lrYAaVWcrBZqejTOOnsg+Y+3Wjx1qd3ZafZ2WkyCLVNVu0sbaQru8stku4HcqgYjPGRXUeF/D1h4a0tbHTY2CljJLLI26SeQ/ekdjyzH1/pWtOHNqyJSsZHh7webe/XVvEd5/a+tDmNymyG1HpDHzt92OWPr2rrqKK6ErGYUUUUAMmiSaF4pVDRupVlPQg9RXlMvwE8Iu5ZZdXjB/hW74H5ivWaKLCaT3PGbn9nvw24PkarrcJ7fvY3A/NKyn/Z2iyfL8UThc8brJSf0YV73RSshckex4Kn7OsHHmeKLo+u2zQf1NW4v2d9HH+v8Qaw3psWJf/ZDXt9FHKg5I9jxBv2d9FJO3xBrIHv5R/8AZKo6p+ztGLdzpHiS4E4Hyrd26srexK4I+uDXvtFHKg5I9j4/1T4ReOtOkKjRkvUzgPaXCMD74bBFZh+HXjZTg+FNT/Axn/2avtOilyIj2MD4pb4f+NF6+E9W/BEP8moj+H/jWRtq+FNVBP8AeVFH5lq+1qKXIhewifHFt8KvHdwwCeHZIie81xGo/ma6DQPgn45E+/zrHRjnl47x9x/79jn8TX1PRTUUio04x2PPdC+F2lxafbJ4nuLrX7xB873dxK0JOe0TOV44HPpXdWNna2FstvY28NtAv3Y4kCKPwFWKKdjQDRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBGUMpVgCpGCCMg1xmoeALOO5kvvC91N4f1Bzuc2gBt5T/wBNID8jfUYPvXaUUbgefJeeMrMmC+8MwahInS6sL1I45B67JMMp9ufrStqPi+TAt/ByofW41OJR/wCOhjXoFFR7OJXMzidD8Oaxd+I7TW/FL2KNYxutnZWZZ1jdxhpHdgNzbflGAAMn1rtqKKpK2iE3cKKKKYgooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Thomas test evaluates quadriceps flexibility. In this test, the patient sits on the edge of the examination table and pulls one knee to his or her chest, then lies supine with the second leg falling into passive hip extension, as depicted in (A) above. It is important that the knee be held snugly to the chest and the lumbar spine be held in neutral, not lordotic, position while the patient is supine. A positive test, indicating tight hip flexors, is demonstrated by the inability of the hip of the second leg to remain extended while the first is fully flexed, as depicted in (B) above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_7_29823=[""].join("\n");
var outline_f29_7_29823=null;
